WO2024052513A1 - Heterocyclic derivatives as janus kinase inhibitors - Google Patents
Heterocyclic derivatives as janus kinase inhibitors Download PDFInfo
- Publication number
- WO2024052513A1 WO2024052513A1 PCT/EP2023/074692 EP2023074692W WO2024052513A1 WO 2024052513 A1 WO2024052513 A1 WO 2024052513A1 EP 2023074692 W EP2023074692 W EP 2023074692W WO 2024052513 A1 WO2024052513 A1 WO 2024052513A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrazolo
- ethyl
- methoxy
- dihydro
- benzo
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title description 20
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 152
- 208000006673 asthma Diseases 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 10
- -1 -(CH2)mNR4R5 Chemical group 0.000 claims description 220
- 239000000203 mixture Substances 0.000 claims description 50
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 14
- 239000012453 solvate Substances 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 11
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 10
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 108091000080 Phosphotransferase Proteins 0.000 claims description 9
- 102000020233 phosphotransferase Human genes 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 206010069351 acute lung injury Diseases 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 5
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 239000006199 nebulizer Substances 0.000 claims description 5
- 239000003380 propellant Substances 0.000 claims description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 4
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 claims description 4
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 4
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 4
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims description 4
- 229940112141 dry powder inhaler Drugs 0.000 claims description 4
- 102000052502 human ELANE Human genes 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 229940071648 metered dose inhaler Drugs 0.000 claims description 3
- 239000003595 mist Substances 0.000 claims description 3
- 150000007970 thio esters Chemical group 0.000 claims description 3
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 claims description 2
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 claims description 2
- 108010014632 NF-kappa B kinase Proteins 0.000 claims description 2
- 239000012828 PI3K inhibitor Substances 0.000 claims description 2
- 102000038030 PI3Ks Human genes 0.000 claims description 2
- 108091007960 PI3Ks Proteins 0.000 claims description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 claims description 2
- 229940124748 beta 2 agonist Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 239000003226 mitogen Substances 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 239000003149 muscarinic antagonist Substances 0.000 claims description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 2
- 239000003590 rho kinase inhibitor Substances 0.000 claims description 2
- 125000005518 carboxamido group Chemical group 0.000 claims 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 111
- 102000042838 JAK family Human genes 0.000 abstract description 40
- 108091082332 JAK family Proteins 0.000 abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
- 201000010099 disease Diseases 0.000 abstract description 11
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 abstract description 9
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 abstract description 9
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 abstract description 9
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 abstract description 9
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 abstract description 7
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 108020003175 receptors Proteins 0.000 abstract description 6
- 102000005962 receptors Human genes 0.000 abstract description 6
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 abstract description 5
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 abstract description 5
- 208000027866 inflammatory disease Diseases 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract description 2
- 108091005682 Receptor kinases Proteins 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 273
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 133
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 88
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 55
- 239000000047 product Substances 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- 235000019439 ethyl acetate Nutrition 0.000 description 43
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 42
- 239000000243 solution Substances 0.000 description 41
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 37
- 239000002904 solvent Substances 0.000 description 35
- 238000003818 flash chromatography Methods 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 31
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 30
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- 230000000875 corresponding effect Effects 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 21
- 239000007858 starting material Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 19
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 239000003960 organic solvent Substances 0.000 description 18
- 238000001816 cooling Methods 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 15
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
- 239000007832 Na2SO4 Substances 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- 150000007530 organic bases Chemical class 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 239000007821 HATU Substances 0.000 description 7
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 7
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 7
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 108010019477 S-adenosyl-L-methionine-dependent N-methyltransferase Proteins 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000013058 crude material Substances 0.000 description 6
- 150000007529 inorganic bases Chemical class 0.000 description 6
- 239000012948 isocyanate Substances 0.000 description 6
- 150000002513 isocyanates Chemical class 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 238000000825 ultraviolet detection Methods 0.000 description 6
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 5
- ZPGVBVUVOXWXDJ-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine Chemical compound O1C(C)(C)C(C)(C)OB1C1=C2N=CC=CN2N=C1 ZPGVBVUVOXWXDJ-UHFFFAOYSA-N 0.000 description 5
- HQHSKXNZULRANW-UHFFFAOYSA-N 6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid Chemical compound ClC1=NC=C2C(C(=O)O)=NNC2=C1 HQHSKXNZULRANW-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- 108090000176 Interleukin-13 Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 239000004012 Tofacitinib Substances 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 125000004103 aminoalkyl group Chemical group 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 229960000215 ruxolitinib Drugs 0.000 description 5
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229960001350 tofacitinib Drugs 0.000 description 5
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- OZGSEIVTQLXWRO-UHFFFAOYSA-N 2,4,6-trichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=C(Cl)C=C1Cl OZGSEIVTQLXWRO-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 206010014950 Eosinophilia Diseases 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 229950000971 baricitinib Drugs 0.000 description 4
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 239000007822 coupling agent Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000005580 one pot reaction Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- 238000012799 strong cation exchange Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 3
- SFJMFSWCBVEHBA-UHFFFAOYSA-M copper(i)-thiophene-2-carboxylate Chemical compound [Cu+].[O-]C(=O)C1=CC=CS1 SFJMFSWCBVEHBA-UHFFFAOYSA-M 0.000 description 3
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000007247 enzymatic mechanism Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 238000010931 ester hydrolysis Methods 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000009520 phase I clinical trial Methods 0.000 description 3
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- VEKWVLWWZITZTK-UHFFFAOYSA-N 1,2-dimethylcyclohexane-1,2-diamine Chemical compound CC1(N)CCCCC1(C)N VEKWVLWWZITZTK-UHFFFAOYSA-N 0.000 description 2
- URTPNQRAHXRPMP-UHFFFAOYSA-N 1-phenylmethoxycarbonylpiperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C(=O)OCC1=CC=CC=C1 URTPNQRAHXRPMP-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 238000013313 FeNO test Methods 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- LMRGIWYBLKXQGS-UHFFFAOYSA-M dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane methanesulfonate palladium(2+) 2-phenylaniline Chemical compound [Pd+2].CS([O-])(=O)=O.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 LMRGIWYBLKXQGS-UHFFFAOYSA-M 0.000 description 2
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical group CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- XIWBSOUNZWSFKU-UHFFFAOYSA-N ethyl piperidine-3-carboxylate Chemical compound CCOC(=O)C1CCCNC1 XIWBSOUNZWSFKU-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N fumaric acid group Chemical group C(\C=C\C(=O)O)(=O)O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940125369 inhaled corticosteroids Drugs 0.000 description 2
- 210000004964 innate lymphoid cell Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- ZEUXAIYYDDCIRX-UHFFFAOYSA-N losartan carboxylic acid Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 ZEUXAIYYDDCIRX-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid group Chemical group C(\C=C/C(=O)O)(=O)O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid group Chemical group C(C(=O)O)(=O)O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- YPVIBMSSBSPICH-UHFFFAOYSA-N (1-methylpiperidin-4-yl) piperidine-4-carboxylate Chemical compound C1CN(C)CCC1OC(=O)C1CCNCC1 YPVIBMSSBSPICH-UHFFFAOYSA-N 0.000 description 1
- JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 1
- UTAHFAJHGGPJEQ-UHFFFAOYSA-N (2-phenylphenyl)phosphane Chemical compound PC1=CC=CC=C1C1=CC=CC=C1 UTAHFAJHGGPJEQ-UHFFFAOYSA-N 0.000 description 1
- JNUZADQZHYFJGW-JOCHJYFZSA-N (2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide Chemical compound FC=1C(=NC(=NC=1)NC1=C(C(=CC=C1)S(=O)(=O)C)F)C1=CNC2=C(C=CC=C12)NC([C@@H](COC)N1CCN(CC1)C)=O JNUZADQZHYFJGW-JOCHJYFZSA-N 0.000 description 1
- ZZJHCOUWDLIGPH-MMALYQPHSA-N (3S,4S)-4-fluoropyrrolidin-3-ol hydrochloride Chemical compound Cl.O[C@H]1CNC[C@@H]1F ZZJHCOUWDLIGPH-MMALYQPHSA-N 0.000 description 1
- QSIYYVYVUHTKQY-ZCFIWIBFSA-N (3r)-1-(2-fluoroethyl)pyrrolidin-3-ol Chemical compound O[C@@H]1CCN(CCF)C1 QSIYYVYVUHTKQY-ZCFIWIBFSA-N 0.000 description 1
- FLVFPAIGVBQGET-RXMQYKEDSA-N (3r)-1-methylpyrrolidin-3-ol Chemical compound CN1CC[C@@H](O)C1 FLVFPAIGVBQGET-RXMQYKEDSA-N 0.000 description 1
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 1
- VGTADGNSGCICTA-UHFFFAOYSA-N (4-methylmorpholin-2-yl)methanol Chemical compound CN1CCOC(CO)C1 VGTADGNSGCICTA-UHFFFAOYSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- ZMVSVQMWFTZSJQ-UHFFFAOYSA-N 1-benzylpiperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1CC1=CC=CC=C1 ZMVSVQMWFTZSJQ-UHFFFAOYSA-N 0.000 description 1
- JTLAIKFGRHDNQM-UHFFFAOYSA-N 1-bromo-2-fluoroethane Chemical compound FCCBr JTLAIKFGRHDNQM-UHFFFAOYSA-N 0.000 description 1
- BSSKDKZDQARXEH-UHFFFAOYSA-N 1-bromo-5-fluoro-4-methoxy-2-nitrobenzene Chemical compound COC1=CC([N+]([O-])=O)=C(Br)C=C1F BSSKDKZDQARXEH-UHFFFAOYSA-N 0.000 description 1
- MXUXZWFVAPTPAG-UHFFFAOYSA-N 1-methoxy-2-methylpropan-2-ol Chemical compound COCC(C)(C)O MXUXZWFVAPTPAG-UHFFFAOYSA-N 0.000 description 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
- XSGMJDQRZDWEPW-UHFFFAOYSA-N 1-propan-2-ylazetidin-3-ol Chemical compound CC(C)N1CC(O)C1 XSGMJDQRZDWEPW-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- RPTBUKFXLSZAKD-UHFFFAOYSA-N 2-bromoethylcarbamic acid Chemical compound OC(=O)NCCBr RPTBUKFXLSZAKD-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- JKRSQNBRNIYETC-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-ol Chemical compound CN1CCN(CCCO)CC1 JKRSQNBRNIYETC-UHFFFAOYSA-N 0.000 description 1
- PYSGFFTXMUWEOT-UHFFFAOYSA-N 3-(dimethylamino)propan-1-ol Chemical compound CN(C)CCCO PYSGFFTXMUWEOT-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- MMJQJSQOTGZCHX-UHFFFAOYSA-N 3-hydroxycyclobutane-1-carbonitrile Chemical compound OC1CC(C#N)C1 MMJQJSQOTGZCHX-UHFFFAOYSA-N 0.000 description 1
- MTMGQKFGZHMTTK-UHFFFAOYSA-N 3-methoxypyrazin-2-amine Chemical compound COC1=NC=CN=C1N MTMGQKFGZHMTTK-UHFFFAOYSA-N 0.000 description 1
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 1
- NDYHLSOVAPQOPI-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,3]thiazolo[4,5-c]pyridine Chemical compound C1NCCC2=C1N=CS2 NDYHLSOVAPQOPI-UHFFFAOYSA-N 0.000 description 1
- LMOOYAKLEOGKJR-UHFFFAOYSA-N 4-(bromomethyl)oxane Chemical compound BrCC1CCOCC1 LMOOYAKLEOGKJR-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- SRQJSMFCZYZSLB-UHFFFAOYSA-N 5,6,7,8-tetrahydro-1,7-naphthyridine Chemical compound C1=CN=C2CNCCC2=C1 SRQJSMFCZYZSLB-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- ZGCFHYKQHHBJJZ-UHFFFAOYSA-N 6-chloro-1h-pyrazolo[4,3-c]pyridin-3-amine Chemical compound ClC1=NC=C2C(N)=NNC2=C1 ZGCFHYKQHHBJJZ-UHFFFAOYSA-N 0.000 description 1
- XLJYIYIBJUWRLF-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-2h-1,4-benzoxazine Chemical compound O1CCNC2=CC(OC)=CC=C21 XLJYIYIBJUWRLF-UHFFFAOYSA-N 0.000 description 1
- HYPXPTICMYBXMR-UHFFFAOYSA-N 7-bromo-6-methoxy-3,4-dihydro-2H-1,4-benzoxazine Chemical compound COC1=CC2=C(OCCN2)C=C1Br HYPXPTICMYBXMR-UHFFFAOYSA-N 0.000 description 1
- WDKNRIQDGSVRBO-UHFFFAOYSA-N 7-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound C1CCNC2=CC(OC)=CC=C21 WDKNRIQDGSVRBO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004229 Alkannin Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 101100087530 Caenorhabditis elegans rom-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000005750 Corey-Bakshi-Shibata reduction reaction Methods 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 101710181613 Interleukin-31 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 229940125772 JTE-052 Drugs 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 101100305983 Mus musculus Rom1 gene Proteins 0.000 description 1
- ITNFPSJJBYFVEA-UHFFFAOYSA-N N-[3-[5-chloro-2-(difluoromethoxy)phenyl]-1-[2-[4-[2-cyanoethyl(methyl)amino]piperidin-1-yl]-2-oxoethyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=NN(C=C1NC(=O)C=1C=NN2C1N=CC=C2)CC(=O)N2CCC(CC2)N(C)CCC#N)OC(F)F ITNFPSJJBYFVEA-UHFFFAOYSA-N 0.000 description 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920000538 Poly[(phenyl isocyanate)-co-formaldehyde] Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 102000015774 TYK2 Kinase Human genes 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- 238000010751 Ullmann type reaction Methods 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UXRDAJMOOGEIAQ-CKOZHMEPSA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-10,13-dimethyl-16-methylidene-3-oxo-1,2,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UXRDAJMOOGEIAQ-CKOZHMEPSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- UAHVOECKJGGQPK-UHFFFAOYSA-N [3-(2-methoxy-2-oxoethyl)phenyl]methylazanium;chloride Chemical compound Cl.COC(=O)CC1=CC=CC(CN)=C1 UAHVOECKJGGQPK-UHFFFAOYSA-N 0.000 description 1
- BXKSGDDGASLCQF-UHFFFAOYSA-N [N].C1COCCO1 Chemical compound [N].C1COCCO1 BXKSGDDGASLCQF-UHFFFAOYSA-N 0.000 description 1
- ADROLXVDPJSKRZ-UHFFFAOYSA-N [[(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium Chemical compound CCOC(=O)C(C#N)=NO[C+](N(C)C)N1CCOCC1 ADROLXVDPJSKRZ-UHFFFAOYSA-N 0.000 description 1
- GPDHNZNLPKYHCN-DZOOLQPHSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCOC(=O)C(\C#N)=N/OC(=[N+](C)C)N1CCOCC1 GPDHNZNLPKYHCN-DZOOLQPHSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 1
- FDIRIOAEXPIEBL-UHFFFAOYSA-L copper;thiophene-2-carboxylate Chemical compound [Cu+2].[O-]C(=O)C1=CC=CS1.[O-]C(=O)C1=CC=CS1 FDIRIOAEXPIEBL-UHFFFAOYSA-L 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- LOWWYYZBZNSPDT-ZBEGNZNMSA-N delgocitinib Chemical compound C[C@H]1CN(C(=O)CC#N)[C@@]11CN(C=2C=3C=CNC=3N=CN=2)CC1 LOWWYYZBZNSPDT-ZBEGNZNMSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000011982 enantioselective catalyst Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- FDWYQACDSWSSAS-UHFFFAOYSA-N ethyl 1-(2-aminoethyl)piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCN(CCN)CC1 FDWYQACDSWSSAS-UHFFFAOYSA-N 0.000 description 1
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 1
- KTVUZBJHOAPDGC-UHFFFAOYSA-N ethyl 3-hydroxycyclobutane-1-carboxylate Chemical compound CCOC(=O)C1CC(O)C1 KTVUZBJHOAPDGC-UHFFFAOYSA-N 0.000 description 1
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003487 fedratinib Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 229950006663 filgotinib Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910001853 inorganic hydroxide Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 150000003951 lactams Chemical group 0.000 description 1
- 208000017804 lesions in lung Diseases 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VVBSXSVVMNGQIN-UHFFFAOYSA-N methyl pyrrolidine-3-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1CCNC1 VVBSXSVVMNGQIN-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005648 named reaction Methods 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000012041 precatalyst Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960000697 propantheline Drugs 0.000 description 1
- KQLLAOIBGJBQCJ-UHFFFAOYSA-N propyl 2-(methylamino)acetate Chemical compound CCCOC(=O)CNC KQLLAOIBGJBQCJ-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RPDWRWNLPKMAFW-UHFFFAOYSA-N tert-butyl 7-methoxy-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound C1CCN(C(=O)OC(C)(C)C)C2=CC(OC)=CC=C21 RPDWRWNLPKMAFW-UHFFFAOYSA-N 0.000 description 1
- TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- the present invention relates to chemical compounds that are derivatives useful as JAK inhibitors, such as JAK 1, useful for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
- the JAK family consists of non-receptor tyrosine protein kinases and has four main members, JAK1, JAK2, JAK3, and TYK2. More than 50 cytokines and growth factors bind to type I and II receptors noncovalently associated with different combinations of JAK kinases.
- the signalling triggered by the ligands consists in tyrosine phosphorylation of receptors by JAK and recruitment of one or more STATs proteins. Tyrosine-phosphorylated STATs dimerize and are then transported into the nucleus through the nuclear membrane to regulate specific genes. JAKs have seven homology domains (the JAK homology domain, JH).
- JH1 is the first JH, known as the kinase domain, and is composed of approximately 250 amino acid residues.
- JH1 encodes a kinase protein that constitutes the kinase structure domain that phosphorylates a substrate;
- JH2 is a pseudokinase domain which regulates the activity of the kinase domain.
- JAK3 is expressed in the bone marrow and lymphatic system, as well as endothelial cells and vascular smooth muscle cells; other members are expressed in almost all tissues (Hu X et al., Signal Transduct Target Ther. 2021, 26;6(l):402).
- JAK/STAT signalling Many cellular processes are downstream JAK/STAT signalling: hematopoiesis, immune balance, tissue repair, inflammation, apoptosis, and adipogenesis. Different biological responses are regulated by specific pairing of JAK isoforms. JAK1/JAK3 combination mediates IL-2, -4, -7, -9, -15, and -21 signalling that is relevant for growth/maturation of lymphoid cells, differentiation/homeostasis of T-cells/NK cells, B-cell class switching and other inflammatory processes.
- JAK1/TYK2-JAK1/JAK2 regulate the signal associated with the innate immune response, such as IL-6 and the type I interferons, involved into naive T cell differentiation, T cell homeostasis, granulopoiesis and other inflammatory processes.
- JAK2 frequently associates with itself (JAK2/ JAK2) controlling the signalling of various cytokines and growth factors, such as IL-3, IL-5, granulocyte macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), and thrombopoietin (TPO) (Hodge et al., Clin Exp Rheumatol 2016; 34(2):318-28).
- cytokines and growth factors such as IL-3, IL-5, granulocyte macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), and thrombopoietin (TPO)
- JAK/STAT pathways in immune fitness.
- overexpression or mutations involving some JAK isoforms as well as aberrant JAK/STAT signalling drive malignancies of hematopoietic and lymphoid tissues as well as inflammatory disorders.
- FDA Food and Drug Administration
- EU- approved JAK inhibitors are in clinical use.
- Two (ruxolitinib and fedratinib) small molecules are in use for hematologic disorders as myelofibrosis and polycythemia vera; six JAK inhibitors (tofacitinib, baricitinib, ruxololitinib, filgotinib, upadicitinib and delgocitinib in Japan) result in use for immune-mediated disorders as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and acute graft-versus-host disease.
- the small molecules targeting JAK/STAT represent an attractive option also for the therapy of fibrotic disorders.
- inflammatory cytokines IL-4, IL-3, IL-6, IL-11, IL-31, etc
- growth factors FGF, VEGF, etc.
- Ruxolitinib tested in a bleomycin-induced fibrosis mouse model ameliorated the fibrotic lesions in lung, and reduced levels of fibrotic molecular markers (Zhang, Y et al., Ann. Rheum. Dis.
- Baricitinib was demonstrated to be a safe immune modulator that reduces the biomarkers’ levels of lung fibrosis and inflammation in RA patients, including a subgroup with interstitial lung disease (D’ Alessandro M et al., Int. Immunopharmacol. 2020, 86, 106748).
- JAK inhibitors In COVID-19, there are some JAK inhibitors undergoing clinical trials, and they are tofacitinib, baricitinib, and ruxolitinib. Baricitinib and ruxolitinib were associated with a reduced risk of mortality. They reduced the use of invasive mechanical ventilation and had a borderline impact on the admission rate of the intensive care unit and the incidence of acute respiratory distress syndrome (ARDS). (Wijaya, I. et al. Clin. Epidemiol. Glob. Health 2021, 11, 100755). Ruxolitinib also was tested in COVID-19 patients, and improved the clinical symptoms and chest computed tomography images (Cao Y. et al., J. Allergy Clin. Immunol. 2020 146, 137-146).
- Asthma can be included in the plethora of immune-mediated diseases for which pathogenesis is characterized by an essential role of JAK/STAT signalling. Asthma is a chronic inflammatory disease of the airways due to a complex interplay between immune response, genetic susceptibility and nonspecific external stimuli like cold, allergens and exercise leading to hyperresponsiveness, remodelling of the airways, ultimately contributing to airflow limitation. Severe asthma affects 5% to 15% of the population with adult asthma (which is 300 million people worldwide) and represents a public health issue associated with increased mortality, increased hospitalizations, significant burden of symptoms, health care costs, and missed work and school (Steve NG et al., J Allergy Clin Immunol 2021;148:953-63).
- Severe asthma represents a subset of difficult-to-treat asthma and occurs in patients whose disease remains uncontrolled despite the use of high doses of inhaled corticosteroids (ICSs) combined with long-acting P-agonists or other controllers.
- ICSs inhaled corticosteroids
- four types of biologies are licensed for severe asthma, i.e. omalizumab (anti -immunoglobulin E) antibody, mepolizumab and reslizumab (anti-interleukin [IL]-5antibody), benralizumab (anti-IL- 5 receptor a antibody) and dupilumab (anti-IL-4 receptor alpha antibody).
- the type 2 pathway is defined by activation of cytokines derived from TH2 cells and group 2 innate lymphoid cells (ILC2s); these include IL-4, IL-5, and IL-13 that cause airway inflammation by activating eosinophils, B cells, airway epithelial cells, and other cell types
- cytokines derived from TH2 cells and group 2 innate lymphoid cells include IL-4, IL-5, and IL-13 that cause airway inflammation by activating eosinophils, B cells, airway epithelial cells, and other cell types
- Biomarkers of type 2 asthma include blood/sputum eosinophilia and elevated levels of fractional exhaled nitric oxide (FENO) and IgE.
- Type 2-low asthma is characterized by absence of type 2-high cytokines and biomarkers, and it manifests either increased levels of neutrophils in the airways or a paucigranulocytic profile, with normal levels of airway neutrophils and eosinophils.
- Type 2-low asthma is currently not well understood, and it likely encompasses multiple distinct endotypes.
- T2 low endotypes under investigation include IL-6, IL- 17A/F, IL-23, Type I interferons, CXCL10, TNF, alarmins (TSLP, IL-25, IL-33), IL-lp, IL-8, IFN-y (Hinks TSC et al., ERJ 2021, 57 (1) 2000528).
- JAK/STAT pathway Almost all the mediators mentioned above both for T2 and T2-low endotypes activate JAK/STAT pathway, here the rationale for the potential use of JAK inhibitors in both endotypes of severe asthma. Targeting simultaneously several cytokines by JAK inhibitors may offer advantage over the biologies (for no-responder patients) and standard therapies (for patients who remain uncontrolled) considering their administration on top of ICS.
- JAK1/3 inhibitor R256 (now referred as AZD0449) orally given showed be effective in decreasing airway resistance, BAL eosinophilia, mucus production and if administered during sensitization, also TH2 cytokine responses (Ashino S et al., J Allergy Clin Immunol 2014; 133: 1162-74).
- iJak-381 from Genentech given as dry powder reduced BAL eosinophilia, CCL11, airway resistance, and Muc5AC in OVA- challenged mice.
- COPD Chronic obstructive pulmonary disease
- IL-6 IL-6, IFN-y, IL-2, etc.
- Phosphorylated-STAT4+ cells were found to be increased in COPD compared to non- smokers healthy controls.
- a JAKi should preferably possess additional properties that may further limit the systemic exposure after inhalation.
- JAK inhibitors and particularly inhaled JAK inhibitors that have potential for giving compounds with an improved safety.
- JAK enzymes In view of the number of pathological responses which are mediated by JAK enzymes, there is a continuing need for inhibitors of JAK enzymes which can be useful in the treatment of many disorders and particularly respiratory diseases.
- n, K, V and Q and Ri are as defined in the detailed description of the invention; or a pharmaceutically acceptable salt thereof, that are useful as JAK kinase inhibitors.
- the present invention provides a compound of formula (I) for use as a medicament. In one aspect the present invention provides the use of a compound of the invention for the manufacture of a medicament.
- the present invention provides the use of a compound of the invention for the preparation of a medicament for the treatment of any disease associated with JAK enzyme mechanisms.
- the present invention provides a method for prevention and/or treatment of any disease associated with JAK enzyme mechanisms as above defined, said method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of the invention.
- the compounds of the invention are used alone or combined with other active ingredients and may be administered for the prevention and/or treatment of a pulmonary disease including asthma, Chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), interstitial lung diseases and idiopathic pulmonary fibrosis (IPF), acute lung injury and acute espiratory distress syndrome (ARDS).
- COPD chronic obstructive pulmonary disease
- COPD chronic obstructive pulmonary disease
- CF cystic fibrosis
- IPF interstitial lung diseases and idiopathic pulmonary fibrosis
- ARDS acute lung injury and acute espiratory distress syndrome
- salts refers to derivatives of compounds of formula I) wherein the parent compound is suitably modified by converting any of the free acid or basic group, if present, into the corresponding addition salt with any base or acid conventionallyntended as being pharmaceutically acceptable.
- Suitable examples of said salts may thus include mineral or organic acid addition salts of basic residues such as amino groups, as well as mineral or organic basic addition salts of acid esidues such as carboxylic groups.
- Cations of inorganic bases which can be suitably used to prepare salts of the invention comprise ions of alkali or alkaline earth metals such as potassium, sodium, calcium or magnesium.
- Those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt comprise, for example, salts of hydrochloric, hydrobromic, sulfuric, phosphoric, methane sulfonic, camphor sulfonic, acetic, oxalic, maleic, fumaric, succinic and citric acids.
- Many organic compounds can form complexes with solvents in which they are reacted or rom which they are precipitated or crystallized. These complexes are known as “solvates” which are a further object of the invention.
- Polymorphs and crystalline forms of compounds of formula I), or of pharmaceutically acceptable salts, or solvates thereof are a further object of the invention.
- Halogen or “Halo-“ or “halogen atoms” includes fluorine, chlorine, bromine, and iodine atom ; meaning Fluoro, Chloro, Bromo, Iodo as substituent.
- (C 1 -C 6 )Alkyl refers to straight-chained or branched alkyl groups wherein the number of carbon atoms is in the range 1 to 6. Particular alkyl groups are for example methyl, ethyl, n-propyl, isopropyl, t-butyl, 3-methylbutyl and the like.
- (C 1 -C 6 )Haloalkyl refer to the above defined “(C 1 -C 6 )alkyl” groups wherein one or more hydrogen atoms are replaced by one or more halogen atoms, which can be the same or different from each other. Examples include halogenated, poly-halogenated and fully halogenated alkyl groups wherein all of the hydrogen atoms are replaced by halogen atoms, e.g. trifluoromethyl or difluoro methyl groups.
- (C1-Cx) hydroxyalkyl or “(C1-Cx) aminoalkyl” refer to the above defined “(C 1 -C x ) alkyl” groups wherein one or more hydrogen atoms are replaced by one or more hydroxy (OH) or amino group respectively, and wherein x is an integer up to 10.
- (C 1 - C 6 )hydroxyalkyl or “(C 1 -C 6 )aminoalkyl” refers to said hydroxy- or amino-alkyl groups wherein the number of carbon atoms is in the range 1 to 6.
- the definition of aminoalkyl encompasses alkyl groups (i.e.
- (C 1 -C 6 )alkyl groups substituted by one or more amino groups (-NR 4 R 5 ).
- An example of aminoalkyl is a mono- aminoalkyl group such as R 4 R 5 N-(C 1 -C 6 )alkyl, or –(CH 2 ) m NR 4 R 5 .
- R 4 and R 5 and m are as defined in the detailed description of the invention.
- the said heterocyclic radical might be further optionally substituted on the available points in the ring, namely on a carbon atom, or on an heteroatom or hetero-group available for substitution.
- heterocycle radicals are 1-pyrrolidinyl, 1- piperidinyl, 1-piperazinyl, 4-morpholinyl, piperazin-4yl-2-one, 4-methylpiperazine-1-yl.
- (C 3 -C 10 )cycloalkyl likewise “(C 3 -C 6 )cycloalkyl” refers to saturated cyclic hydrocarbon groups containing the indicated number of ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and polycyclic ring systems such as adamantan-yl.
- Aryl refers to mono, bi- or tri-cyclic carbon ring systems which have 6 to 20, preferably from 6 to 15 ring atoms, wherein at least one ring is aromatic.
- heteroaryl refers to mono-, bi- or tri-cyclic ring systems with 5 to 20, preferably from 5 to 15 ring atoms, in which at least one ring is aromatic and in which at least one ring atom is a heteroatom (e.g. N, S or O).
- aryl or heteroaryl monocyclic ring systems include, for instance, phenyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furanyl radicals and the like.
- aryl or heteroaryl bicyclic ring systems include naphthalenyl, biphenylenyl, purinyl, pteridinyl, pyrazolopyrimidinyl, benzotriazolyl, benzoimidazole-yl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, indazolyl, benzothiopheneyl, benzodioxinyl, dihydrobenzodioxinyl, indenyl, dihydro-indenyl, dihydrobenzo[1,4]dioxinyl, benzothiazole-2-yl, dihydrobenzodioxepinyl, benzooxazinyl, 1,2,3,4-tetrahydroisoquinoline-6-yl, 4,5,6,7- tetrahydrothiazolo[4,5-c]pyridine, 4,5,6,7-tetrahydrobenzo
- aryl or heteroaryl tricyclic ring systems include fluorenyl radicals as well as benzocondensed derivatives of the aforementioned heteroaryl bicyclic ring systems.
- heterocycloalkyl i.e. heterocyclic radical or group
- Said heterocycloalkyl is further optionally substituted on the vailable points in the ring, namely on a carbon atom, or on an heteroatom available for ubstitution.
- Substitution on a carbon atom includes spiro disubstitution as well as substitution on two djacent carbon atoms, in both cases thus form additional condensed 5 to 6 membered heterocyclic ing.
- Examples of (C 3 -C 6 ) heterocycloalkyl are represented by: oxetanyl, tetrahydro-furanyl, pyrrolidinyl, imidazolidinyl, thiazolidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, dihydro- or tetrahydro-pyridinyl, tetrahydropyranyl, pyranyl, 2H- or 4H-pyranyl, dihydro- oretrahydrofuranyl, dihydroisoxazolyl, pyrrolidin-2-one-yl, dihydropyrrolyl, 5-oxopyrrolidin-3-yl, 1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl, 1,1-dioxidothiomorpholino, octahydrocyclopenta[c]pyrrol-5-yl, 4,5
- heterocycle radicals are 1-methyl-2-pyrrolidinyl, 1-piperidinyl, 1- piperazinyl, 4-morpholinyl, piperazin-4-yl-2-one, 4-methylpiperazine-1-yl, 1-methylpiperidin-4- yl, 4-metylpiperazine-1-yl-2-one, 7-methyl-2,7-diazaspiro[3.5]nonan-2-yl, 2-methyl-2,9- diazaspiro[5.5]undecan-9-yl, 9-methyl-3,9-diazaspiro[5.5]undecan-3-yl, and (3aR,6aS)-5-methyl- octahydropyrrolo[3,4-c]pyrrol-2-yl.
- Aryl(C 1 -C 6 )alkyl refers to an aryl ring linked to a straight-chained or branched lkyl group wherein the number of constituent carbon atoms is in the range from 1 to 6, e.g. phenylmethyl (i.e. benzyl), phenylethyl or phenylpropyl.
- Heteroaryl(C 1 -C 6 )alkyl refers to an heteroaryl ring linked to a straight-packedd or branched alkyl group wherein the number of constituent carbon atoms is in the range rom 1 to 6, e.g. furanylmethyl.
- alkanoyl refers to HC(O)- or to alkylcarbonyl groups (e.g. (C 1 -C 6 )alkylC(O)-) wherein the group “alkyl” has the meaning above defined. Examples include formyl, acetyl, propanoyl, butanoyl.
- alkylcarbonyl groups e.g. (C 1 -C 6 )alkylC(O)-
- alkyl has the meaning above defined. Examples include formyl, acetyl, propanoyl, butanoyl.
- (C 1 -C 6 )Alkylthio refers to the above hydrocarbon linked through a sulfur bridge.
- the derived expression “(C 1 -C 6 )haloalkoxy” or “(C 1 -C 6 )haloalkoxyl” refers to the above defined haloalkyl, linked through an oxygen bridge.
- Example of (C 1 -C 6 )haloalkoxy is difluoromethoxy, trifluoromethoxy.
- (C 3 -C 6 )heterocycloalkyl-(C 1 -C 6 )alkyl and “(C 3 - C 6 )cycloalkyl-(C 1 -C 6 )alkyl” refer to the above defined heterocycloalkyl and cycloalkyl groups linked to the rest of the molecule via an alkyl group of the indicated number of carbons, for example piperidin-4-yl-methyl, cyclohexylethyl.
- (C 1 -C 6 )alkoxy (C 1 -C 6 )alkyl refers to the above defined alkoxy group linked to the rest of the molecule via an alkyl group of the indicated number of carbons, for example methoxymethyl.
- (C 1 -C 6 )haloalkoxy(C 1 -C 6 )alkyl refers to the above defined (C 1 -C 6 )haloalkoxy” group linked to the rest of the molecule via an alkyl group of the indicated number of carbons, for example difluoromethoxypropyl.
- (C 1 -C 6 )alkoxycarbonyl refers to the above defined alkoxy group linked to the rest of the molecule via an carbonyl group.
- (C 1 -C 6 )alkoxycarbonyl-(C 1 -C 6 )alkyl refers to the above defined alkoxy group linked to the rest of the molecule via an carbonyl group further enchained with an alkyl group of the indicated number of carbons, for example methoxycarbonylmethyl.
- (C 1 -C 6 )alkoxycarbonyl-(C 1 -C 6 )alkylthio consequently refer to the indicated enchained groups like methoxycarbonylmethylthio.
- Other derived expression will be apparent in their meaning e.g. “halo-((C 1 -C 6 )alkyl(C 3 -C 8 )heterocycloalkyl)” refer to enchained groups like 4-fluoro-1- methylpyrrolidin-3-yl.
- bracketed group is a lateral group, not included into the chain, and brackets are used, when deemed useful, to help disambiguating linear chemical formulas; e.g. the sulfonyl group -SO2- might be also represented as–S(O)2– to disambiguate e.g. with respect to the sulfinic group –S(O)O–.
- physiological acceptable anions selected among chloride, bromide, iodide, trifluoroacetate, formate, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, p-toluenesulfonate, pamoate and naphthalene disulfonate may be present.
- acidic groups such as COOH groups
- physiological cation salts may be present as well, for instance including alkaline or alkaline earth metal ions.
- Compounds of formula (I) when they contain one or more stereogenic center may exist as optical stereoisomers. Where the compounds of the invention have at least one stereogenic center, they may accordingly exist as enantiomers. Where the compounds of the invention possess two or more stereogenic centers, they may additionally exist as diastereoisomers. It is to be understood that all such single enantiomers, diastereoisomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
- the absolute configuration (R) or (S) for carbon bearing a stereogenic center is assigned on the basis of Cahn-Ingold-Prelog nomenclature rules based on groups’ priorities.
- Single stereoisomer when reported near the chemical name of a compound indicate that the isomer was isolated as single diastereoisomer or enantiomer (e.g via chiral chromatography) but the absolute configuration at the relevant stereogenic center was not determined/assigned.
- Atropisomers result from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers (Bringmann G et al, Angew. Chemie Int. Ed. 44 (34), 5384-5427, 2005. doi:10.1002/anie.200462661).
- Atropisomers as conformers that interconvert with a half-life of more than 1000 seconds at a given temperature (Oki M, Topics in Stereochemistry 14, 1-82, 1983).
- Atropisomers differ from other chiral compounds in that in many cases they can be equilibrated thermally whereas in the other forms of chirality isomerization is usually only possible 35 chemically. Separation of atropisomers is possible by chiral resolution methods such as selective crystallization. In an atropo-enantioselective or atroposelective synthesis one atropisomer is formed at the expense of the other.
- Atroposelective synthesis may be carried out by use of chiral auxiliaries like a Corey Bakshi Shibata (CBS) catalyst, an asymmetric catalyst derived from proline, or by approaches based on thermodynamic equilibration when an isomerization reaction favors one atropisomer over the other.
- CBS Corey Bakshi Shibata
- Racemic forms of compounds of formula (I) as well as the individual atropisomers (substantially free of its corresponding enantiomer) and stereoisomer-enriched atropisomer mixtures are included in the scope of the present invention.
- the invention further concerns the corresponding deuterated derivatives of compounds of formula (I).
- deuterated derivative means that at least one position occupied by a hydrogen atom is occupied by deuterium in an amount above its natural abundance.
- the percent of deuterium at that position is at least 90%, more preferably at least 95%, even more preferably 99%.
- All preferred groups or embodiments described above and here below for compounds of formula (I) may be combined among each other and apply as well mutatis mutandis.
- the present invention provides compounds of general formula (I), acting as JAK inhibitors, to processes for the preparation thereof, pharmaceutical compositions comprising them either alone or in combination with one or more active ingredient, in admixture with one or more pharmaceutically acceptable carriers.
- the present invention provides compounds of formula (I) I wherein 25 R 1 is selected from pyrazolo[1,5-a]pyrimidin-3-yl and (3-oxo-3,4-dihydropyrazin-2- yl)amino; graphically represented respectively by compounds of formula I-1 or I-2 I-2 wherein the substituent group is comprising at least one ester or thioester moiety (i.e.
- V is a divalent group selected from C(O)O, C(O)N(R 6 ), N(R 6 )C(O)O
- Q is selected from the group consisting of (C 1 -C 6 )alkoxycarbonyl, -(CH 2 ) m NR 4 R 5 , (C 3 - C 8 )cycloalkyl and (C 3 -C 6 )heterocycloalkyl; wherein said (C 3 -C 8 )cycloalkyl and (C 3 - 15 C 6 )heterocycloalkyl are optionally substituted by one or more substituent group selected from the group consisting of (C 1 -C 6 )alkoxycarbonyl(CH 2 ) m , that is preferably (C 1 -C 6 )alkoxycarbonyl (when m is zero), (C3-C8)cycloalkyl-oxycarbonyl, NC-(C1-
- Preferred, in the above group are compounds of formula I-1 wherein K is O; represented by the formula (Ia) Ia wherein V is C(O)N(R 6 ), Q is (C 3 -C 6 )heterocycloalkyl, preferably a piperidine moiety, substituted by a group selected from (C 1 -C 6 )alkoxycarbonyl, (C 3 -C 8 )cycloalkyl-oxycarbonyl, NC-(C 1 -C 6 ) alkoxycarbonyl, (C 1 - C 6 )haloalkyl-oxycarbonyl, (C 1 -C 6 )alkyl(C 3 -C 8 )heterocycloalkyl-oxycarbonyl, (C 1 - C 6 )hydroxyalkyl -oxycarbonyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl -oxycarbonyl and (C 1 - C 6 )alkylthi
- Particularly preferred compounds in this embodiment are: - c]pyridine-3-carboxamido)ethyl)piperidine-4-carboxylate
- Example C hemical Name A further preferred embodiment in the above group of compounds of formula (I) is that wherein V is a divalent group C(O)O; Q is selected from the group consisting of (C 1 -C 6 )alkoxycarbonyl, -(CH 2 ) m NR 4 R 5 , and (C 3 - C 6 )heterocycloalkyl optionally substituted by one or more group selected from (C 1 -C 10 )alkyl and halogen; n and m are in each occurrence independently 0 or an integer selected from 1, 2, 3 and 4; R 4 and R 5, the same or different, are selected from the group consisting of -H, (C 1 -C 6 )alkyl, single enantiomers, diastereoisomers and mixtures thereof or a pharmaceutically acceptable salt or solvate thereof
- V is a divalent group selected from N(R6)C(O)O
- Q is selected from the group consisting of (C 1 -C 6 )alkoxycarbonyl
- 20 n is an integer selected from 1, 2, 3 and 4
- R6 is in each occurrence independently selected from the group consisting of H, (C 1 -C 6 )alkyl; single enantiomers, diastereoisomers and mixtures thereof or a pharmaceutically acceptable salt or solvate thereof.
- V is a divalent group selected from C(O)N(R 6 );
- Q is (C 3 -C 6 )heterocycloalkyl substituted by one (C 1 -C 6 )alkoxycarbonyl(CH 2 ) m ;
- n is an integer selected from 1, 2, 3 and 4;
- R 6 is in each occurrence independently selected from the group consisting of H, (C1-C6)alkyl; single enantiomers, diastereoisomers and mixtures thereof or a pharmaceutically acceptable salt or solvate thereof.
- the present invention provides the compounds of examples 1-59, as listed in the table below, or pharmaceutical acceptable salts and solvates thereof.
- Preferred compounds showed a drop of at least 10 fold or more in the functional activity 5 (such as inhibition of pSTAT6 in BEAS cells stimulated with IL-13) of the predicted carboxylic acid metabolite. More preferred compounds showed a drop even higher than 100 fold, even more preferred higher than 200 fold. Even more preferred are compounds according to the invention that, in addition to the previous properties, show an high clearance at least in in-vitro stability assays in human and/or mice representative tissues as for example liver microsomes, and/or hepatocytes, and/or plasma, with an half-life less than or equal to 30 min using well established and validated assays. Those assays were adapted from literature methods (Kevin J.
- the compounds of the invention can be prepared from readily available starting materials using general methods and procedures as described in the experimental part below or by using slightly modified processes readily available to those of ordinary skill in the art. Although a particular embodiment of the present invention may be shown or described herein, those skilled in the art will recognize that all embodiments or aspects of the present invention can be prepared using the methods described herein or by using other known methods, reagents and starting materials. When typical or preferred process conditions (i.e. reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated.
- process conditions i.e. reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.
- I-2 Compounds of formula (I-1) can be prepared according to scheme 1 starting from intermediates of formula IIa (or IIb, or IIc) by removing of PG 1 by mean of procedures well known to those skilled in the art.
- a suitable protective group for protecting secondary amines of intermediates IIa (or IIb, or IIc) can be carbamate type protective groups such as Boc (tert- butoxycarbonyl). Boc group can be easily removed by treating Boc protected intermediate IIa (or IIb, or IIc) in acidic conditions with an organic or an inorganic strong acid.
- Boc group can be cleaved by treating the intermediates with trifluoroacetic acid neat or in mixture with an organic solvent such as DCM, DCE, THF or similar, typically at room temperature overnight.
- the group Q' present in intermediates of formula IIa is a group of formula Q that can undergo a single step functional group interconversion to generate a compound of formula I-1.
- Example 43, 44 and 45 were prepared from example 29, 30 and 9 respectively by transesterification with an appropriate alcohol to provide the desired ester.
- a transesterification reaction can be carried out by reacting parent ester with an excess of the desired alcohol, in the presence of a strong inorganic acid such as sulfuric acid or hydrochloric acid, by heating at high temperature or up to boiling point of the alcohol.
- Intermediate IIa (or IIb, or IIc) can be obtained by direct introduction of pyrazolo[1,5- a]pyrimidin-3-yl moiety through a metal/palladium catalyzed cross coupling reaction such as Suzuki coupling, Stille coupling or similar (Strategic application of named reactions in organic synthesis, L. Kurti, B. Czako, Ed. 2005) by reaction of intermediate IIIa (or respectively IIIb or IIIc) with intermediate VI.
- a metal/palladium catalyzed cross coupling reaction such as Suzuki coupling, Stille coupling or similar (Strategic application of named reactions in organic synthesis, L. Kurti, B. Czako, Ed. 2005) by reaction of intermediate IIIa (or respectively IIIb or IIIc) with intermediate VI.
- a suitable palladium catalyzed cross coupling for introducing pyrazolo[1,5-a]pyrimidin-3-yl moiety can be performed by reacting intermediate IIIa (or IIIb, or IIIc) with the corresponding boronic acid or boron pinacolate (intermediate VI, where A is dihydroxyboryl or 4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl) in the presence of a palladacycle precatalyst as XPhos-Pd-G3 [(2-Dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′- amino-1,1′-biphenyl)]palladium(II) methanesulfonate], or in the presence of Pd catalyst such as tetrakistriphenylphosphinepalladium(0) or PdCl 2 (dppf)
- Boronic acid and boronic pinacolate esters are generally commercially available or may be readily prepared by those skilled in the art starting from commercially available reagents.
- Intermediates of formula IIIa may be obtained from intermediate IVa by means of amide coupling with the corresponding amine Va.
- An amide coupling can be performed by reacting the amine and the acid in an organic solvent like DMF, DCM, or THF, in the presence of a coupling agent like HATU((1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate), HBTU (O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate) or COMU ((1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino- morpholino-carbenium) and in the presence of an organic base like DIPEA, TEA, or pyridine.
- a coupling agent like HATU((1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b
- Intermediate of formula IIIb may be obtained from intermediate IVa and an alcohol intermediate Vb through a two steps / one pot process that involves: 1) Acylazide formation and Curtius rearrangement to give an isocyanate intermediate and 2) one pot reaction of isocyanate 35 with alcohol Vb to form the corresponding carbamate.
- the corresponding acyl azide of intermediate IIIb can be prepared by reaction with an azide source as azido(trimethyl)silane, in the presence of a suitable coupling agents such as T3P and with an organic base like TEA or DIPEA, in an organic solvent such as 2-methyl-THF, DMF or toluene.
- intermediate IIIb may be prepared from intermediate IVb and intermediate Vb by a two steps / one pot process that involve: 1) isocyanate formation and 2) one pot reaction with alcohol Vb to form the corresponding carbamate.
- Intermediate IVb can be reacted with bis(trichloromethyl) carbonate in an organic solvent as DCM or THF, at low temperature like dry ice temperature (-78oC), in the presence of an organic base like TEA or DIPEA for times up to 1 or 2 hours to form the corresponding isocyanate; addition of intermediate Vb and reaction at room temperature lead to the formation of carbamate of formula IIIb.
- intermediate IIa may be obtained from intermediate VIIa and intermediate Va by an amide coupling using the same procedure described above for intermediate IIIa from IVa and Va.
- intermediate IIc may be obtained from intermediate VIIa and intermediate Vb by esterification reaction promoted by a coupling agent like EDC (1-etil-3-(3- dimetilamminopropil)carbodiimmide) or DIC (N, N′-diisopropilcarbodiimmide), in an organic solvent as DCM or THF, in the presence of an organic base like DMAP or pyridine, at room temperature for few hours (typically 2-4 hours).
- EDC 1-etil-3-(3- dimetilamminopropil)carbodiimmide
- DIC N, N′-diisopropilcarbodiimmide
- Intermediate VIIa can be obtained from intermediate IVa and VI by a Suzuki coupling in a similar way to that described above for the reaction of intermediate IIIa (or respectively IIIb or IIIc) with an intermediate VI.
- Intermediate IVa (or IVb) can be prepared according to scheme 2.
- Intermediate IVa (or IVb) can be prepared by means of N-arylation of intermediate VIIIa (or VIIIb) with a halide intermediate IX by using copper catalyzed Ullmann type reaction.
- An Ullmann reaction between a NH heteroaryl and an aryl/heteroaryl halide can be performed in the presence of a suitable copper(I) catalyst/promoter such as CuI, Cu 2 O or CuTC (copper thiophene carboxylate), ligandless or with a suitable ligand such as N,N-dimethylglicine, proline, phenantroline or dimethylcyclohexane-1,2-diamine (DMCHA), in the presence of an inorganic base such as K 2 CO 3 or Cs 2 CO 3 , by heating (typically 90-150oC) in a polar organic solvent such as DMSO, DMF or DMA, overnight or longer.
- a suitable copper(I) catalyst/promoter such as CuI, Cu 2 O or CuTC (copper thiophene carboxylate)
- ligandless or with a suitable ligand such as N,N-dimethylglicine, proline, phenantroline or dimethylcyclohe
- Intermediate IX may be obtained from intermediate X in a two steps process that involves PG 1 introduction (Boc group introduction) and halogenation or inverting the sequence of the steps. Insertion of Boc group can be carried out by reacting the anilino intermediate with Boc 2 O in an organic solvent like THF or DCM, in the presence of an organic base like DMAP or pyridine, at room temperature for several hours up to overnight (typically 12 hours).
- Halogenation reaction can be carried out by reacting the aryl derivative with a source of electrophilic bromine or iodine such as 1,3-Dibromo-5,5-dimethyl-imidazolidine-2,4-dione, N-bromosuccinimide or N- iodosuccinimide, in an organic solvent like ethyl acetate, DMF, or DCM, at temperature around 0oC or higher (up to 40oC).
- a source of electrophilic bromine or iodine such as 1,3-Dibromo-5,5-dimethyl-imidazolidine-2,4-dione, N-bromosuccinimide or N- iodosuccinimide
- an organic solvent like ethyl acetate, DMF, or DCM
- intermediate IVa where K is S and PG 1 is H
- intermediate VIIIa may be obtained from intermediate VIIIa by means of a multistep synthetic sequence reported in scheme 3.
- Intermediate VIIIa and intermediate XII can undergo an aromatic nucleophilic substitution (SNAr) to give 5 intermediate XI, for example by reacting them in an organic solvent like DMF or 1,4-dioxane, in the presence of an organic base like DBU or DIPEA, at RT for few hours (typically 4 hours); addition of methyl halide like MeI at the end of SNAr reaction can lead to in situ methylation of the carboxylic acid and formation of intermediate XI.
- SNAr aromatic nucleophilic substitution
- Intermediate XI can be reacted with mercaptoethanol under Pd-catalyzed C-S coupling conditions to give intermediate XII.
- C-S coupling can be performed by reacting aryl bromide XI and mercaptoethanol in the presence of a suitable catalytic system like as Pd 2 (dba) 3 / Xantphos or another suitable palladium source / phosphine source, in an organic solvent as 1,4-dioxane, toluene or DMA, in the presence of an organic base like DIPEA or DBU, at temperature up to 100oC for few hours (typically 3 -5 hours).
- a suitable catalytic system like as Pd 2 (dba) 3 / Xantphos or another suitable palladium source / phosphine source
- Intermediate XII can be converted into intermediate XIII by a two steps process that involves: 1) nitro reduction and 2) chlorination.
- Nitro reduction can be performed by treating intermediate XII with a reducing agent like iron powder or zinc powder, in an organic solvent like methanol or ethanol, in the presence of an aqueous solution of a weakly acid inorganic salt like ammonium chloride, by heating at temperature up to 80oC for few hours (typically 4-5 hours).
- Subsequent conversion of alcohol to the corresponding chloride can be achieved by reaction with neat thionyl chloride or oxalyl chloride at low temperature (around 0oC).
- Chloride intermediate XIII can be cyclized to give intermediate XIV by heating (typically 80-100oC) in an appropriate organic solvent like DMF or 1,4-dioxane, in presence of an inorganic base like potassium carbonate or sodium carbonate and in the presence of an additive like sodium iodide.
- intermediate XIV can be converted to intermediate IVa (where K is S and PG 1 is H) by ester hydrolysis performed by treating the methyl ester in a water-miscible organic solvent like THF or methanol, in the presence of an aqueous solution of an inorganic base like lithium hydroxide or sodium hydroxide, for few hours (typically 2-4 hours) at temperature up to 40oC.
- intermediate IIIa can be prepared from intermediate XV by displacement of Lg'' by alkylation with primary/secondary nitrogen present in Q' moiety by treating at room temperature for few hours (typically 5-7 hours) the amine Q' and halide XV in an organic solvent like DMF or 1,4-dioxane, in the presence of an organic base like DIPEA or TEA.
- Intermediate XV can be obtained from intermediate IVa and XVI by an amide coupling reaction using similar conditions to those reported in scheme 1 for the conversion of intermediate IVa and intermediate Va to intermediate IIIa.
- intermediate IIIa' (or IIIb') can be prepared from esterification with an alcohol of formula r-OH with the corresponding acid of formula XVIIa (or XVIIb) by using similar conditions to those reported in scheme 1 for the transformation of intermediates VIIa and Vb into IIc.
- Intermediate XVIIa (or XVIIb) can be obtained from corresponding intermediate IIIa (or IIIb), where Q' is a metyl ester (Q' is q-COOMe) or ethyl ester (Q' is q-COOEt), by hydrolysis in basic conditions in analogy to what described in scheme 4 for the conversion of intermediate XIV to intermediate IVa.
- the group Q'' present in intermediates of formula IIIa' (or IIIb') is a group that can undergo a single step functional group interconversion and/or PG deprotection to give a group of formula Q.
- Intermediates IIIa' (or IIIb') can be converted to compound of formula I-1 by using similar methods reported in scheme 1 to convert intermediate IIIa (or IIIb) to compound of formula I-1.
- IIa can be transformed in IIa’ by a two steps process can allow transformation of group Q’ to Q’’.
- ester hydrolysis of Q’ of IIa generates an acid intermediate that can be submitted to an esterification with a proper alcohol (r-OH) to give intermediate IIa’.
- Methyl ester or ethyl ester hydrolysis can be carried out by reacting ester 15 derivative with LiOH, NaOH or a suitable inorganic hydroxide in a mixture of water with THF, DMF or a suitable polar organic solvent.
- the acid can be transformed in an ester by activation of acid with a proper coupling agent like 2,4,6-trichlorobenzoyl chloride or HATU, followed by reaction with the corresponding alcohol in the presence of an organic base like TEA, DMAP or DIEA in an organic polar solvent like DMF.
- This procedure can also apply to the preparation of thioesters by replacing the alcohol (r-OH) with the proper thiol derivative (r-SH).
- compound of formula I-1 when Q contain a terminal CN group, may be prepared from the corresponding intermediate IIa that contain in Q’ a leaving group such as Br or Cl and alkylated with an inorganic cyanide salt like NaCN or KCN in an organic polar solvent like DMF by heating at temperature around 800C or higher.
- Compound of formula I-2 can be prepared like to compounds of formula I-1 by using similar synthetic sequences by introducing pyrazin-2(1H)-one-3-aminyl moiety instead of pyrazol[1,5- a]pyrimidine-3-yl moiety.
- Scheme 7 An example of such scheme modifications is provided by scheme 7.
- a suitable palladium catalyzed cross coupling for introducing pyrazin-2(1H)-one-3-aminyl moiety is a Buchwald-Hartwig coupling.
- Intermediate IVa and intermediate XVIII can be reacted, to give intermediate XIX, in the presence of a suitable ligand palladacyle system such as XPhos-Pd-G3 (2- Dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′- biphenyl)]palladium(II) methanesulfonate) or RuPhos-Pd-G3 (2-Dicyclohexylphosphino-2′,6′- diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate) or in general a suitable Pd source (for example Pd 2 (dba) 3 or Pd(OAc) 2 ) with a suitable phosphine ligand such as
- intermediate XX Deprotection of PG 2 from intermediate XIX to give intermediate XX can be carried out by treatment of the protected precursor with TMS-Cl (trimethylsilyl chloride) and sodium iodide in acetonitrile for 1 to 5 h at 60 - 100oC; under these conditions also PG 1 when it is Boc can be deprotected.
- compound of formula I-2 can be prepared by reaction of intermediate XX with intermediate Va under amide coupling conditions similarly to what described in scheme 1 for the preparation of IIIa from IVa and Va.
- the compounds of the invention are inhibitors of kinase activity, in particular inhibiting JAK kinase activity for the treatment of JAK-dependent diseases.
- the invention provides compounds according to the invention, i.e. a compound of formula (I) or a pharmaceutical composition thereof, for use as a medicament, preferably for the prevention and /or treatment of respiratory and specifically pulmonary disease.
- the invention provides the use of a compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of disorders 15 associated with JAK mechanisms, particularly for the treatment of disorders such as respiratory and pulmonary diseases.
- the invention provides compounds of formula (I) for use in the prevention and /or treatment of pulmonary disease selected from the group consisting of asthma, chronic obstructive pulmonary disease COPD, idiopathic pulmonary fibrosis (IPF)acute lung injury and acute respiratory distress syndrome (ARDS).
- pulmonary disease selected from the group consisting of asthma, chronic obstructive pulmonary disease COPD, idiopathic pulmonary fibrosis (IPF)acute lung injury and acute respiratory distress syndrome (ARDS).
- the invention provides a method for the prevention and/or treatment of disorders associated with JAK mechanisms, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the invention.
- the invention provides methods for the prevention and/or treatment wherein the disorder is a respiratory disease selected from asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), acute lung injury and acute respiratory distress syndrome (ARDS).
- COPD chronic obstructive pulmonary disease
- IPF idiopathic pulmonary fibrosis
- ARDS acute respiratory distress syndrome
- Preferred is the use of the compounds of the invention for the prevention of the aforesaid disorders.
- Equally preferred is the use of the compounds of the invention for the treatment of the aforesaid disorders.
- the disorder that can be treated by the compound of the present invention is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease such as idiopathic pulmonary fibrosis (IPF), acute lung injury and acute respiratory distress syndrome (ARDS).
- the disorder is selected from asthma and chronic obstructive pulmonary disease (COPD).
- the methods of treatment of the invention comprise administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
- effective amount in reference to a compound of formula (I) or a pharmaceutically acceptable salt thereof or other pharmaceutically active agent means an amount of the compound sufficient to treat the patient's condition but low enough to avoid serious side effects and it can nevertheless be routinely determined by the skilled artisan.
- the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. Typical daily dosages may vary depending upon the particular route of administration chosen.
- the invention also provides pharmaceutical compositions of compounds of formula (I) in admixture with one or more pharmaceutically acceptable carrier or excipient, for example those described in Remington’s Pharmaceutical Sciences Handbook, XVII Ed., Mack Pub., N.Y., U.S.A.
- the present invention is also directed to use of the compounds of the invention and their pharmaceutical compositions for various route of administration.
- Administration of the compounds of the invention and their pharmaceutical compositions may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermally, and by ocular administration.
- solid oral dosage forms can be used for administering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders.
- the compounds of the present invention can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and known excipients, including suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
- diluents such as sucrose, mannitol, lactose, starches
- excipients including suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
- Time release capsules, tablets and gels are also advantageous.
- liquid oral dosage forms can also be used for administering compounds of the invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs.
- dosage forms can also contain suitable known inert diluents such as water and suitable known excipients such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention.
- the compounds of the present invention may be formulated as injectable composition, for example to be injected intravenously, in the form of an isotonic sterile solution. Other preparations are also possible.
- Suppositories for rectal administration of the compounds of the invention can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols.
- Formulations for vaginal administration can be in the form of cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such as suitable carriers, are also known.
- the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose. Topical administration may also involve transdermal administration via means such as transdermal patches.
- Compounds of the invention may exhibit profile suitable for oral route administration.
- optimization of drugs for oral delivery needs certain characteristics that allow orally administered 35 compound to be absorbed by GI (gastrointestinal) tract and to be poorly cleared in order to give a good bioavailability (F%), thus to maintain a sufficient concentration in plasma and target tissues for a time adequate to sustain pharmacological effect.
- one or more features of the compounds need to be optimized such as, and not limited to, maximizing membrane permeability and reducing metabolic hot spots (optimizing in-vitro clearance).
- the compounds according to the invention may also preferably be administered by inhalation. Some preferred compounds of the invention exhibit profile suitable for inhalatory route administration.
- Drugs optimized for inhaled delivery require certain characteristics that allow the compound, when administered to the lung to maintain a sufficient local concentration (lung retention) to exert a pharmacological effect of the desired duration, with minimal drug absorption in the GI tract for the swallowed fraction and in general non-relevant levels in unwanted compartments (i.e. plasma).
- one or more features of a compounds were optimized such as, and not limited to, membrane permeability, dissolution rate and the compound’s basicity to enhance its binding to the phospholipid-rich lung tissue or through lysosomal trapping.
- compounds of invention show one or more of the features above in the range desirable for an inhaled compound.
- a JAKi should preferably possess additional properties that may further limit the systemic exposure after inhalation.
- a way to limit systemic exposure, after local administration, might be to design soft-drug that means the introduction of specific moieties, like for example esters in the present invention, which favour a controlled rapid systemic metabolism (in the liver and/or in the blood) into predicted functionally less active, or even negligibly active, metabolites compared to parent compound.
- one way resulted in the optimization of 'suitably designed esters derivatives' which having corresponding predicted carboxylic acid metabolites showing a drop in functional activity (like cell based activity).
- such optimized esters can be substrates of liver and/or blood esterases that may be beneficial for achieving an enhanced clearance in-vivo.
- preferred compounds of the invention showed one or more of the following properties: high biochemical activity on target, strong functional activity (like cell based activity), a rapid clearance in representative assays (stability in liver microsomes and/or hepatocytes, plasma stability) and drop in the functional activity of the predicted carboxylic acid metabolite so that they can have potential for giving compounds with an improved safety.
- Inhalable preparations include inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations and may be administered through a suitable inhalation 35 device which may be respectively selected from dry powder inhaler, pressurized metered dosed inhaler, or a nebulizer.
- a suitable inhalation 35 device which may be respectively selected from dry powder inhaler, pressurized metered dosed inhaler, or a nebulizer.
- dry powder single- or multi-dose inhalers known from the prior art may be utilized. In that case the powder may be filled in gelatine, plastic or other capsules, cartridges or blister packs or in a reservoir.
- a diluent or carrier e.g. lactose or any other additive suitable for improving the respirable fraction may be added to the powdered compounds of the invention.
- Inhalation aerosols containing propellant gas such as hydrofluoroalkanes may contain the compounds of the invention either in solution or in dispersed form.
- the propellant-driven formulations may also contain other ingredients such as co-solvents, stabilizers and optionally other excipients.
- the propellant-free inhalable formulations comprising the compounds of the invention may be in the form of solutions or suspensions in an aqueous, alcoholic or hydroalcoholic medium and they may be delivered by jet or ultrasonic nebulizers known from the prior art or by soft-mist nebulizers such as Respimat £ , a registered trademark of Boehringer Ingelheim Pharmaceuticals (Wachtel, H., Kattenbeck, S., Dunne, S. et al.
- the compounds of the invention regardless of the route of administration, can be administered as the sole active agent or in combination (i.e. as co-therapeutic agents administered in fixed dose combination or in combined therapy of separately formulated active ingredients) with other pharmaceutical active ingredients.
- the compounds of the invention can be administered as the sole active agent or in combination with other pharmaceutical active ingredients including those currently used in the treatment of respiratory disorders, and known to the skilled person, such as beta2-agonists, antimuscarinic agents, corticosteroids, mitogen-activated kinases (P38 MAP kinases) inhibitors, PI3K inhibitors (phosphoinositide 3-kinases), nuclear factor kappa-B kinase subunit beta inhibitors (IKK2), Rho kinase inhibitors (ROCKi), human neutrophil elastase (HNE) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, leukotriene modulators, non-steroidal anti-inflammatory agents (NSAIDs) and mucus regulators).
- other pharmaceutical active ingredients including those currently used in the treatment of respiratory disorders, and known to the skilled person, such as beta2-agonists, antimuscarinic agents, corticosteroids, mitogen-activated kinases (P38 MAP kinases
- the invention is also directed to a kit comprising the pharmaceutical compositions of compounds of the invention alone or in combination with or in admixture with one or more pharmaceutically acceptable carriers and/or excipients and a device which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler or a nebulizer.
- a device which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler or a nebulizer.
- the dosages of the compounds of the invention depend upon a variety of factors including the particular disease to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, 35 and pharmacokinetic profile of the compound.
- a pharmaceutical composition comprising a compound of the invention suitable to be administered by inhalation is in various respirable forms, such as inhalable powders (DPI), propellant-containing metering aerosols (PMDI) or propellant-free inhalable formulations (e.g. UDV).
- DPI inhalable powders
- PMDI propellant-containing metering aerosols
- UDV propellant-free inhalable formulations
- the invention is also directed to a device comprising the pharmaceutical composition comprising a compound according to the invention, which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler and a nebulizer particularly soft mist nebulizer.
- SCX-2 cartridge refers to a Bond Elut® pre-packed polypropylene column containing a non-end-capped propylsulphonic acid functionalised silica strong cation exchange sorbent.
- MDAP mass directed automatic purification
- NMR spectra were obtained on a Bruker Avance III 600 (5 mm RT inverse probe head), Bruker DRX 500, Bruker Avance AV 400 (5 mm RT direct probehead) or Bruker DPX 300 spectrometers using standard Bruker pulse sequences.
- NMR spectra were recorded with Varian MR-400 spectrometer operating at 400 Mhz or a Varian Unity Inova 400 spectrometer with a 5 mm inverse detection triple resonance probe operating at 400 MHz.
- DMSO-d 6 or CDCl 3 were used as solvents. Chemical shifts are given in relative to internal standard tetramethylsilane or solvent residual peak. All experiments were recorded at 298 K, unless stated differently.
- HPLC-MDAP Method 1 Agilent 1290 Infinity II Purification System; Column: Waters XBridge® (C18, 100 mm x 19 mm i.d., 5 ⁇ m), mobile phase A: 0.1% (v/v) formic acid in water, mobile phase B: acetonitrile; .
- a “similar” or “analogous” procedure means that such a procedure may involve minor variations, for example reaction temperature, reagent/solvent amount, reaction time, work-up conditions and/or chromatographic purification conditions.
- the stereochemistry of the compounds in the Examples, where indicated, has been assigned on the assumption that absolute configuration at resolved stereogenic centres of starting materials is maintained throughout any subsequent reaction conditions. Unless otherwise stated, where absolute configuration (R) or (S) is reported in the compound name, ee% has to be considered equal or greater than 90%.
- Step 2 Ethyl 1-(2-aminoethyl)piperidine-4-carboxylate (Intermediate 1)
- a solution of intermediate 1-1 (1.77 g, 5.9 mmol) and TFA (8.8 mL, 118 mmol) in DCM (14 mL) was stirred at RT overnight. Volatiles were removed in vacuo and crude product passed through an SCX cartridge, washed with EtOH (500 mL) and eluted with 15% aq. NH 3 in EtOH (100 mL) to afford the title product (1.16 g).
- RM was concentrated to dryness and taken with dry DCM (10 ml) and the solution added dropwise to a mixture of -methylpiperidin-4-ol (230 mg, 1.994 mmol) and DIPEA (697 ⁇ l, 3.99 mmol) in dry DCM.
- RM was quenched by the addition of aq. sat. NaHCO 3 (20 ml) and the organic layer separated, dried over Na 2 SO 4 and concentrated to dryness.
- the crude material was purified by chromatography on Si cartridge by eluting with 0-20% MeOH in DCM to afford the title product (391 mg).
- Step 2 tert-Butyl 7-bromo-6-methoxy-2,3-dihydro-4H e-4-carboxylate (Intermediate 3)
- THF 15 mL
- DMAP 840.9 mg, 6.88 mmol
- Boc 2 O 2.80 g, 13.19 mmol
- RM was partitioned between EtOAc (50 mL) / water (30 mL). The organic layer was washed with 2M aq. citric acid (2x20 mL), sat. aq. NaCl (20 mL) and evaporated in vacuo.
- Step 2 tert-Butyl 6-bromo-7-methoxy-3,4-dihydroquinoline- -carboxylate (Intermediate 4)
- a solution of intermediate 4-1 (228 mg, 0.86 mmol) in EtOAc (10 mL) was cooled to 0°C.
- 1,3-dibromo-5,5-dimethyl-imidazolidine-2,4-dione (124 mg, 43.3 mmol) was added portion wise over 15 min.
- RM was stirred at 0 °C for 20 min, then quenched with 10 % (w/w) aq. K 2 CO 3 (20 mL).
- the organic layer was separated, washed with sat. aq.
- Step 2 tert-butyl 7-iodo-6-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Intermediate 5)
- Intermediate 5-step 1 (5.9g, 22.1 mmol) was dissolved in DMF (60mL), then N- Iodohydroxysuccinimide (12.7g, 111 mmol) added and RM stirred at 40°C overnight. RM was quenched in cold water and extracted with EtOAc. Combined organic layers were evaporated to dryness and the residue purified by chromatography on silica gel by gradient elution from 1:1 to 3:2 DCM-Hexane to afford the title compound (7.38g).
- Step 2 Methyl 6-chloro-1-(5-((2-hydroxyethyl)thio)-2-methoxy-4-nitrophenyl)-1H- pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 6-2)
- Intermediate 6-1 5.0 g, 11 mmol
- 2-sulfanylethanol (1.13 mL, 12 mmol
- DIPEA 5.91 mL, 20 mmol
- Xantphos 820 mg, 1.4 mmol
- Pd 2 (dba) 3 330 mg, 0.57 mmol
- 1,4-dioxane 100 mL
- Step 4 Methyl 1-(4-amino-5-((2-chloroethyl)thio)-2-methoxyphenyl)-6-chloro-1H- pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 6-4)
- Intermediate 6-3 (4.4 g, 11 mmol) was mixed with thionyl chloride (12 mL, 165 mmol) at 0 °C.
- RM was warmed to RT and stirred for 2 h, then volatiles removed in vacuo and the residue taken with sat. aq. NaHCO 3 .
- the formed slurry was sonicated and solid collected by filtration, washed with water and dried.
- Step 5 Methyl 6-chloro-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-1H- pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 6-5)
- a mixture of intermediate 6-4 (2.70 g, 6.32 mmol), K 2 CO 3 (2.62 g, 19 mmol) and NaI (189 mg, 1.26 mmol) in DMF (80 mL) was stirred at 90°C overnight. After cooling to RT, RM was diluted with water (200 mL). The formed precipitate was filtered, washed several times with water and dried.
- Step 6 6-Chloro-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-1H-pyrazolo[4,3- c]pyridine-3-carboxylic acid (Intermediate 6)
- Intermediate 6-5 (730 mg, 1.87 mmol) was suspended in THF (15 mL) and added with a solution of LiOH (1.0 M in water, 9 mL, 9 mmol).
- RM was stirred at 40 °C for 2.5h.
- Organic solvent was removed in vacuo and the residue diluted with water.
- the pH was adjusted to 2.5 using aq. 1M HCl.
- the formed precipitate was filtered, washed several times with water and dried to afford the title compound (698 mg).
- Intermediates 13s-13aa The following intermediates were prepared in a similar manner to intermediate 13r from the indicated starting materials. It is additionally stated if base, solvent, additive or temperature were varied.
- Intermediate Structure Starting material LCMS z z z z z z z z z z z z z z z Intermediate 13ab Step 1 tert-Butyl 7-(6-chloro-3-((2-((3-(2-methoxy-2- oxoethyl)benzyl)amino)ethyl)carbamoyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3- dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Intermediate 13ab-1) The t ared in a similar manner of intermediate 13r starting with Intermediate 11d and methyl 2-[3-(aminomethyl)phenyl]acetate hydroch
- Step 2 1-Methoxy-2-methylpropan-2-yl 1-(2-(6-chloro-1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine-4- carboxylate (Intermediate 13ac)
- the title compound was prepared in a similar manner of intermediate 13r starting with intermediate 13ac-1 and intermediate 2a.
- Reaction mixture was refluxed for 3 h., diluted with EtOAc (25 mL), washed with sat. aq. NaHCO 3 (3x15 mL) and sat. aq. NaCl (15 mL). Organic layer was dried over Na 2 SO 4 and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-35 % DCM/MeOH/NH 4 OH (90:15:1.5) in DCM to afford the desired product.
- RM was stirred at -78°C for 1 h. Ethyl 2-hydroxyacetate (79 ⁇ L, 0.83 mmol) and TEA (58.1 ⁇ L, 0.42 mmol) were added and RM stirred overnight reaching RT. RM was quenched with sat. aq. NaHCO 3 and water, then extracted with DCM (4 ⁇ 10 mL). Combined organic layers were washed with sat. aq. NaCl, dried over Na 2 SO 4 and solvent evaporated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-40 % EtOAc in DCM to afford the title product (92 mg).
- RM was refluxed for 1h before addition of a solution of ethyl (1s,3s)-3-hydroxycyclobutane-1-carboxylate (38.3 mg, 0.26 mmol) and TEA (55.5 ⁇ L) in 2-Me- THF (150 ⁇ L). RM was stirred at RT and refluxed overnight. After cooling to RT, RM was diluted with EtOAc (25 mL), washed with sat. aq. NaHCO 3 (3x15 mL) and sat. aq. NaCl (15 mL). Organic layer was dried over Na 2 SO 4 and concentrated in vacuo.
- Step 2 (R)-1-(2-(((Benzyloxy)carbonyl)amino)ethyl)pyrrolidine-3-carboxylic acid (Intermediate 17-2)
- Solution of Intermediate 17-1 140 mg, 0.46 mmol
- ethanol 1.2 mL
- NaOH 2.0 M in water, 560 ⁇ L, 1.1 mmol
- RM was stirred at RT for 1h.
- RM was quenched with aq.2N HCl (560 ⁇ L), then stirred at RT for 15 min. Ethanol was partially removed by evaporation, followed by acetone addition.
- Step 3 (R)-1-(2-Fluoroethyl)pyrrolidin-3-yl (R)-1-(2- (((benz xy)carbonyl)amino)ethyl)pyrrolidine-3-carboxylate (Intermediate 17)
- Intermediate 17-2 (135 mg, 0.46 mmol)
- Intermediate 16 (73.8 mg, 0.55 mmol)
- 2,4,6-trichlorobenzoyl chloride 86.6 ⁇ L, 0.55 mmol
- TEA 129 ⁇ L, 0.92 mmol
- DMAP (14.1 mg, 0.25 mmol
- RM was poured in a mixture of EtOAc and water (10 mL each) and pH adjusted from 5.5 to 3.5 using aq. 1.0 M HCl. Aqueous layer was basified with 2M NaOH to pH 9.5 and extracted with EtOAc (2x10 mL). Combined organic layers were washed with sat. aq. NH 4 Cl (2x), sat. aq. NaCl, dried over Na 2 SO 4 and solvent removed in vacuo to afford the title product (162 mg).
- RM was diluted with EtOAc (15 mL) and washed with sat. aq. NaHCO 3 (3x10 mL) and sat. aq. NaCl (10 mL). Organics were dried over Na 2 SO 4 and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-100 % DCM/MeOH (9:1) in DCM to afford the desired product (42 mg).
- Step 2 5- a] 20 carboxylate (Example 9)
- TFA 2.06 mL, 27.8 mmol
- RM stirred at RT overnight.
- RM was evaporated in vacuo and the residue loaded on a SCX cartridge, washed with ethanol, and eluted with 15 % aqueous ammonia in ethanol.
- the crude material thus obtained was purified by flash chromatography on Si cartridge by eluting with 0-100 % DCM/MeOH/NH 4 OH (90:9:0.5) in DCM to afford the title product (246 mg).
- RM was diluted with sat.aq. NaHCO 3 , DCM (5 mL) and the pH adjusted to 9.5. Aqueous layer was extracted with DCM/i-PrOH (3:1; 4x5 mL) and the combined organic layers were passed through a phase separator and solvents removed in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-70 % DCM/MeOH/NH 4 OH (90:5:0.5) in DCM to afford the title product (28 mg).
- Example 44 to 45 The following Examples were prepared in a similar manner to example 43 from the indicated starting materials.
- RM was partitioned between EtOAc (10 mL) and water (5 mL). The organic layer was washed with sat. aq. NaCl (5 mL) and solvent removed in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-20 % DCM/MeOH/NH 4 OH (90:9:0.5) in DCM to afford the title product (6.6 mg).
- RM was diluted with water and washed with EtOAc. After pH acidification of aqueous layer to 5 by using aq. 1.0 M HCl and cooling on ice for 30 min, the formed precipitate was filtered, washed with water several times and dried to afford the title compound (842 mg).
- Example 47-intermediate 2 tert-butyl 7-(3-((2-(4-((3-cyanocyclobutoxy)carbonyl)piperidin-1-yl)ethyl)carbamoyl)- 6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3-dihydro- 20 4H-benzo[b][1,4]oxazine-4-carboxylate-(Example 47-intermediate 2) To a mixture of Example 47-intermediate 1 (70.0 mg, 0.10 mmol), 2,4,6-trichlorobenzoyl chloride (39 ⁇ L, 0.25 mmol) and 3-hydroxycyclobutanecarbonitrile (21.4 ⁇ L, 0.25 mmol) in dry DMF
- RM was diluted with EtOAc (15 mL) and washed with sat. aq. NaHCO 3 (3x10 mL), sat. aq. NH4Cl (15 mL) and sat. aq. NaCl (10 mL). Organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-50 % DCM/MeOH (95:5) in DCM to afford the title product (47 mg).
- RM was stirred for 2 h at RT, then diluted with DCM, cooled to 0 °C, neutralized with aq. sat. NaHCO 3 and extracted with DCM (3x10 mL). Combined organic layers were passed through phase separator and solvent removed in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-50 % DCM/MeOH (9:1) in DCM to afford the title product (31 mg).
- Example-48-intermediate 1 and Example 49-intermediate 1 The following intermediates were prepared in a similar manner to example 47-intermediate 1 from the indicated starting materials.
- Example 48 to 53 The following Examples were prepared with a two-step process (step 1 and step 2) similarly to Example 47-step 2 and step 3 respectively from the indicated starting materials. It is additionally stated if base, solvent, temperature or coupling reagent were varied.
- Example 54-intermediate 2 A mixture of Example 54-intermediate 1 (32.0 mg, 0.04 mmol) and NaCN (10.0 mg, 0.20 mmol) in DMF (1.0 mL) was stirred at 80 °C for 1.5 h.
- RM was diluted with EtOAc (15 mL), washed with sat. aq. NaHCO 3 (3x10 mL) and sat. aq. NaCl (10 mL). Organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-70 % DCM/MeOH (9:1) in DCM to afford the title product (28 mg).
- Example 55 1-(4-(tert-Butoxycarbonyl)-6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl pyrazolo[4,3-c]pyridine-3-carboxylic acid (Example 55- Intermediate 1) To a previously degassed mixture of aqueous potassium phosphate (1.0 M, 2.17 mL, 2.2 mmol) and THF (5 mL), intermediate 7 (500 mg, 1.1 mmol), 3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (372 mg, 1.5 mmol) and XPhos-PdG3 (46 mg, 54 ⁇ mol) were added and RM stirred at 70 o C for 1.5h.
- aqueous potassium phosphate 1.0 M, 2.17 mL,
- RM was diluted with water (15 mL) and basified to pH 10. RM was washed with EtOAc (2x20 mL) and aqueous layer filtered through a pad of diatomaceous earth and washed with water (100 mL). A mixture of MEK (methylethyl ketone) and i-BMK (isobutylmethyl ketone) (5:1 - 150 mL) was added and pH adjusted to 4.5. Organic layer was separated, dried over Na 2 SO 4 , filtered, and evaporated to dryness to give the title product (560 mg) that was used in the next synthetic steps without further purification.
- MEK methylethyl ketone
- i-BMK isobutylmethyl ketone
- Example 55-Intermediate 1 (171 mg, 0.32 mmol), DIPEA (507 ⁇ L, 2.96 mmol) and HATU (169 mg, 0.44 mmol) were added and RM stirred at RT for 1h. A second equivalent of HATU and were added and RM stirred at RT for further 1h. RM was quenched with sat. aq. NH4Cl and the formed precipitate collected by filtration, washed several times with water.
- RM was heated at 100 o C for 20h. After cooling to RT, RM was diluted with water (30 mL) and extracted with EtOAc (2x15 mL). Aqueous layer was acidified with 1N HCl (20 mL) and extracted with MEK (methylethyl ketone) (3x15 mL). Combined organic layers were dried over Na 2 SO 4 , filtered and solvent removed in vacuo. The residue was suspended in water (30 mL) and extracted with EtOAc (2x20 mL). Combined organic layers were dried over Na 2 SO 4 , filtered and solvent removed in vacuo to afford the title compound (84mg) that was used in the next synthetic steps without further purifications.
- Example 58- intermediate 2 A mixture of Example 58-intermediate 1 (84 mg, 0.15), sodium iodide (92 mg, 0.61 mmol) and TMS-Cl (78 ⁇ L, 0.61 mmol) in acetonitrile (2.0 mL) was stirred at 85 o C for 3 h.
- Example A1 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine-4-carboxylic acid (Example A1)
- a solution of example 9 (46.1 mg, 0.06 mmol) in THF (6 mL) was treated with solution of LiOH.H 2 O (6.60 mg, 0.18 mmol) in water (2 mL). RM was stirred at RT overnight.
- Example 46-intermediate 1 1- Methoxy-3,4-dihydro-2H-b enzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin- 3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Example A9) See procedure for the preparation of Example 46-intermediate 1.
- Example A11 The following examples were prepared in a similar manner to example A1 from the indicated starting material. E : z , , , 2H), 1.42-1.50 (m,2H).
- Example A12 2-(1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidin-4-yl)acetic acid (Example A1 Title compound was prepared on a similar manner to step 3 of Example 47 starting from Example 48-Intermediate 1.
- the ULight peptide substrate (LANCE Ulight-JAK-1 (Tyr1023) Peptide, Perkin Elmer, TRF0121) is phosphorylated. It is then captured by Eu-anti-phospho-substrate antibody (LANCE Eu-W1024 Anti-phosphotyrosine (PT66), Perkin Elmer, AD0069), which bring the Eu-chelate donor and ULight acceptor dyes into close proximity. Upon excitation at 320 nm, the Eu-chelate transfers its energy to the ULight dye, resulting in a fluorescent light emission at 665 nm.
- Compound testing Serial dilutions of compounds in pure DMSO are prepared from 10 mM DMSO stock solutions. Compounds were tested in 384-well plate for 11 consecutive 5-fold dilutions starting from 20 ⁇ M highest concentration (20 ⁇ M – 2 pM). 200 nL of compound were transferred from mother plate to test plate by using Mosquito (TTP labtech). Assay was performed in 384-well Perkin Elmer test plate in 20 ⁇ L assay volume (kinase reaction) and 40 ⁇ L total volume (stopping reagent and antibody detection reagents).
- Predicted acid metabolites showed measurable values in terms of pIC50 (BEAS) higher than 5.
- BEAS pIC50
- a numerical limit or range is stated herein, the endpoints are included.
Abstract
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
Description
HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
FIELD OF THE INVENTION
The present invention relates to chemical compounds that are derivatives useful as JAK inhibitors, such as JAK 1, useful for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
BACKGROUND OF THE INVENTION
The JAK family consists of non-receptor tyrosine protein kinases and has four main members, JAK1, JAK2, JAK3, and TYK2. More than 50 cytokines and growth factors bind to type I and II receptors noncovalently associated with different combinations of JAK kinases. The signalling triggered by the ligands consists in tyrosine phosphorylation of receptors by JAK and recruitment of one or more STATs proteins. Tyrosine-phosphorylated STATs dimerize and are then transported into the nucleus through the nuclear membrane to regulate specific genes. JAKs have seven homology domains (the JAK homology domain, JH). Starting from the carboxyl terminus, JH1 is the first JH, known as the kinase domain, and is composed of approximately 250 amino acid residues. JH1 encodes a kinase protein that constitutes the kinase structure domain that phosphorylates a substrate; JH2 is a pseudokinase domain which regulates the activity of the kinase domain. JAK3 is expressed in the bone marrow and lymphatic system, as well as endothelial cells and vascular smooth muscle cells; other members are expressed in almost all tissues (Hu X et al., Signal Transduct Target Ther. 2021, 26;6(l):402). Many cellular processes are downstream JAK/STAT signalling: hematopoiesis, immune balance, tissue repair, inflammation, apoptosis, and adipogenesis. Different biological responses are regulated by specific pairing of JAK isoforms. JAK1/JAK3 combination mediates IL-2, -4, -7, -9, -15, and -21 signalling that is relevant for growth/maturation of lymphoid cells, differentiation/homeostasis of T-cells/NK cells, B-cell class switching and other inflammatory processes. Combinations of JAK1/TYK2-JAK1/JAK2, regulate the signal associated with the innate immune response, such as IL-6 and the type I interferons, involved into naive T cell differentiation, T cell homeostasis, granulopoiesis and other inflammatory processes. (Howell MD et al., Front. Immunol. 2019, 10, 2342). JAK2 frequently associates with itself (JAK2/ JAK2) controlling the signalling of various cytokines and growth factors, such as IL-3, IL-5, granulocyte macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), and thrombopoietin (TPO) (Hodge et al., Clin Exp Rheumatol 2016; 34(2):318-28).
Genetically modified mouse models and human diseases prove the importance of JAK/STAT pathways in immune fitness. In particular, overexpression or mutations involving some JAK isoforms as well as aberrant JAK/STAT signalling drive malignancies of hematopoietic
and lymphoid tissues as well as inflammatory disorders. Currently, several Food and Drug Administration (FDA)- and/or EU- approved JAK inhibitors are in clinical use. Two (ruxolitinib and fedratinib) small molecules are in use for hematologic disorders as myelofibrosis and polycythemia vera; six JAK inhibitors (tofacitinib, baricitinib, ruxololitinib, filgotinib, upadicitinib and delgocitinib in Japan) result in use for immune-mediated disorders as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and acute graft-versus-host disease. Moreover, some of these drugs as well as others are currently under phase II and III of clinical trials for indications that span from autoimmune diseases (lupus, vitiligo, etc ), inflammatory bowel disease to Non-Hodgkin lymphoma and COVID-19 (Hu X. et al., Sig Transduct Target Ther 2021, 6: 402).
The small molecules targeting JAK/STAT represent an attractive option also for the therapy of fibrotic disorders. In fact, inflammatory cytokines (IL-4, IL-3, IL-6, IL-11, IL-31, etc) and growth factors (FGF, VEGF, etc.) involved in the fibrotic processes activate JAK/STAT pathway. Ruxolitinib tested in a bleomycin-induced fibrosis mouse model ameliorated the fibrotic lesions in lung, and reduced levels of fibrotic molecular markers (Zhang, Y et al., Ann. Rheum. Dis. 2017, 76, 1467-1475) while tofacitinib acted as a preventive agent in experimental dermal and pulmonary fibrosis (Wang, W et al., Scleroderma Relat. Disord. 2020, 5, 40-50). In patients, some case reports were studied. A single-6case report corroborated the efficacy and safety of tofacitinib in combination with nintedanib in the management of an aggressive interstitial lung disease with poor prognosis (Conca, W et al., Front. Pharmacol. 2020, 11, 5857619). Baricitinib was demonstrated to be a safe immune modulator that reduces the biomarkers’ levels of lung fibrosis and inflammation in RA patients, including a subgroup with interstitial lung disease (D’ Alessandro M et al., Int. Immunopharmacol. 2020, 86, 106748).
In COVID-19, there are some JAK inhibitors undergoing clinical trials, and they are tofacitinib, baricitinib, and ruxolitinib. Baricitinib and ruxolitinib were associated with a reduced risk of mortality. They reduced the use of invasive mechanical ventilation and had a borderline impact on the admission rate of the intensive care unit and the incidence of acute respiratory distress syndrome (ARDS). (Wijaya, I. et al. Clin. Epidemiol. Glob. Health 2021, 11, 100755). Ruxolitinib also was tested in COVID-19 patients, and improved the clinical symptoms and chest computed tomography images (Cao Y. et al., J. Allergy Clin. Immunol. 2020 146, 137-146).
Asthma can be included in the plethora of immune-mediated diseases for which pathogenesis is characterized by an essential role of JAK/STAT signalling. Asthma is a chronic inflammatory disease of the airways due to a complex interplay between immune response, genetic susceptibility and nonspecific external stimuli like cold, allergens and exercise leading to hyperresponsiveness, remodelling of the airways, ultimately contributing to airflow limitation. Severe asthma affects
5% to 15% of the population with adult asthma (which is 300 million people worldwide) and represents a public health issue associated with increased mortality, increased hospitalizations, significant burden of symptoms, health care costs, and missed work and school (Steve NG et al., J Allergy Clin Immunol 2021;148:953-63). Severe asthma represents a subset of difficult-to-treat asthma and occurs in patients whose disease remains uncontrolled despite the use of high doses of inhaled corticosteroids (ICSs) combined with long-acting P-agonists or other controllers. To date, four types of biologies are licensed for severe asthma, i.e. omalizumab (anti -immunoglobulin E) antibody, mepolizumab and reslizumab (anti-interleukin [IL]-5antibody), benralizumab (anti-IL- 5 receptor a antibody) and dupilumab (anti-IL-4 receptor alpha antibody). Despite their efficacy, many patients continue to experience exacerbations or uncontrolled disease, indicating a need for more novel therapies (Israel E, Reddel HK. N Engl J Med 2017; 377:965-76).
Recently, the better understanding of asthma pathobiology brought to a shift from a phenotypic classification system to the introduction of the “endotype” concept. According to the latter, classification is performed on the basis of pathophysiologic mechanisms and clinical biomarkers associated with a given patient (Wenzel SE et a., Am J Respir Crit Care Med 2021;203:809-21). There are two major endotypes in asthma: type 2 and non-type 2. The type 2 pathway is defined by activation of cytokines derived from TH2 cells and group 2 innate lymphoid cells (ILC2s); these include IL-4, IL-5, and IL-13 that cause airway inflammation by activating eosinophils, B cells, airway epithelial cells, and other cell types Biomarkers of type 2 asthma include blood/sputum eosinophilia and elevated levels of fractional exhaled nitric oxide (FENO) and IgE. The type 2-low pathway is characterized by absence of type 2-high cytokines and biomarkers, and it manifests either increased levels of neutrophils in the airways or a paucigranulocytic profile, with normal levels of airway neutrophils and eosinophils. Type 2-low asthma is currently not well understood, and it likely encompasses multiple distinct endotypes. Potential mediators and/or biomarkers of T2 low endotypes under investigation include IL-6, IL- 17A/F, IL-23, Type I interferons, CXCL10, TNF, alarmins (TSLP, IL-25, IL-33), IL-lp, IL-8, IFN-y (Hinks TSC et al., ERJ 2021, 57 (1) 2000528).
Almost all the mediators mentioned above both for T2 and T2-low endotypes activate JAK/STAT pathway, here the rationale for the potential use of JAK inhibitors in both endotypes of severe asthma. Targeting simultaneously several cytokines by JAK inhibitors may offer advantage over the biologies (for no-responder patients) and standard therapies (for patients who remain uncontrolled) considering their administration on top of ICS.
Despite strong rationale of JAK inhibitors in asthma, safety concerns may arise by administration of systemic inhibitors or may limits administration into particular asthma subjects such as children. Considering that Asthma is a lung restricted disease, inhalatory route of
administration for a JAK inhibitor may offers the advantage of therapeutic efficacy while limiting systemic exposure and correlated side effects. To date, some companies are developing inhaled JAK inhibitor for asthma treatment. Astrazeneca pipeline include AZD-0449 (completed Phase I clinical trial) and AZD-4604 (ongoing Phase I clinical trial); Theravance Biopharma is starting a new preclinical program on TD-8236 inhaled JAK inhibitor and Kinaset/Vectura is developing VR588 (ongoing Phase I clinical trial) as inhalatory compound. Many preclinical studies sponsored by the companies mentioned above demonstrated the efficacy of JAK inhibitors in the modulation of asthma. In the preclinical phase of drug development, JAK1/3 inhibitor R256 (now referred as AZD0449) orally given showed be effective in decreasing airway resistance, BAL eosinophilia, mucus production and if administered during sensitization, also TH2 cytokine responses (Ashino S et al., J Allergy Clin Immunol 2014; 133: 1162-74). iJak-381 from Genentech given as dry powder reduced BAL eosinophilia, CCL11, airway resistance, and Muc5AC in OVA- challenged mice. Moreover, it reduced BAL eosinophilia, neutrophilia, CCL11, and CXCL1 in a in mouse model of chronic exposure to AAH allergens (Dengler HS et al., Sci Transl Med 2018;10:eaao2151). Moreover, an oral JAK inhibitor as Tofacitinib, formulated for being administered as aerosol, reduced eosinophils count in a house dust mite mouse model of asthma (Younis US et al., AAPS PharmSci-Tech 2019;20: 167).
Another respiratory disease that could benefit from lung restricted JAK inhibition is Chronic obstructive pulmonary disease (COPD), an inflammatory disease of the lung, most commonly resulting from cigarette smoke exposure, characterised by a largely irreversible and progressive airflow limitation. Despite inflammatory cytokines are drivers of chronic airway inflammation and some of them trigger JAK/STAT activation (IL-6, IFN-y, IL-2, etc.), the role of this pathway in COPD pathogenesis is poorly characterized. Phosphorylated-STAT4+ cells (Di Stefano A et al., Eur Respir J. 2004 Jul; 24(l):78-85) were found to be increased in COPD compared to non- smokers healthy controls. In another study, phosphorylated-STAT3+ and phosphorylated- STAT1+ cells counts were higher in lung biopsies of COPD patients than non-smokers controls while it was not possible to reproduce previous data on phosphorylated-STAT4 molecule (Yew- Booth L et al., Eur Respir J 2015; 46(3):843-5). These data might also suggest a therapeutic use of JAK inhibitors also in COPD disease.
Despite inhalatory administration, safety concerns may still arise by drug levels reaching systemic circulation following inhalation of a JAKi. In addition to a well suited profile for inhalation, a JAKi should preferably possess additional properties that may further limit the systemic exposure after inhalation.
Strong need remains for JAK inhibitors, and particularly inhaled JAK inhibitors that have potential for giving compounds with an improved safety.
In view of the number of pathological responses which are mediated by JAK enzymes, there is a continuing need for inhibitors of JAK enzymes which can be useful in the treatment of many disorders and particularly respiratory diseases.
Thus, the finding of novel safe and potent JAK inhibitor suitable for local administration to the lungs for treatment of asthma and respiratory disease still remains an important need.
SUMMARY OF THE INVENTION
I
Wherein n, K, V and Q and Ri are as defined in the detailed description of the invention; or a pharmaceutically acceptable salt thereof, that are useful as JAK kinase inhibitors.
It is another object of the present invention to provide pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
In one aspect, the present invention provides a compound of formula (I) for use as a medicament. In one aspect the present invention provides the use of a compound of the invention for the manufacture of a medicament.
In a further aspect, the present invention provides the use of a compound of the invention for the preparation of a medicament for the treatment of any disease associated with JAK enzyme mechanisms.
In another aspect, the present invention provides a method for prevention and/or treatment of any disease associated with JAK enzyme mechanisms as above defined, said method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of the invention.
In a particular aspect the compounds of the invention are used alone or combined with other active ingredients and may be administered for the prevention and/or treatment of a pulmonary disease including asthma, Chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), interstitial lung diseases and idiopathic pulmonary fibrosis (IPF), acute lung injury and acute espiratory distress syndrome (ARDS). DETAILED DESCRIPTION OF THE INVENTION Definitions The term “Pharmaceutically acceptable salts” refers to derivatives of compounds of formula I) wherein the parent compound is suitably modified by converting any of the free acid or basic group, if present, into the corresponding addition salt with any base or acid conventionallyntended as being pharmaceutically acceptable. Suitable examples of said salts may thus include mineral or organic acid addition salts of basic residues such as amino groups, as well as mineral or organic basic addition salts of acid esidues such as carboxylic groups. Cations of inorganic bases which can be suitably used to prepare salts of the invention comprise ions of alkali or alkaline earth metals such as potassium, sodium, calcium or magnesium. Those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt comprise, for example, salts of hydrochloric, hydrobromic, sulfuric, phosphoric, methane sulfonic, camphor sulfonic, acetic, oxalic, maleic, fumaric, succinic and citric acids. Many organic compounds can form complexes with solvents in which they are reacted or rom which they are precipitated or crystallized. These complexes are known as “solvates” which are a further object of the invention. Polymorphs and crystalline forms of compounds of formula I), or of pharmaceutically acceptable salts, or solvates thereof are a further object of the invention. The term “Halogen” or “Halo-“ or “halogen atoms” includes fluorine, chlorine, bromine, and iodine atom ; meaning Fluoro, Chloro, Bromo, Iodo as substituent. The term “(C1-C6)Alkyl” refers to straight-chained or branched alkyl groups wherein the number of carbon atoms is in the range 1 to 6. Particular alkyl groups are for example methyl, ethyl, n-propyl, isopropyl, t-butyl, 3-methylbutyl and the like. The expressions “(C1-C6)Haloalkyl” refer to the above defined “(C1-C6)alkyl” groups wherein one or more hydrogen atoms are replaced by one or more halogen atoms, which can be the same or different from each other. Examples include halogenated, poly-halogenated and fully halogenated alkyl groups wherein all of the hydrogen atoms are replaced by halogen atoms, e.g. trifluoromethyl or difluoro methyl groups.
By way of analogy, the terms “(C1-Cx) hydroxyalkyl” or “(C1-Cx) aminoalkyl” refer to the above defined “(C1-Cx) alkyl” groups wherein one or more hydrogen atoms are replaced by one or more hydroxy (OH) or amino group respectively, and wherein x is an integer up to 10. Thus, “(C1- C6)hydroxyalkyl” or “(C1-C6)aminoalkyl” refers to said hydroxy- or amino-alkyl groups wherein the number of carbon atoms is in the range 1 to 6. The definition of aminoalkyl encompasses alkyl groups (i.e. “(C1-C6)alkyl” groups) substituted by one or more amino groups (-NR4R5). An example of aminoalkyl is a mono- aminoalkyl group such as R4R5N-(C1-C6)alkyl, or –(CH2)mNR4R5. Wherein R4 and R5 and m are as defined in the detailed description of the invention. With reference to the substituent R4 and R5 as above defined, it is here further explained that when either R4 and R5 are taken together with the nitrogen atom they are linked to form a 5 to 6 membered heterocyclic radical, at least one further ring carbon atom in the said heterocyclic radical may be replaced by at least one heteroatom or hetero-group (e.g. N, NH, S or O) or may bear an - oxo (=O) substituent group. The said heterocyclic radical might be further optionally substituted on the available points in the ring, namely on a carbon atom, or on an heteroatom or hetero-group available for substitution. Thus, Examples of said heterocycle radicals are 1-pyrrolidinyl, 1- piperidinyl, 1-piperazinyl, 4-morpholinyl, piperazin-4yl-2-one, 4-methylpiperazine-1-yl. The term “(C3-C10)cycloalkyl” likewise “(C3-C6)cycloalkyl” refers to saturated cyclic hydrocarbon groups containing the indicated number of ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and polycyclic ring systems such as adamantan-yl. The expression “Aryl” refers to mono, bi- or tri-cyclic carbon ring systems which have 6 to 20, preferably from 6 to 15 ring atoms, wherein at least one ring is aromatic. The expression “heteroaryl” refers to mono-, bi- or tri-cyclic ring systems with 5 to 20, preferably from 5 to 15 ring atoms, in which at least one ring is aromatic and in which at least one ring atom is a heteroatom (e.g. N, S or O). Examples of aryl or heteroaryl monocyclic ring systems include, for instance, phenyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furanyl radicals and the like. Examples of aryl or heteroaryl bicyclic ring systems include naphthalenyl, biphenylenyl, purinyl, pteridinyl, pyrazolopyrimidinyl, benzotriazolyl, benzoimidazole-yl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, indazolyl, benzothiopheneyl, benzodioxinyl, dihydrobenzodioxinyl, indenyl, dihydro-indenyl, dihydrobenzo[1,4]dioxinyl, benzothiazole-2-yl, dihydrobenzodioxepinyl, benzooxazinyl, 1,2,3,4-tetrahydroisoquinoline-6-yl, 4,5,6,7-
tetrahydrothiazolo[4,5-c]pyridine, 4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl, 5,6,7,8-tetrahydro-1,7- naphthyridine, radicals and the like. Examples of aryl or heteroaryl tricyclic ring systems include fluorenyl radicals as well as benzocondensed derivatives of the aforementioned heteroaryl bicyclic ring systems. The derived expression “(C3-C10)heterocycloalkyl” likewise “(C3-C6)heterocycloalkyl” efers to saturated or partially unsaturated mono, bi- or tri- cycloalkyl groups of the indicated number of carbons, in which at least one ring carbon atom is replaced by at least one heteroatom e.g. N, NH, S or O) and/or may bear an -oxo (=O) substituent group (e.g. C(=O), S(=O)2). Said heterocycloalkyl (i.e. heterocyclic radical or group) is further optionally substituted on the vailable points in the ring, namely on a carbon atom, or on an heteroatom available for ubstitution. Substitution on a carbon atom includes spiro disubstitution as well as substitution on two djacent carbon atoms, in both cases thus form additional condensed 5 to 6 membered heterocyclic ing. Examples of (C3-C6) heterocycloalkyl are represented by: oxetanyl, tetrahydro-furanyl, pyrrolidinyl, imidazolidinyl, thiazolidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, dihydro- or tetrahydro-pyridinyl, tetrahydropyranyl, pyranyl, 2H- or 4H-pyranyl, dihydro- oretrahydrofuranyl, dihydroisoxazolyl, pyrrolidin-2-one-yl, dihydropyrrolyl, 5-oxopyrrolidin-3-yl, 1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl, 1,1-dioxidothiomorpholino, octahydrocyclopenta[c]pyrrol-5-yl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl; 4,5,6,7-etrahydrothiazolo[5,4-c]pyridine-2-yl radicals and the like. Examples of said heterocycle radicals are 1-methyl-2-pyrrolidinyl, 1-piperidinyl, 1- piperazinyl, 4-morpholinyl, piperazin-4-yl-2-one, 4-methylpiperazine-1-yl, 1-methylpiperidin-4- yl, 4-metylpiperazine-1-yl-2-one, 7-methyl-2,7-diazaspiro[3.5]nonan-2-yl, 2-methyl-2,9- diazaspiro[5.5]undecan-9-yl, 9-methyl-3,9-diazaspiro[5.5]undecan-3-yl, and (3aR,6aS)-5-methyl- octahydropyrrolo[3,4-c]pyrrol-2-yl. The term “Aryl(C1-C6)alkyl” refers to an aryl ring linked to a straight-chained or branched lkyl group wherein the number of constituent carbon atoms is in the range from 1 to 6, e.g. phenylmethyl (i.e. benzyl), phenylethyl or phenylpropyl. Likewise the term “Heteroaryl(C1-C6)alkyl” refers to an heteroaryl ring linked to a straight- hained or branched alkyl group wherein the number of constituent carbon atoms is in the range rom 1 to 6, e.g. furanylmethyl. The term “alkanoyl”, refers to HC(O)- or to alkylcarbonyl groups (e.g. (C1-C6)alkylC(O)-) wherein the group “alkyl” has the meaning above defined. Examples include formyl, acetyl, propanoyl, butanoyl.
The term “(C1-C10) alkoxy” or “(C1-C10) alkoxyl”, likewise “(C1-C6) alkoxy” or “(C1-C6) alkoxyl” etc., refers to a straight or branched hydrocarbon of the indicated number of carbons, linked to the rest of the molecule through an oxygen bridge. “(C1-C6)Alkylthio” refers to the above hydrocarbon linked through a sulfur bridge. The derived expression “(C1-C6)haloalkoxy” or “(C1-C6)haloalkoxyl” refers to the above defined haloalkyl, linked through an oxygen bridge. Example of (C1-C6)haloalkoxy is difluoromethoxy, trifluoromethoxy. Likewise derived expression “(C3-C6)heterocycloalkyl-(C1-C6)alkyl” and “(C3- C6)cycloalkyl-(C1-C6)alkyl” refer to the above defined heterocycloalkyl and cycloalkyl groups linked to the rest of the molecule via an alkyl group of the indicated number of carbons, for example piperidin-4-yl-methyl, cyclohexylethyl. The derived expression “(C1-C6)alkoxy (C1-C6)alkyl” refers to the above defined alkoxy group linked to the rest of the molecule via an alkyl group of the indicated number of carbons, for example methoxymethyl. Likewise “(C1-C6)haloalkoxy(C1-C6)alkyl” refers to the above defined (C1-C6)haloalkoxy” group linked to the rest of the molecule via an alkyl group of the indicated number of carbons, for example difluoromethoxypropyl. Likewise “(C1-C6)alkoxycarbonyl” refers to the above defined alkoxy group linked to the rest of the molecule via an carbonyl group. “(C1-C6)alkylthiocarbonyl-” refers to the above alkylthio group linked to the rest of the molecule via a carbonyl group (C=O). “(C1-C6)alkoxycarbonyl-(C1-C6)alkyl” refers to the above defined alkoxy group linked to the rest of the molecule via an carbonyl group further enchained with an alkyl group of the indicated number of carbons, for example methoxycarbonylmethyl. “(C1-C6)alkoxycarbonyl-(C1-C6)alkylthio” consequently refer to the indicated enchained groups like methoxycarbonylmethylthio. Other derived expression will be apparent in their meaning e.g. “halo-((C1-C6)alkyl(C3-C8)heterocycloalkyl)” refer to enchained groups like 4-fluoro-1- methylpyrrolidin-3-yl. An oxo moiety is represented by (O) as an alternative to the other common representation, e.g. (=O). Thus, in terms of general formula, the carbonyl group is herein preferably represented as –C(O)– as an alternative to the other common representations such as –CO–, –(CO)– or – C(=O)–. In general the bracketed group is a lateral group, not included into the chain, and brackets are used, when deemed useful, to help disambiguating linear chemical formulas; e.g. the sulfonyl
group -SO2- might be also represented as–S(O)2– to disambiguate e.g. with respect to the sulfinic group –S(O)O–. When a numerical index the statement (value) “p is zero” or “p is 0” means that the substituent or group bearing the index p (e.g. Ip) is absent, that is to say no substituent, other than H when needed, is present. Likewise when the index is attached to a bridging divalent group (e.g. (CH2)m) the statement “m in each occurrence is zero…” or “m is 0” means that the bridging group is absent, that is to say it is a bond. Whenever basic amino or quaternary ammonium groups are present in the compounds of formula (I), physiological acceptable anions, selected among chloride, bromide, iodide, trifluoroacetate, formate, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, p-toluenesulfonate, pamoate and naphthalene disulfonate may be present. Likewise, in the presence of acidic groups such as COOH groups, corresponding physiological cation salts may be present as well, for instance including alkaline or alkaline earth metal ions. Compounds of formula (I) when they contain one or more stereogenic center, may exist as optical stereoisomers. Where the compounds of the invention have at least one stereogenic center, they may accordingly exist as enantiomers. Where the compounds of the invention possess two or more stereogenic centers, they may additionally exist as diastereoisomers. It is to be understood that all such single enantiomers, diastereoisomers and mixtures thereof in any proportion are encompassed within the scope of the present invention. The absolute configuration (R) or (S) for carbon bearing a stereogenic center is assigned on the basis of Cahn-Ingold-Prelog nomenclature rules based on groups’ priorities. “Single stereoisomer”, “single diastereoisomer” or “single enantiomer”, when reported near the chemical name of a compound indicate that the isomer was isolated as single diastereoisomer or enantiomer (e.g via chiral chromatography) but the absolute configuration at the relevant stereogenic center was not determined/assigned. Atropisomers result from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers (Bringmann G et al, Angew. Chemie Int. Ed. 44 (34), 5384-5427, 2005. doi:10.1002/anie.200462661). Oki defined atropisomers as conformers that interconvert with a half-life of more than 1000 seconds at a given temperature (Oki M, Topics in Stereochemistry 14, 1-82, 1983). Atropisomers differ from other chiral compounds in that in many cases they can be equilibrated thermally whereas in the other forms of chirality isomerization is usually only possible 35 chemically.
Separation of atropisomers is possible by chiral resolution methods such as selective crystallization. In an atropo-enantioselective or atroposelective synthesis one atropisomer is formed at the expense of the other. Atroposelective synthesis may be carried out by use of chiral auxiliaries like a Corey Bakshi Shibata (CBS) catalyst, an asymmetric catalyst derived from proline, or by approaches based on thermodynamic equilibration when an isomerization reaction favors one atropisomer over the other. Racemic forms of compounds of formula (I) as well as the individual atropisomers (substantially free of its corresponding enantiomer) and stereoisomer-enriched atropisomer mixtures are included in the scope of the present invention. The invention further concerns the corresponding deuterated derivatives of compounds of formula (I). In the context of the present invention, deuterated derivative means that at least one position occupied by a hydrogen atom is occupied by deuterium in an amount above its natural abundance. Preferably, the percent of deuterium at that position is at least 90%, more preferably at least 95%, even more preferably 99%. All preferred groups or embodiments described above and here below for compounds of formula (I) may be combined among each other and apply as well mutatis mutandis. As above mentioned, the present invention provides compounds of general formula (I), acting as JAK inhibitors, to processes for the preparation thereof, pharmaceutical compositions comprising them either alone or in combination with one or more active ingredient, in admixture with one or more pharmaceutically acceptable carriers. In a first aspect the present invention provides compounds of formula (I)
I wherein 25 R1 is selected from pyrazolo[1,5-a]pyrimidin-3-yl and (3-oxo-3,4-dihydropyrazin-2- yl)amino;
graphically represented respectively by compounds of formula I-1 or I-2
I-2 wherein the substituent group
is comprising at least one ester or thioester moiety (i.e. by selecting appropriate combination of V, Q, R4 and R5); V is a divalent group selected from C(O)O, C(O)N(R6), N(R6)C(O)O; Q is selected from the group consisting of (C1-C6)alkoxycarbonyl, -(CH2)mNR4R5, (C3- C8)cycloalkyl and (C3-C6)heterocycloalkyl; wherein said (C3-C8)cycloalkyl and (C3- 15 C6)heterocycloalkyl are optionally substituted by one or more substituent group selected from the group consisting of (C1-C6)alkoxycarbonyl(CH2)m, that is preferably (C1-C6)alkoxycarbonyl
(when m is zero), (C3-C8)cycloalkyl-oxycarbonyl, NC-(C1-C6) alkoxycarbonyl, (C1-C6)haloalkyl- oxycarbonyl, (C3-C8)heterocycloalkyl-oxycarbonyl, (C1-C6)alkyl(C3-C8)heterocycloalkyl- oxycarbonyl, (C3-C8)heterocycloalkyl-(C1-C6)alkoxycarbonyl, (C1-C6)alkyl-(C3- C8)heterocycloalkyl-(C1-C6)alkoxycarbonyl, (C1-C6)hydroxyalkyl-oxycarbonyl, (C1- C6)aminoalkyl-oxycarbonyl, (C1-C6)alkoxy-(C1-C6)alkyl-oxycarbonyl, (C1-C6)alkylthiocarbonyl, NC-(C3-C8)cycloalkyl(C1-C6)alkoxycarbonyl, NC-(C3-C8)cycloalkyl-oxycarbonyl, (C1- C6)haloalkyl-(C3-C8)heterocycloalkyl-oxycarbonyl, halo-((C1-C6)alkyl(C3-C8)heterocycloalkyl)- oxycarbonyl, (C1-C6)haloalkyl-(C3-C8)heterocycloalkyl-(C1-C6)alkoxycarbonyl, (C1- C6)haloalkyl-(C3-C8)heterocycloalkyl-oxycarbonyl-(C1-C6)alkyl, (C1-C6)hydroxyalkyl- oxycarbonyl-(C1-C6)alkyl, (C1-C10)alkyl and halogen; K is selected from O, CH2, S; n and m are in each occurrence independently 0 or an integer selected from 1, 2, 3 and 4; R4 and R5, the same or different, are selected from the group consisting of -H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C6)heterocycloalkyl (C1-C6)alkyl-(C3-C8)heterocycloalkyl; (C1-C6)alkoxycarbonyl-methyl; (C1-C6)alkoxycarbonyl-phenyl-methyl; and (C1-C6)alkoxycarbonyl-(C1-C6)alkyl -phenyl-methyl; R6 is in each occurrence independently selected from the group consisting of H, (C1- C6)alkyl, (C1-C6)hydroxyalkyl; or a pharmaceutically acceptable salt or solvate thereof. Preferred, in the above group are compounds of formula I-1 wherein K is O; represented by the formula (Ia)
Ia
wherein V is C(O)N(R6), Q is (C3-C6)heterocycloalkyl, preferably a piperidine moiety, substituted by a group selected from (C1-C6)alkoxycarbonyl, (C3-C8)cycloalkyl-oxycarbonyl, NC-(C1-C6) alkoxycarbonyl, (C1- C6)haloalkyl-oxycarbonyl, (C1-C6)alkyl(C3-C8)heterocycloalkyl-oxycarbonyl, (C1- C6)hydroxyalkyl -oxycarbonyl, (C1-C6)alkoxy(C1-C6)alkyl -oxycarbonyl and (C1- C6)alkylthiocarbonyl; n is in each occurrence independently 0 or an integer selected from 1, 2, 3 and 4; R6 is in each occurrence independently selected from the group consisting of H, (C1- C6)alkyl, (C1-C6)hydroxyalkyl; or a pharmaceutically acceptable salt or solvate thereof. Particularly preferred compounds in this embodiment are: -
c]pyridine-3-carboxamido)ethyl)piperidine-4-carboxylate
Example Chemical Name
A further preferred embodiment in the above group of compounds of formula (I) is that wherein V is a divalent group C(O)O; Q is selected from the group consisting of (C1-C6)alkoxycarbonyl, -(CH2)mNR4R5, and (C3- C6)heterocycloalkyl optionally substituted by one or more group selected from (C1-C10)alkyl and halogen; n and m are in each occurrence independently 0 or an integer selected from 1, 2, 3 and 4; R4 and R5, the same or different, are selected from the group consisting of -H, (C1-C6)alkyl, single enantiomers, diastereoisomers and mixtures thereof or a pharmaceutically acceptable salt or solvate thereof. Another preferred embodiment in the above group of compounds of formula (I), when K is equal to S, is a compound represented by formula (Ib)
Ib wherein V is a divalent group selected from N(R6)C(O)O; Q is selected from the group consisting of (C1-C6)alkoxycarbonyl; 20 n is an integer selected from 1, 2, 3 and 4;
R6 is in each occurrence independently selected from the group consisting of H, (C1-C6)alkyl; single enantiomers, diastereoisomers and mixtures thereof or a pharmaceutically acceptable salt or solvate thereof. Another preferred embodiment in the above group of compounds of formula (I-2), when K is equal to O or S, is a compound represented by formula (Ic)
wherein V is a divalent group selected from C(O)N(R6); Q is (C3-C6)heterocycloalkyl substituted by one (C1-C6)alkoxycarbonyl(CH2)m; n is an integer selected from 1, 2, 3 and 4; R6 is in each occurrence independently selected from the group consisting of H, (C1-C6)alkyl; single enantiomers, diastereoisomers and mixtures thereof or a pharmaceutically acceptable salt or solvate thereof. According to specific embodiments, the present invention provides the compounds of examples 1-59, as listed in the table below, or pharmaceutical acceptable salts and solvates thereof.
yl)carbamoyl)oxy)cyclobutane-1-carboxylate
ethyl 2-(((1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6- - - - - - -
- c]pyridine-3-carboxamido)ethyl)piperidine-4-carboxylate
(tetrahydro-2H-pyran-4-yl)methyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- - - - - - - - - - -
carboxamido)ethyl)octahydrocyclopenta[c]pyrrole-5-carboxylate
ethyl (1R,5S,6r)-3-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- - - - -
carboxamido)ethyl)piperidine-4-carboxylate
2-hydroxy-2-methylpropyl 2-(1-(2-(1-(6-methoxy-3,4-dihydro-2H- - - - - - - - - - -
carboxam do)et y )p per d ne-4-carbot oate The compounds of the invention showed high biochemical potency on JAKs targets (JAK1, JAK2, JAK3 and Tyk2) and high potency on a representative functional assay in cells (such as inhibition of pSTAT6 in BEAS cells stimulated with IL-13). Preferred compounds showed a drop of at least 10 fold or more in the functional activity 5 (such as inhibition of pSTAT6 in BEAS cells stimulated with IL-13) of the predicted carboxylic acid metabolite. More preferred compounds showed a drop even higher than 100 fold, even more preferred higher than 200 fold.
Even more preferred are compounds according to the invention that, in addition to the previous properties, show an high clearance at least in in-vitro stability assays in human and/or mice representative tissues as for example liver microsomes, and/or hepatocytes, and/or plasma, with an half-life less than or equal to 30 min using well established and validated assays. Those assays were adapted from literature methods (Kevin J. Coe & Tatiana Koudriakova, Metabolic Stability Assessed by Liver Microsomes and Hepatocytes, Methods in Pharmacology and Toxicology,2013; L Di, EH Kerns, Y Hong, H Chen, Development and application of high throughput plasma stability assay for drug discovery, International journal of pharmaceutics, 2005) and validated respect to generally accepted literature references (i.e. verapamil for human/mice microsomes/hepatocytes and propantheline for plasma stability in human/mice). During lead optimization, high turnover in tissue stability tests is commonly deemed predictive of an high systemic clearance in-vivo that may further contribute to limit the systemic exposure after inhalation, making these preferred compounds particularly suited for inhaled administration. The compounds of the invention, including all the compounds hereabove listed, can be prepared from readily available starting materials using general methods and procedures as described in the experimental part below or by using slightly modified processes readily available to those of ordinary skill in the art. Although a particular embodiment of the present invention may be shown or described herein, those skilled in the art will recognize that all embodiments or aspects of the present invention can be prepared using the methods described herein or by using other known methods, reagents and starting materials. When typical or preferred process conditions (i.e. reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. While the optimum reaction conditions may vary depending on the particular reactants or solvent used, such conditions can be readily determined by those skilled in the art by routine optimization procedures. Processes of preparation described below and reported in the following schemes should not be viewed as limiting the scope of the synthetic methods available for the preparation of the compounds of the invention. In some cases, a step is needed in order to mask or protect sensitive or reactive moieties, generally known protective groups (PG) could be employed, in accordance with general principles of chemistry (Protective group in organic syntheses, 3rd ed. T. W. Greene, P. G. M. Wuts). Compounds of formula I-1 and I-2, here reported again for clarity, including all here above listed, can be usually prepared according to the procedures shown in the schemes below. Where a specific detail or step differs from the general schemes it has been detailed in the specific examples, 35 and/or in additional schemes.
I-2 Compounds of formula (I-1) can be prepared according to scheme 1 starting from intermediates of formula IIa (or IIb, or IIc) by removing of PG1 by mean of procedures well known to those skilled in the art. A suitable protective group for protecting secondary amines of intermediates IIa (or IIb, or IIc) can be carbamate type protective groups such as Boc (tert- butoxycarbonyl). Boc group can be easily removed by treating Boc protected intermediate IIa (or IIb, or IIc) in acidic conditions with an organic or an inorganic strong acid. For example, Boc group can be cleaved by treating the intermediates with trifluoroacetic acid neat or in mixture with an organic solvent such as DCM, DCE, THF or similar, typically at room temperature overnight. 15 The group Q' present in intermediates of formula IIa (or IIb, or IIc) is a group of formula Q that can undergo a single step functional group interconversion to generate a compound of formula
I-1. Example 43, 44 and 45 were prepared from example 29, 30 and 9 respectively by transesterification with an appropriate alcohol to provide the desired ester. A transesterification reaction can be carried out by reacting parent ester with an excess of the desired alcohol, in the presence of a strong inorganic acid such as sulfuric acid or hydrochloric acid, by heating at high temperature or up to boiling point of the alcohol. It is apparent that in the case such conversions are not needed (when Q' is already Q and/or PG1 is H), any general approach described below for the preparation of intermediate IIa (or IIb, or IIc) will provide a compound of general formula I-1. Intermediate IIa (or IIb, or IIc) can be obtained by direct introduction of pyrazolo[1,5- a]pyrimidin-3-yl moiety through a metal/palladium catalyzed cross coupling reaction such as Suzuki coupling, Stille coupling or similar (Strategic application of named reactions in organic synthesis, L. Kurti, B. Czako, Ed. 2005) by reaction of intermediate IIIa (or respectively IIIb or IIIc) with intermediate VI. For example, a suitable palladium catalyzed cross coupling for introducing pyrazolo[1,5-a]pyrimidin-3-yl moiety can be performed by reacting intermediate IIIa (or IIIb, or IIIc) with the corresponding boronic acid or boron pinacolate (intermediate VI, where A is dihydroxyboryl or 4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl) in the presence of a palladacycle precatalyst as XPhos-Pd-G3 [(2-Dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′- amino-1,1′-biphenyl)]palladium(II) methanesulfonate], or in the presence of Pd catalyst such as tetrakistriphenylphosphinepalladium(0) or PdCl2(dppf)2, in an organic solvent such as THF, 1,4- dioxane, 1,2-dimethoxyethane, 2-propanol or DMF, with or without water, in the presence of an inorganic base like K3PO4 or Cs2CO3, under heating (typically in the range of 50-100ºC) for few hours (typically 1 to 5h). Boronic acid and boronic pinacolate esters are generally commercially available or may be readily prepared by those skilled in the art starting from commercially available reagents. Intermediates of formula IIIa may be obtained from intermediate IVa by means of amide coupling with the corresponding amine Va. An amide coupling can be performed by reacting the amine and the acid in an organic solvent like DMF, DCM, or THF, in the presence of a coupling agent like HATU((1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate), HBTU (O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate) or COMU ((1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino- morpholino-carbenium) and in the presence of an organic base like DIPEA, TEA, or pyridine. Intermediate of formula IIIb may be obtained from intermediate IVa and an alcohol intermediate Vb through a two steps / one pot process that involves: 1) Acylazide formation and Curtius rearrangement to give an isocyanate intermediate and 2) one pot reaction of isocyanate 35 with alcohol Vb to form the corresponding carbamate. The corresponding acyl azide of
intermediate IIIb can be prepared by reaction with an azide source as azido(trimethyl)silane, in the presence of a suitable coupling agents such as T3P and with an organic base like TEA or DIPEA, in an organic solvent such as 2-methyl-THF, DMF or toluene. Subsequent Curtius rearrangement is done by thermal degradation around solvent reflux temperature (generally from 50ºC to 100ºC) for few hours (generally 1-3 hours) to give the corresponding isocyanate; after isocyanate formation, addition of alcohol intermediate Vb and continuing reflux overnight lead to the formation of carbamate of formula IIIb. In some cases, reaction of IVa with intermediate Vb can lead also to formation of intermediate IIIc that can be isolated from the same reaction together with intermediate IIIb.
In another approach, intermediate IIIb may be prepared from intermediate IVb and intermediate Vb by a two steps / one pot process that involve: 1) isocyanate formation and 2) one pot reaction with alcohol Vb to form the corresponding carbamate. Intermediate IVb can be reacted with bis(trichloromethyl) carbonate in an organic solvent as DCM or THF, at low temperature like dry ice temperature (-78ºC), in the presence of an organic base like TEA or DIPEA for times up to 1 or 2 hours to form the corresponding isocyanate; addition of intermediate Vb and reaction at room temperature lead to the formation of carbamate of formula IIIb. In a different approach, intermediate IIa may be obtained from intermediate VIIa and intermediate Va by an amide coupling using the same procedure described above for intermediate IIIa from IVa and Va. In a different approach, intermediate IIc may be obtained from intermediate VIIa and intermediate Vb by esterification reaction promoted by a coupling agent like EDC (1-etil-3-(3- dimetilamminopropil)carbodiimmide) or DIC (N, N′-diisopropilcarbodiimmide), in an organic solvent as DCM or THF, in the presence of an organic base like DMAP or pyridine, at room temperature for few hours (typically 2-4 hours). Intermediate VIIa can be obtained from intermediate IVa and VI by a Suzuki coupling in a similar way to that described above for the reaction of intermediate IIIa (or respectively IIIb or IIIc) with an intermediate VI. Intermediate IVa (or IVb) can be prepared according to scheme 2. Intermediate IVa (or IVb) can be prepared by means of N-arylation of intermediate VIIIa (or VIIIb) with a halide intermediate IX by using copper catalyzed Ullmann type reaction. An Ullmann reaction between a NH heteroaryl and an aryl/heteroaryl halide (bromide or iodide) can be performed in the presence of a suitable copper(I) catalyst/promoter such as CuI, Cu2O or CuTC (copper thiophene carboxylate), ligandless or with a suitable ligand such as N,N-dimethylglicine, proline, phenantroline or dimethylcyclohexane-1,2-diamine (DMCHA), in the presence of an inorganic base such as K2CO3 or Cs2CO3, by heating (typically 90-150ºC) in a polar organic solvent such as DMSO, DMF or DMA, overnight or longer.
Intermediate IX may be obtained from intermediate X in a two steps process that involves PG1 introduction (Boc group introduction) and halogenation or inverting the sequence of the steps. Insertion of Boc group can be carried out by reacting the anilino intermediate with Boc2O in an organic solvent like THF or DCM, in the presence of an organic base like DMAP or pyridine, at room temperature for several hours up to overnight (typically 12 hours). Halogenation reaction can be carried out by reacting the aryl derivative with a source of electrophilic bromine or iodine such as 1,3-Dibromo-5,5-dimethyl-imidazolidine-2,4-dione, N-bromosuccinimide or N- iodosuccinimide, in an organic solvent like ethyl acetate, DMF, or DCM, at temperature around 0ºC or higher (up to 40ºC).
In another approach, intermediate IVa, where K is S and PG1 is H, may be obtained from intermediate VIIIa by means of a multistep synthetic sequence reported in scheme 3. Intermediate VIIIa and intermediate XII can undergo an aromatic nucleophilic substitution (SNAr) to give 5 intermediate XI, for example by reacting them in an organic solvent like DMF or 1,4-dioxane, in the presence of an organic base like DBU or DIPEA, at RT for few hours (typically 4 hours);
addition of methyl halide like MeI at the end of SNAr reaction can lead to in situ methylation of the carboxylic acid and formation of intermediate XI. Intermediate XI can be reacted with mercaptoethanol under Pd-catalyzed C-S coupling conditions to give intermediate XII. C-S coupling can be performed by reacting aryl bromide XI and mercaptoethanol in the presence of a suitable catalytic system like as Pd2(dba)3 / Xantphos or another suitable palladium source / phosphine source, in an organic solvent as 1,4-dioxane, toluene or DMA, in the presence of an organic base like DIPEA or DBU, at temperature up to 100ºC for few hours (typically 3 -5 hours). Intermediate XII can be converted into intermediate XIII by a two steps process that involves: 1) nitro reduction and 2) chlorination. Nitro reduction can be performed by treating intermediate XII with a reducing agent like iron powder or zinc powder, in an organic solvent like methanol or ethanol, in the presence of an aqueous solution of a weakly acid inorganic salt like ammonium chloride, by heating at temperature up to 80ºC for few hours (typically 4-5 hours). Subsequent conversion of alcohol to the corresponding chloride can be achieved by reaction with neat thionyl chloride or oxalyl chloride at low temperature (around 0ºC). Chloride intermediate XIII can be cyclized to give intermediate XIV by heating (typically 80-100ºC) in an appropriate organic solvent like DMF or 1,4-dioxane, in presence of an inorganic base like potassium carbonate or sodium carbonate and in the presence of an additive like sodium iodide. Finally, intermediate XIV can be converted to intermediate IVa (where K is S and PG1 is H) by ester hydrolysis performed by treating the methyl ester in a water-miscible organic solvent like THF or methanol, in the presence of an aqueous solution of an inorganic base like lithium hydroxide or sodium hydroxide, for few hours (typically 2-4 hours) at temperature up to 40ºC.
In another approach (scheme 4), intermediate IIIa can be prepared from intermediate XV by displacement of Lg'' by alkylation with primary/secondary nitrogen present in Q' moiety by treating at room temperature for few hours (typically 5-7 hours) the amine Q' and halide XV in an organic solvent like DMF or 1,4-dioxane, in the presence of an organic base like DIPEA or TEA. Intermediate XV can be obtained from intermediate IVa and XVI by an amide coupling reaction using similar conditions to those reported in scheme 1 for the conversion of intermediate IVa and intermediate Va to intermediate IIIa. In a different approach (scheme 5), intermediate IIIa' (or IIIb') can be prepared from esterification with an alcohol of formula r-OH with the corresponding acid of formula XVIIa (or XVIIb) by using similar conditions to those reported in scheme 1 for the transformation of intermediates VIIa and Vb into IIc.
Intermediate XVIIa (or XVIIb) can be obtained from corresponding intermediate IIIa (or IIIb), where Q' is a metyl ester (Q' is q-COOMe) or ethyl ester (Q' is q-COOEt), by hydrolysis in basic conditions in analogy to what described in scheme 4 for the conversion of intermediate XIV to intermediate IVa. The group Q'' present in intermediates of formula IIIa' (or IIIb') is a group that can undergo a single step functional group interconversion and/or PG deprotection to give a group of formula Q. Intermediates IIIa' (or IIIb') can be converted to compound of formula I-1 by using similar methods reported in scheme 1 to convert intermediate IIIa (or IIIb) to compound of formula I-1. In a different approach (scheme 6), when group Q' in intermediates of formula IIa contain a methyl ester or an ethyl ester, IIa can be transformed in IIa’ by a two steps process can allow transformation of group Q’ to Q’’. In the first step, ester hydrolysis of Q’ of IIa generates an acid intermediate that can be submitted to an esterification with a proper alcohol (r-OH) to give intermediate IIa’. Methyl ester or ethyl ester hydrolysis can be carried out by reacting ester 15 derivative with LiOH, NaOH or a suitable inorganic hydroxide in a mixture of water with THF,
DMF or a suitable polar organic solvent. The acid can be transformed in an ester by activation of acid with a proper coupling agent like 2,4,6-trichlorobenzoyl chloride or HATU, followed by reaction with the corresponding alcohol in the presence of an organic base like TEA, DMAP or DIEA in an organic polar solvent like DMF. This procedure can also apply to the preparation of thioesters by replacing the alcohol (r-OH) with the proper thiol derivative (r-SH). In another approach, compound of formula I-1, when Q contain a terminal CN group, may be prepared from the corresponding intermediate IIa that contain in Q’ a leaving group such as Br or Cl and alkylated with an inorganic cyanide salt like NaCN or KCN in an organic polar solvent like DMF by heating at temperature around 80⁰C or higher.
Compound of formula I-2 can be prepared like to compounds of formula I-1 by using similar synthetic sequences by introducing pyrazin-2(1H)-one-3-aminyl moiety instead of pyrazol[1,5- a]pyrimidine-3-yl moiety. An example of such scheme modifications is provided by scheme 7. A suitable palladium catalyzed cross coupling for introducing pyrazin-2(1H)-one-3-aminyl moiety is a Buchwald-Hartwig coupling. For synthetic convenience the lactam group of (3-oxo-3,4- dihydropyrazin-2-yl)amino needs to be masked as an alkoxyimmino group, where PG2 is methyl, (such as a methoxy immino, -C(OMe)=N-) subsequently deprotected at the end of the synthesis of intermediate XIX. Intermediate IVa and intermediate XVIII can be reacted, to give intermediate XIX, in the presence of a suitable ligand palladacyle system such as XPhos-Pd-G3 (2- Dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′- biphenyl)]palladium(II) methanesulfonate) or RuPhos-Pd-G3 (2-Dicyclohexylphosphino-2′,6′- diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate) or in general a suitable Pd source (for example Pd2(dba)3 or Pd(OAc)2) with a suitable phosphine ligand such as biphenylphosphine ligand type (RuPhos, X-Phos, or similar), in the presence of a strong 25 organic base such as sodium tert-butoxide or an inorganic base such as Cs2CO3, in an organic solvent such 1,4-dioxane, THF or toluene, under heating at high temperature (typically 80-120ºC),
for a few hours (typically overnight). Deprotection of PG2 from intermediate XIX to give intermediate XX can be carried out by treatment of the protected precursor with TMS-Cl (trimethylsilyl chloride) and sodium iodide in acetonitrile for 1 to 5 h at 60 - 100ºC; under these conditions also PG1 when it is Boc can be deprotected. Finally, compound of formula I-2 can be prepared by reaction of intermediate XX with intermediate Va under amide coupling conditions similarly to what described in scheme 1 for the preparation of IIIa from IVa and Va.
As herein described in detail, the compounds of the invention are inhibitors of kinase activity, in particular inhibiting JAK kinase activity for the treatment of JAK-dependent diseases. In one aspect the invention provides compounds according to the invention, i.e. a compound of formula (I) or a pharmaceutical composition thereof, for use as a medicament, preferably for the prevention and /or treatment of respiratory and specifically pulmonary disease. In a further aspect the invention provides the use of a compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of disorders 15 associated with JAK mechanisms, particularly for the treatment of disorders such as respiratory
and pulmonary diseases. In particular the invention provides compounds of formula (I) for use in the prevention and /or treatment of pulmonary disease selected from the group consisting of asthma, chronic obstructive pulmonary disease COPD, idiopathic pulmonary fibrosis (IPF)acute lung injury and acute respiratory distress syndrome (ARDS). Moreover, the invention provides a method for the prevention and/or treatment of disorders associated with JAK mechanisms, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the invention. In particular, the invention provides methods for the prevention and/or treatment wherein the disorder is a respiratory disease selected from asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), acute lung injury and acute respiratory distress syndrome (ARDS). Preferred is the use of the compounds of the invention for the prevention of the aforesaid disorders. Equally preferred is the use of the compounds of the invention for the treatment of the aforesaid disorders. Generally speaking, compounds which are JAK inhibitors may be useful in the treatment of many disorders associated with JAK enzyme mechanisms. In one embodiment, the disorder that can be treated by the compound of the present invention is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease such as idiopathic pulmonary fibrosis (IPF), acute lung injury and acute respiratory distress syndrome (ARDS). In a further embodiment, the disorder is selected from asthma and chronic obstructive pulmonary disease (COPD). The methods of treatment of the invention comprise administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof. As used herein, " effective amount" in reference to a compound of formula (I) or a pharmaceutically acceptable salt thereof or other pharmaceutically active agent means an amount of the compound sufficient to treat the patient's condition but low enough to avoid serious side effects and it can nevertheless be routinely determined by the skilled artisan. The compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. Typical daily dosages may vary depending upon the particular route of administration chosen. 35 The invention also provides pharmaceutical compositions of compounds of formula (I) in
admixture with one or more pharmaceutically acceptable carrier or excipient, for example those described in Remington’s Pharmaceutical Sciences Handbook, XVII Ed., Mack Pub., N.Y., U.S.A. The present invention is also directed to use of the compounds of the invention and their pharmaceutical compositions for various route of administration. Administration of the compounds of the invention and their pharmaceutical compositions may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermally, and by ocular administration. Various solid oral dosage forms can be used for administering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders. The compounds of the present invention can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and known excipients, including suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like. Time release capsules, tablets and gels are also advantageous. Various liquid oral dosage forms can also be used for administering compounds of the invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs. Such dosage forms can also contain suitable known inert diluents such as water and suitable known excipients such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention. The compounds of the present invention may be formulated as injectable composition, for example to be injected intravenously, in the form of an isotonic sterile solution. Other preparations are also possible. Suppositories for rectal administration of the compounds of the invention can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols. Formulations for vaginal administration can be in the form of cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such as suitable carriers, are also known. For topical administration the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose. Topical administration may also involve transdermal administration via means such as transdermal patches. Compounds of the invention may exhibit profile suitable for oral route administration. Optimization of drugs for oral delivery needs certain characteristics that allow orally administered 35 compound to be absorbed by GI (gastrointestinal) tract and to be poorly cleared in order to give a
good bioavailability (F%), thus to maintain a sufficient concentration in plasma and target tissues for a time adequate to sustain pharmacological effect. To enhance oral bioavailability, one or more features of the compounds need to be optimized such as, and not limited to, maximizing membrane permeability and reducing metabolic hot spots (optimizing in-vitro clearance). For the treatment of the diseases of the respiratory tract, the compounds according to the invention, as above said, may also preferably be administered by inhalation. Some preferred compounds of the invention exhibit profile suitable for inhalatory route administration. Drugs optimized for inhaled delivery require certain characteristics that allow the compound, when administered to the lung to maintain a sufficient local concentration (lung retention) to exert a pharmacological effect of the desired duration, with minimal drug absorption in the GI tract for the swallowed fraction and in general non-relevant levels in unwanted compartments (i.e. plasma). For this purpose, one or more features of a compounds were optimized such as, and not limited to, membrane permeability, dissolution rate and the compound’s basicity to enhance its binding to the phospholipid-rich lung tissue or through lysosomal trapping. In some embodiments, compounds of invention show one or more of the features above in the range desirable for an inhaled compound. inhalation, a JAKi should preferably possess additional properties that may further limit the systemic exposure after inhalation. A way to limit systemic exposure, after local administration, might be to design soft-drug that means the introduction of specific moieties, like for example esters in the present invention, which favour a controlled rapid systemic metabolism (in the liver and/or in the blood) into predicted functionally less active, or even negligibly active, metabolites compared to parent compound. For this purpose, one way resulted in the optimization of 'suitably designed esters derivatives' which having corresponding predicted carboxylic acid metabolites showing a drop in functional activity (like cell based activity). Further advantageously, such optimized esters can be substrates of liver and/or blood esterases that may be beneficial for achieving an enhanced clearance in-vivo. Thus, preferred compounds of the invention showed one or more of the following properties: high biochemical activity on target, strong functional activity (like cell based activity), a rapid clearance in representative assays (stability in liver microsomes and/or hepatocytes, plasma stability) and drop in the functional activity of the predicted carboxylic acid metabolite so that they can have potential for giving compounds with an improved safety. Inhalable preparations include inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations and may be administered through a suitable inhalation 35 device which may be respectively selected from dry powder inhaler, pressurized metered dosed
inhaler, or a nebulizer. For administration as a dry powder, single- or multi-dose inhalers known from the prior art may be utilized. In that case the powder may be filled in gelatine, plastic or other capsules, cartridges or blister packs or in a reservoir. A diluent or carrier, e.g. lactose or any other additive suitable for improving the respirable fraction may be added to the powdered compounds of the invention. Inhalation aerosols containing propellant gas such as hydrofluoroalkanes may contain the compounds of the invention either in solution or in dispersed form. The propellant-driven formulations may also contain other ingredients such as co-solvents, stabilizers and optionally other excipients. The propellant-free inhalable formulations comprising the compounds of the invention may be in the form of solutions or suspensions in an aqueous, alcoholic or hydroalcoholic medium and they may be delivered by jet or ultrasonic nebulizers known from the prior art or by soft-mist nebulizers such as Respimat£, a registered trademark of Boehringer Ingelheim Pharmaceuticals (Wachtel, H., Kattenbeck, S., Dunne, S. et al. Pulm Ther (2017) 3: 19. The compounds of the invention, regardless of the route of administration, can be administered as the sole active agent or in combination (i.e. as co-therapeutic agents administered in fixed dose combination or in combined therapy of separately formulated active ingredients) with other pharmaceutical active ingredients. The compounds of the invention can be administered as the sole active agent or in combination with other pharmaceutical active ingredients including those currently used in the treatment of respiratory disorders, and known to the skilled person, such as beta2-agonists, antimuscarinic agents, corticosteroids, mitogen-activated kinases (P38 MAP kinases) inhibitors, PI3K inhibitors (phosphoinositide 3-kinases), nuclear factor kappa-B kinase subunit beta inhibitors (IKK2), Rho kinase inhibitors (ROCKi), human neutrophil elastase (HNE) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, leukotriene modulators, non-steroidal anti-inflammatory agents (NSAIDs) and mucus regulators). The invention is also directed to a kit comprising the pharmaceutical compositions of compounds of the invention alone or in combination with or in admixture with one or more pharmaceutically acceptable carriers and/or excipients and a device which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler or a nebulizer. The dosages of the compounds of the invention depend upon a variety of factors including the particular disease to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, 35 and pharmacokinetic profile of the compound.
A pharmaceutical composition comprising a compound of the invention suitable to be administered by inhalation is in various respirable forms, such as inhalable powders (DPI), propellant-containing metering aerosols (PMDI) or propellant-free inhalable formulations (e.g. UDV). The invention is also directed to a device comprising the pharmaceutical composition comprising a compound according to the invention, which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler and a nebulizer particularly soft mist nebulizer. The following examples illustrate the invention in more detail. The features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof. PREPARATION OF INTERMEDIATES AND EXAMPLES General Experimental details Chemical Names of the compounds were generated with Structure To Name Enterprise 10.0 Cambridge Software or latest. Purification by 'chromatography' or 'flash chromatography’ refers to purification using a Biotage SP1, or Interchim puriFlash purification system, or Biotage Isolera Four purification system equipped with Biotage Dalton 2000 mass detector, or equivalent MPLC using a pre-packed polypropylene column containing stationary phase (cartridge). Where products were purified using a Si cartridge, this refers to an Interchim (or equivalent) pre-packed polypropylene column containing unbounded activated silica with spherical particles with average size of 15 μm or Isolute® (or equivalent) pre-packed polypropylene column containing unbounded activated silica with irregular particles with average size of 50 μm. Fractions containing the desired product (identified by TLC and/or LCMS analysis) were pooled and concentrated in vacuo. Purification by 'reverse phase chromatography' or 'reverse phase flash flash chromatography' refers to purification on MPLC instrument with with C18 functionalized silica cartridges, as Biotage Sfar C18 or equivalents. Where an SCX-2 cartridge was used, ‘SCX-2 cartridge’ refers to a Bond Elut® pre-packed polypropylene column containing a non-end-capped propylsulphonic acid functionalised silica strong cation exchange sorbent. Where preparative HPLC-MDAP was used for purification (MDAP: mass directed automatic purification) fractions containing the desired product were pooled and the solvent removed by evaporation or alternatively lyophilised. NMR Methods NMR spectra were obtained on a Bruker Avance III 600 (5 mm RT inverse probe head), Bruker DRX 500, Bruker Avance AV 400 (5 mm RT direct probehead) or Bruker DPX 300
spectrometers using standard Bruker pulse sequences. Alternatively, NMR spectra were recorded with Varian MR-400 spectrometer operating at 400 Mhz or a Varian Unity Inova 400 spectrometer with a 5 mm inverse detection triple resonance probe operating at 400 MHz. DMSO-d6 or CDCl3 were used as solvents. Chemical shifts are given in relative to internal standard tetramethylsilane or solvent residual peak. All experiments were recorded at 298 K, unless stated differently. Coupling constants, (J values) are given in hertz (Hz) and multiplicities are reported using the following abbreviation: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad, nd=not determined. LCMS Methods Method 1 Acquity UPLC coupled with SQD mass spectrometer; Column: Acquity UPLC BEH C18 (50mm x 2.1mm i.d., 1.7μm packing diameter), mobile phase A: 0.1% formic acid in water, mobile phase B: 0.1% formic acid in acetonitrile;
Column temperature: 40 °C; UV detection: from 210 nm to 350 nm; MS conditions: Ionisation Mode: alternate-scan Positive and Negative Electrospray (ES+/ES-), Scan Range: 100 to 1000 AMU. Method 2 Acquity UPLC coupled with SQD mass spectrometer; Column: Acquity UPLC BEH C18 (50mm x 2.1mm i.d., 1.7μm packing diameter), mobile phase A: 10 mM aqueous solution of ammonium bicarbonate (adjusted to pH 10 with ammonia), mobile phase B: acetonitrile;
2.00 0.05 97 3 Column temperature: 40 °C; UV detection: from 210 nm to 350 nm; MS conditions: Ionisation Mode: alternate-scan Positive and Negative Electrospray (ES+/ES-), Scan Range: 100 to 1000 AMU. Method 3
AGILENT LC 1260 Infinity with SFC and Agilent 6540 UHD Accurate-Mass Q-TOF LC/MS; Column: Acquity UPLC BEH C18 (100mm x 2.1mm i.d., 1.7μm packing diameter), mobile phase A: 0.1% formic acid in water, mobile phase B: 0.1% formic acid in acetonitrile; Gradient-Time Flow (mL/min) A % B%
Column temperature: 40 °C; UV detection: from 210 nm to 350 nm; MS conditions: Ionisation Mode: alternate-scan Positive and Negative Electrospray (ES+/ES-), Scan Range: 100 to 1500 AMU. Method 4 AGILENT LC 1260 Infinity with SFC and Agilent 6540 UHD Accurate-Mass Q-TOF LC/MS; Column: Acquity UPLC BEH C18 (100mm x 2.1mm i.d., 1.7μm packing diameter), mobile phase A: 0.05 % aqueous ammonia, mobile phase B: acetonitrile;
Column temperature: 40 °C; UV detection: from 210 nm to 350 nm; MS conditions: Ionisation Mode: alternate-scan Positive and Negative Electrospray (ES+/ES-), Scan Range: 100 to 1000 AMU. Method 5 Shimadzu LCMS-2020 Single Quadrupole Liquid Chromatograph Mass Spectrometer; Column: Acquity UPLC BEH C18 (100mm x 2.1mm i.d., 1.7μm packing diameter), mobile phase A: 0.1 % formic acid in water, mobile phase B: 0.1% formic acid in acetonitrile;
3.00 0.5 80 20
Column temperature: 25 °C; UV detection: 215 nm and 254 nm; MS conditions: Ionisation Mode: alternate-scan Positive and Negative Electrospray (ES+/ES-), Scan Range: 100 to 1000 AMU. Method 6 Acquity UPLC coupled with QDA mass detector; Column: Acquity UPLC CSH C18 (50mm x 2.1mm i.d., 1.7μm packing diameter), mobile phase A: 0.05% (v/v) formic acid in water/MeCN 95/5, mobile phase B: 0.05% (v/v) formic acid in acetonitrile/water 95/5; Gradient – Time Flow (mL/min) A % B%
Column temperature: 40 °C; UV detection: from 210 nm to 350 nm; MS conditions: Ionisation Mode: alternate-scan Positive and Negative Electrospray (ES+/ES-), Scan Range: 100 to 1000 AMU. HPLC-MDAP Method 1 Agilent 1290 Infinity II Purification System; Column: Waters XBridge® (C18, 100 mm x 19 mm i.d., 5 μm), mobile phase A: 0.1% (v/v) formic acid in water, mobile phase B: acetonitrile;
. Abbreviations used: Boc2O = Di-tert-butyl dicarbonate; aq.=aqueous; DBU = 1,8-Diazabicyclo[5.4.0]undec-7- ene; DCC = Dicyclohexylcarbodiimine; DCM = Dichloromethane; DIPEA = N,N- Diisopropylethylamine; DMAP = 4-dimethylaminopyridine; DMCHDA = trans-N,N′- Dimethylcyclohexane-1,2-diamine; DMF = N,N-Dimethylformamide; DMSO = 20 Dimethylsulfoxide; EDC.HCl = Ethyl-N,N-dimethylaminoethyl-carbodiimide. Hydrochloride; EtOAc = Ethyl acetate; HATU = (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate); LCMS = Liquid chromatography-mass spectrometry; 1H-NMR = Proton nuclear magnetic resonance; RM = Reaction mixture; Rt = Retention time; RT = Room temperature; sat.=saturated; T3P® = Propylphosphonic anhydride; TEA = Triethylamine; TFA = Trifluoroacetic acid; THF = Tetrahydrofuran; Xphos–Pd-G3-(2-Dicyclohexylphosphino- 2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate In the procedures that follow, some of the starting materials are identified through an “Intermediate” or “Example” number with indications on Step number. This is provided merely for assistance to the skilled chemist. A “similar” or “analogous” procedure means that such a procedure may involve minor variations, for example reaction temperature, reagent/solvent amount, reaction time, work-up conditions and/or chromatographic purification conditions. The stereochemistry of the compounds in the Examples, where indicated, has been assigned on the assumption that absolute configuration at resolved stereogenic centres of starting materials is maintained throughout any subsequent reaction conditions. Unless otherwise stated, where absolute configuration (R) or (S) is reported in the compound name, ee% has to be considered equal or greater than 90%. PREPARATION OF INTERMEDIATES Intermediate 1 Step 1
Ethyl 1-(2-((tert-butoxycarbonyl)amino)ethyl)piperidine-4-carboxylate (Intermediate 1-1) A suspension of tert-butyl N-(2-bromoethyl)carbamate (3 g, 13.0 mmol), ethyl piperidine- 4-carboxylate (2.1 mL, 13.0 mmol) and K2CO3 (3.7 g, 27 mmol) in DMF (30.0 mL) was stirred at 65 °C for 24 h. After cooling to RT, RM was diluted with water (80 mL) and extracted with EtOAc (3 x 80 mL). Combined organics were washed with sat. aq. NaHCO3 (80 mL) and sat. aq. NaCl (50 mL). Organic solvent was removed in vacuo and residue was purified by flash chromatography on Si cartridge by eluting with 0-50 % DCM:MeOH (93:7) in DCM to afford the title product (3.24 g). 30 LCMS (Method 2): Rt = 1.05 min, ES+ m/z 301.3 [M+H]+.
Step 2
Ethyl 1-(2-aminoethyl)piperidine-4-carboxylate (Intermediate 1) A solution of intermediate 1-1 (1.77 g, 5.9 mmol) and TFA (8.8 mL, 118 mmol) in DCM (14 mL) was stirred at RT overnight. Volatiles were removed in vacuo and crude product passed through an SCX cartridge, washed with EtOH (500 mL) and eluted with 15% aq. NH3 in EtOH (100 mL) to afford the title product (1.16 g). 1H-NMR (300 MHz, CDCl3) δ: 4.13 (q, J=6.9 Hz, 2H), 2.84-2.88 (m, 2H), 2.78 (t, J=6.2 Hz, 2H), 2.39 (t, J=6.2 Hz, 2H), 2.24-230 (m, 1H), 2.02 (t, J=11.5 Hz, 2H), 1.87-1.91 (m, 2H), 1.71- 1.79 (m, 2H), 1.25 (t, J=6.9 Hz, 3H). Intermediate 2a Step 1
1-Methoxy-2-methylpropan-2-yl 1-benzylpiperidine-4-carboxylate (Intermediate 2a- 1) A solution of 1-benzylpiperidine-4-carboxylic acid (500 mg, 2.26 mmol) in DCM (15.0 mL) was treated with oxalyl dichloride (1.94 mL, 22.6 mmol) and DMF (52.2 μL, 0.68 mmol). RM was stirred at RT for 2h, then volatiles were evaporated in vacuo. The residue was taken with DCM (5.0 mL), cooled to 10 °C and followed by the addition of 1-methoxy-2-methyl-propan-2-ol (1.32 mL, 11.3 mmol) and DIPEA (2.52 mL, 18.1 mmol). RM was stirred at RT for 16 h. RM was quenched with water (20 mL) and extracted with DCM (3 x 20 mL). Combined organic layers were passed through a phase separator and solvent removed in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-50% DCM/MeOH (20:1) in DCM to give the desired product. (242 mg). 5 LCMS (Method 1): Rt = 0.64 min, ES+ m/z 306.2 [M+H]+. Step 2
1-Methoxy-2-methylpropan-2-yl piperidine-4-carboxylate (Intermediate 2a) A solution of intermediate 2a-1 (242 mg, 0.27mmol) in MeOH (6 mL) was added with Pd/C (10 %, 77.8 mg, 0.07 mmol) and kept under hydrogen atmosphere at 1 bar (baloon pressure) for 16 h. RM was filtered through a bed of diacetomatous earth and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-100 % DCM/MeOH/NH4OH (90:15:1.5) in DCM To give the title product (113 mg). 1H-NMR (300 MHz, CDCl3) δ: 3.48 (s, 2H), 3.34 (s, 3H), 3.05 (dt, J=12.5, 3.9 Hz, 2H), 2.60 (td, J=12.0, 2.6 Hz, 2H), 2.33 (tt, J=11.0, 3.8 Hz, 1H), 1.79-1.87 (m, 2H), 1.49-1.62 (m, 2H), 1.40 (s, 6H). Intermediate 2b Step 1
1-benzyl 4-((tetrahydro-2H-pyran-4-yl)methyl) piperidine-1,4-dicarboxylate (Intermediate 2b-1) 1-phenylmethoxycarbonylpiperidine-4-carboxylic acid (300 mg, 1.14 mmol) was suspended in a mixture MeCN/DMF 5/2 (7.0 ml), then 4-(bromomethyl)tetrahydro-2H-pyran and cesium carbonate were added and the mixture was stirred at 40ºC for 18h. The mixture was filtered, and the crude purified by chromatography on Si cartridge by eluting with hexane\EtOAc gradient to afford the desired product (300 mg). LCMS (Method 6): Rt = 1.09 min, ES+ m/z 362.2 [M+H]+ Step 2
(Tetrahydro-2H-pyran-4-yl)methyl piperidine-4-carboxylate (Intermediate 2b) 25 A solution of intermediate 2b-1 (300 mg, 0.83mmol) in EtOH (6 mL) was added with Pd/C (5 %, 50 mg ) and pH adjusted below 2 with aq. HBr 2M. RM was kept under hydrogen atmosphere
for 3 h, then filtered through a pad of silica gel and concentrated to dryness to afford the title product (188 mg). LCMS (Method 6): Rt = 0.23 min, ES+ 228.28 m/z [M+H]+ Intermediate 2c Step 1
1-benzyl 4-(1-methylpiperidin-4-yl) piperidine-1,4-dicarboxylate (Intermediate 2c-1) 1-((benzyloxy)carbonyl)piperidine-4-carboxylic acid (350 mg, 1.33 mmol, 82) was suspended in 5 mL of dry DCM, added with a drop of dry DMF and followed by dropwise addition oxalyl chloride (233 μl, 2.66 mmol). After 1h, RM was concentrated to dryness and taken with dry DCM (10 ml) and the solution added dropwise to a mixture of -methylpiperidin-4-ol (230 mg, 1.994 mmol) and DIPEA (697 μl, 3.99 mmol) in dry DCM. After 1h, RM was quenched by the addition of aq. sat. NaHCO3 (20 ml) and the organic layer separated, dried over Na2SO4 and concentrated to dryness. The crude material was purified by chromatography on Si cartridge by eluting with 0-20% MeOH in DCM to afford the title product (391 mg). LCMS (Method 6): Rt = 0.55 min, ES+ 361.3 m/z [M+H]+ Step 2
1-methylpiperidin-4-yl piperidine-4-carboxylate (Intermediate 2c) To a solution of intermediate 2c-1 (400 mg, 1.110 mmol) in EtOH (6 mL) was added Pd/C 5% (50 mg) and pH adjusted below 2 with aq. HCl 2M. The RM was kept under hydrogen atmosphere for 3 h, then filtered through a pad of silica gel and concentrated to dryness to afford the desired compound (230 mg). 25 LCMS (Method 6): Rt = 0.17 min, ES+ 227.3 m/z [M+H]+ Intermediate 3 Step 1
7-Bromo-6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine (Intermediate 3-1) A solution of 6-methoxy-3,4-dihydro-2H-1,4
enzoxazine (3.0 g, 18.20 mmol) in EtOAc (30.0 mL) was cooled to 0°C. 1,3-Dibromo-5,5-dimethyl-imidazolidine-2,4-dione (2.6 g, 9.08 mmol) was added portion-wise over 15 minutes. RM was stirred for additional 30 min at 0°C and quenched with an aqueous K2CO3 solution (10% w/w; 60 mL). The organic layer was separated, washed with sat. aq. NaCl and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-30 % EtOAc in cyclohexane to afford the title product (3.5 g). LCMS (Method 1): Rt = 0.97 min, ES+ m/z 243.9/245.9 [M+H]+. Step 2
tert-Butyl 7-bromo-6-methoxy-2,3-dihydro-4H e-4-carboxylate
(Intermediate 3) THF (15 mL) was added to a mixture of intermediate 3-1 (1.4 g, 5.74 mmol), DMAP (840.9 mg, 6.88 mmol) and Boc2O (2.80 g, 13.19 mmol), then RM stirred at RT overnight. RM was partitioned between EtOAc (50 mL) / water (30 mL). The organic layer was washed with 2M aq. citric acid (2x20 mL), sat. aq. NaCl (20 mL) and evaporated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-10 % EtOAc in cyclohexane to afford the title compound (1.26 g). LCMS (Method 1): Rt = 1.27 min 1H-NMR (300 MHz, CDCl3) δ: 7.56 (brs, 1H), 7.05 (s, 1H), 4.14-4.18 (m, 2H), 3.82 (s, 3H), 3.78-3.82 (m, 2H), 1.53 (s, 9H). Intermediate 4 25 Step 1
tert-Butyl 7-methoxy-3,4-dihydroquinoline-1(2H)-carboxylate (Intermediate 4-1) A solution of 7-methoxy-1,2,3,4-tetrahydroquinoline (500 mg, 3.06 mmol), DMAP (449 mg, 3.68 mmol) and Boc2O (1.54 g, 7.05 mmol) in THF (10 mL) was stirred at RT overnight. A further equivalent of Boc2O was added and stirring proceed at RT. RM was partitioned between EtOAc (50 mL) and water (30 mL). The organic layer was washed with aq.2M citric acid (2x15 mL), sat. aq. NaCl (20 mL) and solvent evaporated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-10 % EtOAc in cyclohexane to afford the title product (228 mg). LCMS (Method 1): Rt = 1.35 min 1H-NMR (300 MHz, DMSO-d6) δ: 7.18 (d, J=2.5 Hz, 1H), 6.98 (d, J=8.6 Hz, 1H), 6.57 (dd, J=8.5, 2.6 Hz, 1H), 3.69 (s, 3H), 3.56-3.60 (m, 2H), 2.63 (t, J=6.46 Hz, 2H), 1.74-1.82 (m, 2H), 1.45 (s, 9H). Step 2
tert-Butyl 6-bromo-7-methoxy-3,4-dihydroquinoline-
-carboxylate (Intermediate 4) A solution of intermediate 4-1 (228 mg, 0.86 mmol) in EtOAc (10 mL) was cooled to 0°C. 1,3-dibromo-5,5-dimethyl-imidazolidine-2,4-dione (124 mg, 43.3 mmol) was added portion wise over 15 min. RM was stirred at 0 °C for 20 min, then quenched with 10 % (w/w) aq. K2CO3 (20 mL). The organic layer was separated, washed with sat. aq. NaCl (20 mL) and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-15 % EtOAc in cyclohexane to afford the title product (240 mg). LCMS (Method 1): Rt = 1.46 min, ES+ m/z 285.9/287.9 [M+H]+. 25 Intermediate 5 Step 1
tert-butyl 6-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Intermediate 5-1) The title compound was prepared in a similar manner of intermediate 4-step 1 starting from 6-methoxy-3,4-dihydro-2H-1,4-benzoxazine. LCMS (Method 5): Rt = 2.5 min 1H-NMR (300 MHz, DMSO-d6) δ: 7.47 – 7.38 (m, 1H), 6.77 (d, J = 8.9 Hz, 1H), 6.57 (dd, J = 8.9, 3.0 Hz, 1H), 4.18 – 4.09 (m, 2H), 3.80 – 3.72 (m, 2H), 3.68 (s, 3H), 1.50 (s, 9H). Step 2
tert-butyl 7-iodo-6-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Intermediate 5) Intermediate 5-step 1 (5.9g, 22.1 mmol) was dissolved in DMF (60mL), then N- Iodohydroxysuccinimide (12.7g, 111 mmol) added and RM stirred at 40°C overnight. RM was quenched in cold water and extracted with EtOAc. Combined organic layers were evaporated to dryness and the residue purified by chromatography on silica gel by gradient elution from 1:1 to 3:2 DCM-Hexane to afford the title compound (7.38g). LCMS (Method 1): Rt = 2.8 min 1H-NMR (300 MHz, DMSO-d6) δ: 7.50 (s, 1H), 7.24 (s, 1H), 4.14 (dd, J = 5.3, 3.8 Hz, 2H), 3.80 – 3.75 (m, 2H), 3.74 (s, 3H), 1.51 (s, 9H). Intermediate 6 Step 1
Methyl 1-(5-bromo-2-methoxy-4-nitrophenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3- carboxylate (Intermediate 6-1) 6-Chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (3.00 g, 15.2 mmol) was added to a solution of 1-bromo-5-fluoro-4-methoxy-2-nitro-benzene (3.80 g, 20.2 mmol) and DBU (5.88 mL, 45.6 mmol) in DMF (48 mL). RM was stirred at RT for 4 h. Iodomethane (3.78 mL, 60.7 mmol) was added and RM stirred at RT overnight. RM was quenched into water (200 mL), the formed precipitate was collected by filtration and dried. The crude material was triturated in EtOAc and washed with EtOAc to give the title product (5.83 g) that was used in the next synthetic step without further purification. LCMS (Method 1): Rt = 1.08 min, ES+ m/z 426.9/428.9/430.9 [M+H]+. Step 2
Methyl 6-chloro-1-(5-((2-hydroxyethyl)thio)-2-methoxy-4-nitrophenyl)-1H- pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 6-2) A degassed mixture of intermediate 6-1 (5.0 g, 11 mmol), 2-sulfanylethanol (1.13 mL, 12 mmol), DIPEA (5.91 mL, 20 mmol), Xantphos (820 mg, 1.4 mmol) and Pd2(dba)3 (330 mg, 0.57 mmol) in 1,4-dioxane (100 mL) was stirred at 100°C under argon for 3 h. After cooling to RT, reaction was quenched with water. The formed precipitate was collected by filtration, washed with a small amount of EtOAc and dried to afford the title compound (5.3 g) that was used in the next synthetic step without further purification. LCMS (Method 1): Rt = 1.08 min, ES+ m/z 439.0/441.0 [M+H]+. Step 3
Methyl 1-(4-amino-5-((2-hydroxyethyl)thio)-2-methoxyphenyl)-6-chloro-1H- pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 6-3) A solution of intermediate 6-2 (5.3 g, 12 mmol) in MeOH (200 mL) was stirred at 80 °C, then followed by the addition of a solution of NH4Cl (6.5 g, 121 mmol) in water (20 mL) and iron powder (6.7 g, 121 mmol). RM was stirred at 80 °C for 4.5 h, then filtered while still hot and the filtrate concentrated in vacuo. The crude material was diluted with sat. aq NaHCO3, the resulting suspension sonicated and the solids collected by filtration. The solid material was washed several times with water and dried to afford the title product (3.13 g). LCMS (Method 1): Rt = 0.92 min, ES+ m/z 409.1/411.1 [M+H]+. Step 4
Methyl 1-(4-amino-5-((2-chloroethyl)thio)-2-methoxyphenyl)-6-chloro-1H- pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 6-4) Intermediate 6-3 (4.4 g, 11 mmol) was mixed with thionyl chloride (12 mL, 165 mmol) at 0 °C. RM was warmed to RT and stirred for 2 h, then volatiles removed in vacuo and the residue taken with sat. aq. NaHCO3. The formed slurry was sonicated and solid collected by filtration, washed with water and dried. The resulting crude was purified by flash chromatography on Si cartridge by eluting with 0-10 % EtOAc in DCM to afford the title product (2.7 g). LCMS (Method 1): Rt = 1.24 min, ES+ m/z 427.0/429.0/431.0 [M+H]+. Step 5
Methyl 6-chloro-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-1H- pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 6-5)
A mixture of intermediate 6-4 (2.70 g, 6.32 mmol), K2CO3 (2.62 g, 19 mmol) and NaI (189 mg, 1.26 mmol) in DMF (80 mL) was stirred at 90°C overnight. After cooling to RT, RM was diluted with water (200 mL). The formed precipitate was filtered, washed several times with water and dried. The resulting material was purified by flash chromatography on Si cartridge by eluting with 0-100 % DCM/Acetonitrile (9:1) in DCM to afford the title product (730 mg). LCMS (Method 1): Rt = 1.13 min, ES+ m/z 391.1/393.1 [M+H]+. Step 6
6-Chloro-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-1H-pyrazolo[4,3- c]pyridine-3-carboxylic acid (Intermediate 6) Intermediate 6-5 (730 mg, 1.87 mmol) was suspended in THF (15 mL) and added with a solution of LiOH (1.0 M in water, 9 mL, 9 mmol). RM was stirred at 40 °C for 2.5h. Organic solvent was removed in vacuo and the residue diluted with water. The pH was adjusted to 2.5 using aq. 1M HCl. The formed precipitate was filtered, washed several times with water and dried to afford the title compound (698 mg). LCMS (Method 1): Rt = 0.95 min, ES+ m/z 377.1/379.0 [M+H]+. Intermediate 7
1-(4-(tert-Butoxycarbonyl)-6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Intermediate 7) Method 1 A degassed mixture of 6-Chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (400 mg, 2.02 mmol), intermediate 3 (733 mg, 2.13 mmol), Cs2CO3 (2.31 g, 7.09 mmol) and thiophene-2- carbonyloxycopper (278 mg, 1.46 mmol) in anhydrous DMSO (7 mL) was stirred under nitrogen
at 110 °C overnight. After cooling to RT, RM was filtered. The filtrate was diluted with MeCN (50 mL) thus the formed precipitate collected by filtration and triturated with MeOH. The crude material was purified by flash chromatography on Si cartridge by eluting with 0-100 % MeOH in EtOAc to afford the title product (150 mg). Method 2 A degassed mixture of 6-Chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (9.4 g, 47.5 mmol), intermediate 5 (18.6 g, 47.5 mmol), Cs2CO3 (54 g, 166.3 mmol) and thiophene-2- carbonyloxycopper (9 g, 47.5 mmol) in DMSO (100 mL) was stirred under argon at 110 °C for 24h. RM was quenched in water and extracted with DCM. Combined organic layers was washed with aq 10% w/w citric acid, aq. sat. NaCl and evaporated to dryness. The residue was purified by chromatography on silica gel by eluting with DCM to DCM (1% v/v MeOH+1%AcOH v/v). The material thus obtained was triturated in ethyl ether to afford the title compound (3.14g). LCMS (Method 1): Rt = 1.22 min, ES+ m/z 461.2/463.2 [M+H]+. Intermediate 8
6-Chloro-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-1H-pyrazolo[4,3- c]pyridine-3-carboxylic acid (Intermediate 8 ) Intermediate 8 was prepared in a similar manner to Intermediate 7 (Method 1) starting from 6-Chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (200 mg, 1.0 mmol) and intermediate 3- 1 (371 mg, 1.5 mmol). LCMS (Method 1): Rt = 0.86 min, ES+ m/z 360.9/362.8 [M+H]+. Intermediate 9
1-(1-(tert-Butoxycarbonyl)-7-methoxy-1,2,3,4-tetrahydroquinolin-6-yl)-6-chloro-1H- pyrazolo[4,3 yridine-3-carboxylic acid (Intermediate 9) A mixture of intermediate 4 (1.04 g, 3.04 mmol), 6-Chloro-1H-pyrazolo[4,3-c]pyridine-3- carboxylic acid (300 mg, 1.52 mmol), thiophene-2-carbonyloxycopper (290 mg, 1.52 mmol) and Cs2CO3 (1.48 g, 4.56 mmol) in DMSO (7 mL) was stirred for 72 h at 100 °C under nitrogen. After cooling to RT, RM was added dropwise to water under stirring. The pH was adjusted to 4 (with aq. HCl 1M) and the formed precipitate filtered, washed with water, and dried. The crude material was purified by flash chromatography on Si cartridge by eluting with 0-50% DCM:MeOH:HCO2H (90:10:0.3) in DCM to afford the title product (330 mg). LCMS (Method 1): Rt = 1.24 min, ES+ m/z 458.9/460.9 [M+H]+. Intermediate 10
tert-Butyl 7-(3-amino-6-chloro-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3- dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Intermediate 10) A degassed mixture of intermediate 3 (408 mg, 1.19 mmol), 6-chloro-1H-pyrazolo[4,3- c]pyridin-3-amine (200 mg, 1.19 mmol), Cs2CO3 (980 mg, 3.01 mmol), DMCHDA (93.5 μL, 0.59 mmol) and CuI (113 mg, 0.59 mmol) in DMSO (4.9 mL) was stirred under argon at 110 °C overnight. After cooling to RT, RM was quenched with sat. aq. NaHCO3 (50 mL) and extracted with EtOAc (5x50 mL). Combined organic layers were washed with sat. aq. NaCl, dried over Na2SO4 and solvent removed in vacuo. The crude residue was purified by flash chromatography on Si cartridge by eluting with 0-50% DCM/MeOH/NH4OH (90:5:0.5) in DCM to afford the title product (282 mg). LCMS (Method 1): Rt = 1.15 min, ES+ m/z 431.9/433.9 [M+H]+. Intermediate 11a
25
tert-Butyl 7-(6-chloro-3-((2-(4-(ethoxycarbonyl)piperidin-1-yl)ethyl)carbamoyl)-1H- pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Intermediate 11a)
A mixture of intermediate 7 (700.0 mg, 1.52 mmol), intermediate 1 (369 mg, 1.82 mmol), DIPEA (1.06 mL, 6.08 mmol), HATU (693 mg, 1.82 mmol) and DMF (12 mL) was stirred at RT for 2.5 h. RM was diluted with water (40 mL) and extracted with EtOAc (2x30 mL). Combined organic layers were washed with sat. aq. NaCl (30 mL) and solvent removed in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-60 % DCM/EtOH/NH4OH (90:5:0.5) in DCM to afford the title product (866 mg). LCMS (Method 1): Rt = 1.02 min, ES+ m/z 643.4/645.4 [M+H]+. Intermediates 11b to 11e The following intermediates were prepared in a similar manner to Intermediate 11a from the indicated starting materials. z z z 1
z 1
Intermediate 12
1-(2-(1-(4-(tert-butoxycarbonyl)-6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- yl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine-4-carboxylic acid (Intermediate 12) To a solution of intermediate 11a (1.0 g, 1.48 mmol) in THF (10 mL), an aqueous 1M solution of LiOH (10.6 mL, 11.8 mmol) was added at RT. RM was stirred at RT for 16h. Volatiles were removed in vacuo and the residue diluted with water. The pH was adjusted to 6.5 using 1M aq. HCl and RM extracted with DCM (3x10 mL). Combined organic layers were evaporated to dryness to give the title product (756 mg). LCMS (Method 1): Rt = 0.99 min, ES+ m/z 615.1/617.1 [M+H]+ Intermediate 13a
tert-Butyl 7-(6-chloro-3-((2-(4-((cyclopentyloxy)carbonyl)piperidin-1- yl)ethyl)carbamoyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3-dihydro-4H- benzo[b][1,4]oxazine-4-carboxylate (Intermediate 13a) A solution of intermediate 12 (80.0 mg, 0.13 mmol), cyclopentanol (102 μL, 0.77 mmol) EDC*HCl (24.7 mg, 0.13 mmol) and DMAP (6.29 mg, 0.05 mmol) in dry DCM (3 mL) was stirred under nitrogen at RT for 3h. RM was diluted with water (10 mL) and extracted with DCM (2x10 mL). Combined organics were washed with sat. aq. NaCl (10 mL) and solvent removed in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-90 % DCM/MeOH/NH4OH (90:9:1.5) in DCM to afford the title product (55 mg). LCMS (Method 2), Rt = 1.54, ES+ m/z 683.4/685.4. Intermediates 13b to 13o The following intermediates were prepared in a similar manner to intermediate 13a from the indicated starting materials. + 4 + 3 + 3
+ 2 + 4 + 4 + 2 + 2
+ 4 + 4 + 4 + 4 + 3
t + 2
Intermediate 13r
tert-Butyl 7-(6-chloro-3-((2-(3-(ethoxycarbonyl)piperidin-1-yl)ethyl)carbamoy H-
pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Intermediate 13r) A solution of intermediate 11d (60 mg, 0.10 mmol), ethyl piperidine-3-carboxylate (16 mg, 0.10 mmol) and DIPEA (71 μL, 0.41 mmol) in DMF (1 mL) was stirred at RT for 6h. Ethyl piperidine-3-carboxylate (16 mg, 0.10 mmol) was added and RM stirred at RT overnight. RM was diluted with EtOAc (10 mL), washed with water (3x10 mL) and sat. aq. NaCl (10 mL). Organic layer was evaporated to dryness and the residue purified by flash chromatography on Si cartridge by eluting with 0-50 % DCM/EtOH/NH4OH (90:5:0.5) in DCM to afford the title product (30.1 mg). LCMS (Method 1), Rt = 1.05, ES+ m/z 643.3/645.4. Intermediates 13s-13aa The following intermediates were prepared in a similar manner to intermediate 13r from the indicated starting materials. It is additionally stated if base, solvent, additive or temperature were varied.
Intermediate Structure Starting material LCMS z z z z
z z z z z
Intermediate 13ab Step 1
tert-Butyl 7-(6-chloro-3-((2-((3-(2-methoxy-2- oxoethyl)benzyl)amino)ethyl)carbamoyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3- dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Intermediate 13ab-1) The t
ared in a similar manner of intermediate 13r starting with Intermediate 11d and methyl 2-[3-(aminomethyl)phenyl]acetate hydrochloride. LCMS (Method 1): Rt = 1.06 min, ES+ m/z 665.3/667.3 [M+H]+ Step 2
tert-Butyl 7-(6-chloro-3-((2-((3-(2-methoxy-2- oxoethyl)benzyl)(methyl)amino)ethyl)carbamoyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6- methoxy-2,3-dihydro-4H-benzo[ 1,4]oxazine-4-carboxylate (Intermediate 13ab)
A solution of intermediate 13ab-1 (64 mg, 0.10 mmol) in MeOH (1 mL) was treated with formic acid (145 μL, 3.8 mmol) and 37 % aq. formaldehyde (287 μL, 3.8 mmol). RM was stirred at RT for 60 h. RM was diluted with EtOAc, washed with sat. aq. NaHCO3 (3x15 mL) and sat. aq. NaCl (15 mL). The organic layer was evaporated in vacuo and the residue purified by flash chromatography on Si cartridge by eluting with 0-45 % DCM/MeOH/NH4OH (90:4:1) in DCM to afford the title product (28 mg). LCMS (Method 2), Rt = 1.46, ES+ m/z 679.2/681.2. Intermediate 13ac Step 1
N-(2-Bromoethyl)-6-chloro-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)- 1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Intermediate 1
A solution of intermediate 11d (100.0 mg, 0.17 mmol) and TFA (642.0 μL, 8.64 mmol) in DCM (1.0 mL) was stirred at RT for 16h, then evaporated to dryness. The residue was dissolved in MeOH (0.5 mL) and passed through a SCX cartridge, washed with MeOH (20 mL) and eluted with 1M methanolic ammonia (20 mL) to afford the desired product (81.9 mg). LCMS (Method 1): Rt = 1.07, ES+ m/z 466.1/468.1. Step 2
1-Methoxy-2-methylpropan-2-yl 1-(2-(6-chloro-1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine-4- carboxylate (Intermediate 13ac) The title compound was prepared in a similar manner of intermediate 13r starting with intermediate 13ac-1 and intermediate 2a. LCMS (Method 1): Rt = 0.85 min, ES+ m/z 601.4/603.4 [M+H]+ Intermediate 13ad
Propyl N-(2-(6-chloro-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-1H- pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)-N-methylglycinate (Intermediate 13ad) A mixture of intermediate 11d (100 mg, 0.20 mmol), propyl 2-(methylamino)acetate (80.0 mg, 0.61 mmol), Na2CO3 (43.0 mg, 0.41 mmol) in acetone (2.0 mL) was stirred at 40 °C for 16h and at 65 °C for 1h. After cooling to RT, solvent was removed in vacuo. The residue was partitioned between EtOAc (10 mL) and water (10 mL), aqueous layer furter extracted with EtOAc (2 x 10 mL). Combined organic layers were washed with sat. aq. NaHCO3 (2 x 10 mL), with sat. aq. NaCl (10 mL) and evaporated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-60 % DCM/MeOH (20:1) in DCM to afford the title product (51.7 mg). LCMS (Method 2): Rt = 1.11 min, ES+ m/z 517.2/519.2 [M+H]+ Intermediate 13ae
3-(Dimethylamino)propyl 6-chloro-1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]thiazin-7-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 13ae) A mixture of intermediate 6 (50.0 mg, 0.13 mmol), T3P® (50.0 % solution in DMF, 155 μL, 0.26 mmol), azido(trimethyl)silane (35.2 μL, 0.26 mmol), TEA (55.5 μL, 0.4 mmol) and 3- (dimethylamino)propan-1-ol (31.4 μL, 0.26 mmol) in THF (1 mL) was refluxed for 3 h. Reaction mixture was refluxed for 3 h., diluted with EtOAc (25 mL), washed with sat. aq. NaHCO3 (3x15 mL) and sat. aq. NaCl (15 mL). Organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-35 % DCM/MeOH/NH4OH (90:15:1.5) in DCM to afford the desired product. LCMS (Method 1): Rt = 0.83 min, ES+ m/z 462.1/464.2 [M+H]+ Intermediate 13af
25
3-(4-Methylpiperazin-1-yl)propyl 6-chloro-1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]thiazin-7-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 13af) The title product was prepared on a similar manner to intermediate 13ae from intermediate 6 (60 mg, 0.16 mmol) and 3-(4-methylpiperazin-1-yl)propan-1-ol (50 mg, 0.32 mmol). LCMS (Method 1): Rt = 0.81 min, ES+ m/z 517.1/519.1 [M+H]+ Intermediates 13ag to 13ai The following intermediates were prepared in a similar manner to intermediate 13r from the indicated starting materials. St rtin t t t
Intermediate 14a
tert-Butyl 7-(6-chloro-3-(((2-ethoxy-2-oxoethoxy)carbonyl)amino)-1H-pyrazolo[4,3- c]pyrid -yl)-6-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Intermediate 14a) A solution of intermediate 10 (90.0 mg, 0.21 mmol) in DCM (5 mL) was cooled to -78°C, then TEA (87.1 μL, 0.63 mmol) and bis(trichloromethyl) carbonate (61.8 mg, 0.21 mmol) were added. RM was stirred at -78°C for 1 h. Ethyl 2-hydroxyacetate (79 μL, 0.83 mmol) and TEA (58.1 μL, 0.42 mmol) were added and RM stirred overnight reaching RT. RM was quenched with sat. aq. NaHCO3 and water, then extracted with DCM (4 × 10 mL). Combined organic layers were washed with sat. aq. NaCl, dried over Na2SO4 and solvent evaporated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-40 % EtOAc in DCM to afford the title product (92 mg). LCMS (Method 1): Rt = 1.29, ES+ m/z 562.1/564.1. Intermediates 14b to 14c The following intermediates were prepared in a similar manner to intermediate 14a from the indicated starting materials. t
t
Intermediate 14d
Ethyl (1s,3s)-3-(((6-chloro-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)- 1H-pyrazolo[4,3-c]pyridin-3-yl)carbamoyl)oxy)cyclobutane-1-carboxylate (Intermediate 14d) To a solution of intermediate 6 (50.0 mg, 0.13 mmol) in 2-Me-THF (1.0 mL), T3P® (50.0 % solution in EtOAc, 119 μL, 0.26 mmol), azido(trimethyl)silane (35.2 μL, 0.26 mmol) and TEA (55.5 μL, 0.40 mmol) were added. RM was refluxed for 1h before addition of a solution of ethyl (1s,3s)-3-hydroxycyclobutane-1-carboxylate (38.3 mg, 0.26 mmol) and TEA (55.5 μL) in 2-Me- THF (150 μL). RM was stirred at RT and refluxed overnight. After cooling to RT, RM was diluted with EtOAc (25 mL), washed with sat. aq. NaHCO3 (3x15 mL) and sat. aq. NaCl (15 mL). Organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-50 % EtOAc in cyclohexane to afford the title product (27 mg). LCMS (Method 1): Rt = 1.08, ES+ m/z 518.0/520.1. Intermediates 14e to 14f The following intermediates were prepared in a similar manner to intermediate 14d from the indicated starting materials. +
+ 1
Intermediate 15
(3S4S)-4-fluoro-1-methylpyrrolidin-3-ol (Intermediate 15)
A mixture of (3S,4S)-4-fluoropyrrolidin-3-ol hydrochloride (50 mg, 0.35 mmol), iodomethane (22.0 μL, 0.35 mmol), and Na2CO3 (75 mg, 0.71 mmol) in MeCN (1.0 mL) were stirred at 80 °C for 18h. RM was cooled to RT and filtered, collected solids washed with DCM (10 mL) and combined organics evaporated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-100 % DCM:MeOH:NH4OH (90:15:0.5) in DCM to afford the title product (8 mg). 1H NMR (500 MHz, CDCl3) δ/ppm: 4.85-5.06 (m, 1H), 4.38 (m, 1H), 3.12-3.30 (m, 1H), 2.97 (br dd, J=9.9, 4.4 Hz, 1H), 2.67-2.79 (m, 2H), 2.47 (s, 3H). Intermediate 16
(R)-1-(2-Fluoroethyl)pyrrolidin-3-ol (Intermediate 16) A mixture of (3R)-pyrrolidin-3-ol (200 mg, 2.3 mmol), K2CO3 (577 mg, 4.2 mmol) and 1- bromo-2-fluoro-ethane (321 mg, 2.5 mmol) in MeCN (3.8 mL) was stirred at 70°C overnight. After cooling to RT, RM was filtered through a plug of diacematous earth and washed with MeCN. Solvent was removed in vacuo to afford title product (282 mg) used in the next synthetic step without further purifications. 1H-NMR (300 MHz, CDCl3) δ: 4.54 (dt, J=47.6, 5.0 Hz, 2H), 4.31-4.37 (m, 1H), 2.91-2.98 (m, 1H), 2.78 (dt, J=28.0, 5.0 Hz, 2H), 2.71-2.76 (m, 1H), 2.60 (dd, J=10.2, 5.2 Hz, 1H), 2.37 (td, J=8.7, 6.5 Hz, 1H), 2.12-2.24 (m, 1H), 1.68-1.78 (m, 1H). Intermediate 17 Step 1
Methyl (R)-1-(2-(((benzyloxy)carbonyl)amino)ethyl)pyrrolidine-3-carboxylate (Intermediate 17-1) A mixture of N-(2-bromoethyl)carbamate (250 mg, 0.97 mmol), methyl (R)-pyrrolidine-3- carboxylate hydrochloride (176 mg, 1.1 mmol) and K2CO3 (402 mg, 2.9 mmol) in MeCN (2 mL) was stirred at 70 °C overnight. After cooling to RT, RM was diluted with water and extracted with EtOAc (2x 15 mL). Combined organics were washed with water (3x15 mL) and passed through phase separator. Solvent was removed affording product (282 mg) that was used in the next step without further purification. 1H-NMR (500 MHz, CDCl3) δ: 7.36-7.38 (m, 4H), 7.30-7.34 (m, 1H), 5.29 (bs, 1H), 5.11 (s, 2H), 3.69 (s, 3H), 3.29-3.35 (m, 2H), 2.98-3.04 (m, 1H), 2.85 (t, J=8.6 Hz, 1H), 2.70-2.73 (m, 1H), 2.53-2.68 (m, 4H), 2.06-2.10 (m, 2H). Step 2
(R)-1-(2-(((Benzyloxy)carbonyl)amino)ethyl)pyrrolidine-3-carboxylic acid (Intermediate 17-2) Solution of Intermediate 17-1 (140 mg, 0.46 mmol) in ethanol (1.2 mL) was treated with NaOH (2.0 M in water, 560 μL, 1.1 mmol). RM was stirred at RT for 1h. RM was quenched with aq.2N HCl (560 μL), then stirred at RT for 15 min. Ethanol was partially removed by evaporation, followed by acetone addition. RM was stirred for 15 min at RT and then filtered through a pad of diatomaceous earth, thoroughly washed with acetone. The filtrate was evaporated to dryness to give the title product (138 mg) that was used in the next synthetic steps without further purifications. 1H-NMR (500 MHz, CDCl3) δ: 7.54 (bs, 1H), 7.35-7.31 (m, 4H), 7.27-7.30 (m, 1H), 5.12 (m, 1H), 5.08 (s, 2H), 3.93 (m, 1H), 3.40-3.61 (m, 3H), 2.88-3.15 (m, 5H), 2.37-2.43 (m, 1H), 2.15-2.22 (m, 1H). Step 3
(R)-1-(2-Fluoroethyl)pyrrolidin-3-yl (R)-1-(2- (((benz xy)carbonyl)amino)ethyl)pyrrolidine-3-carboxylate (Intermediate 17)
To a solution of Intermediate 17-2 (135 mg, 0.46 mmol), Intermediate 16 (73.8 mg, 0.55 mmol) and 2,4,6-trichlorobenzoyl chloride (86.6 μL, 0.55 mmol) in dry THF (3 mL), TEA (129 μL, 0.92 mmol) and DMAP (14.1 mg, 0.25 mmol) were added and RM stirred at RT overnigth. RM was poured in a mixture of EtOAc and water (10 mL each) and pH adjusted from 5.5 to 3.5 using aq. 1.0 M HCl. Aqueous layer was basified with 2M NaOH to pH 9.5 and extracted with EtOAc (2x10 mL). Combined organic layers were washed with sat. aq. NH4Cl (2x), sat. aq. NaCl, dried over Na2SO4 and solvent removed in vacuo to afford the title product (162 mg). 1H-NMR (500 MHz, CDCl3) δ: 7.35-7.31 (m, 4H), 7.27-7.30 (m, 1H), 5.37 (bs, 1H), 5.18- 5.22 (m, 1H), 5.11 (s, 2H), 4.56 (dt, J=47.4, 4.9 Hz, 2H), 3.32 (m, 2H), 2.71-3.03 (m, 8H), 2.57- 2.67 (m, 4H), 2.48-2.52 (m, 1H), 2.24-2.31 (m, 1H), 2.05-2.09 (m, 2H), 2.81-2.88 (m, 1H). Intermediate 19
(S)-1-(2-(1-(4-(tert-Butoxycarbonyl)-6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin- 7-yl)-6-chloro-1H-pyrazolo[4,3-c
3-carboxamido)ethyl)pyrrolidine-3-carboxylic acid (Intermediate 19) Aqueous solution of LiOH solution (1.0 M, 0.65 mL, 0.65 mmol) was added to a solution of Intermediate 13u (80.0 mg, 0.13 mmol) in THF (1.0 mL), an aqueous solution of LiOH (1.0 M, 0.65 mL, 0.65 mmol) was added and RM stirred at RT 30h. THF was evaporated in vacuo followed by addition of water, then pH was adjusted to 6.5. Aqueous mixture was extracted with DCM/i- PrOH (3x10 mL), combined organic layers passed through phase separator and solvent removed in vacuo to afford the title compound (68 mg). 25 LCMS (Method 1): Rt = 0.94 min, ES+ m/z 601.3/603.2 [M+H]+ Intermediate 20a
tert-Butyl 7-(6-chloro-3-((2-((S)-3-((((R)-1-methylpyrrolidin-3- yl)oxy)carbonyl)pyridine-1-yl)ethyl)carbamoyl)-1H-pyrazolo[4,3-c]pyridine-1-yl)-6- methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Intermediate 20a) To a solution of Intermediate 19 (40.0 mg, 66.6 μmol), 2,4,6-trichlorobenzoyl chloride (10.4 μL, 66.6 μmol) and (R)-1-methylpyrrolidin-3-ol (6.44 μL, 66.6 μmol) in dry THF (1 mL), TEA (18.6 μL, 0.13 mmol) and DMAP (2.03 mg, 16.6 μmol) were added and RM stirred at RT for 1 h. RM was diluted with EtOAc (15 mL) and washed with sat. aq. NaHCO3 (3x10 mL) and sat. aq. NaCl (10 mL). Organics were dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-100 % DCM/MeOH (9:1) in DCM to afford the desired product (42 mg). LCMS (Method 2): Rt = 1.27 min, ES+ m/z 684.3/686.3 [M+H]+ Intermediate 20b
tert-Butyl 7-(6-chloro-3-((2-(4-(((1-isopropylazetidin-3-yl)oxy)carbonyl)piperidin-1- yl)ethyl)carbamoyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3-dihydro-4H- benzo[b][1,4]oxazine-4-carboxylate (Intermediate 20b) Title compound was prepared on a similar manner to Intermediate 20a, starting from Intermediate 12 (80 mg, 0.13 mmol) and 1 eq. of 1-isopropylazetidin-3-ol. LCMS (Method 2): Rt = 1.36 min, ES+ m/z 712.3/715.4 [M+H]+ PREPARATION OF EXAMPLES Example 1
Ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine-4- carboxylate (Example 1) A degassed mixture of intermediate 11c (80.0 mg, 0.14 mmol), 3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (49 mg, 0.200 mmol), XPhos Pd G3 (6 mg, 7 μmol), K3PO4 (0.5 M, 572 μL, 0.29 mmol) in a mixture THF/water (1/1, 4.57 mL) was heated at 65 °C for 3.5 h. A further equivalent of of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5- a]pyrimidine and XPhos Pd G3 were added and RM further heated at 100 °C for 1 h. After cooling to RT, RM was diluted with water and extracted with DCM (3x15 mL). Combined organic layers were passed through phase separator and solvent removed in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-90 % DCM/EtOH (90:1) in DCM to afford the desired product (62 mg). LCMS (Method 3): Rt = 4.42 min, ES+ m/z 642.3 [M+H]+ 1H-NMR (500 MHz, DMSO-d6) δ: 9.45 (d, J=1.2 Hz, 1H), 9.23 (dd, J=7.1, 1.7 Hz, 1H), 8.90 (s, 1H), 8.73 (dd, J=4.0, 1.7 Hz, 1H), 8.46 (br t, J=5.8 Hz, 1H), 8.23 (d, J=1.0 Hz, 1H), 7.16 (dd, J=7.0, 4.2 Hz, 1H), 7.08 (s, 1H), 6.63-6.68 (m, 1H), 6.44 (s, 1H), 4.04 (q, J=7.1 Hz, 2H), 3.64 (s, 3H), 3.54-3.62 (m, 2H), 3.36-3.50 (m, 2H), 2.94-3.04 (m, 2H), 2.79-2.91 (m, 2H), 2.42-2.53 (m, 2H), 2.19-2.35 (m, 1H), 2.03 (br t, J=10.3 Hz, 2H), 1.69-1.86 (m, 2H), 1.45-1.65 (m, 2H), 1.16 (t, J=7.1 Hz, 3H). Examples 2 to 8 The following Examples were prepared in a similar manner to Example 1 from the indicated intermediate. It is additionally stated if base, solvent, temperature ligand and/or palladium source were varied.
S M C L R M N- 1 H et a i d e mr e t n I
o r d - y - H5 , h 1 i - H - 2 d - [ o -3 e , t a t - 6- 4, ) 1 1 l - ) - o l e r l d o z 4 [ e c 3- y-7 y - - 3 3 - n a t y h a r o y l o a ) y x - n i u i d p z x e y - n n d b - ( a r o m o i a h z i d i r o l 4 n t c e , - 3 6- y ) p l y / e a i i e h m y p t ] y c a l -y ) l - Ho ru m t - t ] ir c - ) y y x x o y- m 7 1 - a c 6( 4 , y p ] 3 , x o o b h t - n )l b r u - 1 rt 1 [ ( ] a - 4 [ ) a o l r a e i z y-3 c ) S (( b - [ 5 , l y o o c m- a 3 o 1 6 i h -n l y -) z [ o z a m s n a (- t ] i - 4 d i 3- 3 e l r , b o y s - z a p b r 1 a ( ( , n ( 1 [ mi i 1 ( Hr c ) l - 2 ] b r di [ y p r y l 2 y p y l y o ] y ( h z a p ] h t t e n e c e b e l e e p l p l m p a m a 2 m 3 x x a E E x E
, s r b ( 2 4 . 0 1: δ ) d 6 -O S , z H 0 0 3 (
d y o , h i z 4 [ n i 2 , (- 4 e - o z [ p d a - r o 4 y l o d i r 1l Ha r o l i o p ) , p 3 ( z a e p i y - 2 - y z l o p( a y h - - y 6 r - y x ) - p l p- 3 ) o y - l y e 2 t - r a n a d - y 6 r - y t ) e e t l p- ) o a l ht - H e 7- 1 n - i h t l y p ) di o h i y - Hd i y x r e ) x o r d p - 7- 1-) m o mn - i l 6 z y y y ( a -3 p ] x b o r l y 4 , 3 n i l y a x b r ) a h t -y z a -3 o a c - i - h -n c l c i y e x o x - n b i r a 4 1( t ( ] 4 , d i o m m -2 h o t ] 4 , d i c- (- 1 m a - e 1 m 3- 2( [ i r b y - ] y r x m[ i r e 1 b l [ p ] a c o ] h b [ y p n ] i d y o a ) l t e o a i r h z t n e e y m z n b - 1 e y b p ] c e l e p l m p a 4 m 5 x a E x E
3 . 1 = J , d ( 7 4 . 9: δ ) d 6 -O S D, z H 0 0 6 (
t n t I n I - H- -4 2 5 - , , -6 o 1 r [ d o -3 - 3- - , N y ) l - e Ht a l y l h o i z 4 [ - ) x l o y h -7 1 y - - )l x d a o l y - r 4 y o h t t e n i z y o - b r , p 3 ( z - - a r e ) o m e -6 a i 3- a n c- y 6- y x ) p d i t a ( h n - 1 t ] i d i 3- o l - h y mi t - H 1 a c y l y 4 , 1 m e i n i e 7 - - ) x o l g l p [ o ] r d b y i r m n - i l 6 z y- b r a y h r p ) [ o p ] a y p ] (- a 1 x 3 - c n - 3 t e o n z n - e 5 , c- ( o - ] i - m i 2 4 , d i e b 1 3 n m- [ o , 4 (- 1 [ mi i d a i l y H 2 l [ - o z o l N] l b r y [ y r h p y p t e o r a o d r y z a p o z ] a ] c m i y h p ( r y or n d ( i p p e b - 3 d e l e p l m p a 6 m 7 x a E x E
. 9 1 : , = J H, 1 s ( H 1 H 3 H 2 1 , . ) δ 1 ) . 7 , d , z 6 0 . , s ( , s ( , ) H H 2, d 6 - = J d H 7 O, ( d 4 2 . , 1 ) 5 m 4. 3 ( 3 , 6 6 . 4 s z 0 ( H S d 7 . = H, 3 . 1 7 . M ( D4 8 , , 2 ) J 1 , , z ) , 3 H) - 2 1 . 6 2 = z . 9 Hd 1 ( H 1 H9 . , J 5 2 , 2, 2 ) H, ) , MHs ( 2 . . m z , ) H 0 8 4, ( 6 HH 1 0 1 0 , 3 z 0 9 , . ) 0 . 7 7 . 5 6 . 6 2 , , m ( ( H 8 H 1 = J = J m ( f a 3 1 t n I - - 5 6 , ( 1 - [ - 1 o l l 3 , y o p z 4 - a [ o o l e r H p 2 r y o z t a l ) - l o y r p(- a r y x - d 1 y 6- y ) p o - h n i l - b y r i d - Ha c z - 7 a - 1-) - r 4 , e 3 n i l y 3-e p - i y z a - p i 3- n i l x y o ht n i d ir h h t t ] e e 4 , d i y 1 mi p ] c m m[ ] r - b ( [ y 4 p - o 3 z ] n a e b e l p ma 8 x E
Example 9 Step 1
tert-Butyl 7-(3-((2-(4-(ethoxycarbonyl)piperidin-1-yl)ethyl)carbamoyl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3-dihydro- 4H-benzo[b][1,4]oxazine-4-carboxylate (Example 9-intermediate 1) A degassed mixture of intermediate 11a (500 mg, 0.78 mmol), 3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (286 mg, 1.17 mmol), K3PO4 (330 mg, 1.55 mmol) and XPhos PdG3 (66 mg, 78 μmol) in water (4.5 mL) / THF (9 mL) was stirred under nitrogen at 65 °C for 1 h. After cooling to RT, RM was diluted with water (40 mL) and extracted with EtOAc (40 mL and 2 x15 mL). Combined organic layers were washed with water, sat. aq. NaCl (40 mL each), dried over Na2SO4 and evaporated in vacuo. The residue was purified by flash chromatography on Si cartridge eluting with 0-65 % DCM/MeOH/NH4OH (90:5:0.5) in DCM to afford the product (483 mg). LCMS (Method 1), Rt = 0.91, ES+ m/z 726.4. Step 2 ,5- a]
20 carboxylate (Example 9)
To a solution of example 9-intermediate 1 (480 mg, 0.66 mmol) in DCM (10 mL), TFA (2.06 mL, 27.8 mmol) was added, and RM stirred at RT overnight. RM was evaporated in vacuo and the residue loaded on a SCX cartridge, washed with ethanol, and eluted with 15 % aqueous ammonia in ethanol. The crude material thus obtained was purified by flash chromatography on Si cartridge by eluting with 0-100 % DCM/MeOH/NH4OH (90:9:0.5) in DCM to afford the title product (246 mg). LCMS (Method 3), Rt = 4.13 min, ES+ m/z 626.3 [M+H]+ 1H-NMR (500 MHz, DMSO-d6) δ: 9.46 (s, 1H), 9.23 (br d, J=6.7 Hz, 1H), 8.91 (s, 1H), 8.76- 8.72 (m, 1H), 8.45 (br s, 1H), 8.24 (s, 1H), 7.20-7.15 (m, 1H), 6.89 (s, 1H), 6.49 (s, 1H), 6.38 (br s, 1H), 4.14 (br s, 2H), 4.05 (q, J=6.8 Hz, 2H), 3.63 (s, 3H), 3.48-3.36 (m, 5H), 2.86 (br d, J=10.7 Hz, 2H), 2.47-2.44 (overlapped with DMSO, 1H), 2.28 (br s, 1H), 2.04 (br t, J=10.7 Hz, 2H), 1.79 (br d, J=11.6 Hz, 2H), 1.56 (br d, J=9.8 Hz, 2H), 1.17 (t, J=7.2 Hz, 3H) Examples 10 to 42 The following Examples were prepared with a two step process similarly to Example 9 from the indicated starting materials. It is additionally stated if base, solvent, temperature ligand and/or palladium source were varied.
: ) S 3 5 + 3 : d 6 . S . E 4+ ) 5 ] 3 2 + 3 H d 2 . S . E 8+ 3 ] H 2 p e t S 1 p e t S
S m I I -) l - - -) - - y - H 1 - 4 , l y - H 1 - O 4 , 3 - 7 - - ) 4 - 3 - 7 -) 4- O y n x i l y- -3- e n i O y x -n i l y- -3- e n i e o z a x 3-n e n d i o z 3 r O h t a x - n e n d i r m N h t a e o ] i d i i d i e p e e N mo ] i d i i d i e p e n m / - 4 , r er H O 6 1 m i i y p ) t a - 6 4 , r 1 m y i p ) t a ( [ ] r u y p ] l y l y O (- [ ] i r y p ] l y l y t N N H - N 1 b ( [ o p c ] -3 h t x H e o N N H 1( b N - [ o p c ] -3 h t x o c - z a , ) b r 2 z a , e ) b u r N O 2 t ( n - 5 4 S O - 1 e l b , [ o a N c O (- n - 5 4 , [ o r a c - 1 o [ l d o i O 1 e o m l b - 1 [ l d o i m N y N t H o u 2 l z o a r a y x N p b - N o H o 2 l z o a r a x - o z a y o r c r r p b r p - z y o o o r a r p b r N N e d s y y a h p i ( d - c N N l c d y a 6 y i c c y h p ( d - 6 e l e p l e p l 0 p ma m x a x 1 m a 1 1 E E x E
80 :) 3 9 + 3 : ) 3 8 + 3 d 6 . S . E 6+ 6 ] H d 4 . S . E 0+ 8 ] H -(-2 ((-3(- 7l t -t r e t
3 1 3 t 1 n I t n I - - 4 ) l - y H - ,3- - y 7 1-) -4 F - H 1 -4 x -n i l y- - - 3 e F n F 6( - - - 6 - - )l - - 3 e O o z 3 - i 1 H) l y- - n i O h t a - e d e x o n i n i O (- 2 y 3 e d i d i d r e O 2( -o r -7 - n - n i i d r e N m - ] 6 4 , i i r ( y p i e t - N 1 d y n i d i i r y p i e t - 1[ mi r p ] p )l a l l y h i z a m p i p ] )l a l H O N N H N 1 ] ( N - b [ y O 2 o p c ] - y 3 h y x O h t d - x , t e o o r y c- y h y x b H N N H e o 4 , ] p ] 3 , t e o b O (- z a - 4 1 n e 5 [ ) o r a N N r o 3- 4 , 1 a 4 [ ) o r a b , 1 o l d i c O O ul f y x [ ] - 5 , o l d i c N l N y t - [ o n H o 2 l z m o a r a i x N N rt o - h b t [ e o 1 [ o z o l z a m r a x N e p - o z y o 2 , mn o y o N o l c r a y d r p y b r a 2 , e z p b r c N N 2 b a r y a c c y h p i ( d - 6 p ( e l e p l p ma 2 m3 x 1 a 1 E x E
: ) 3 4 + 1 : d 9 . S . + ) 3 5 + 3 . E 0 7 ] d 1 . S + E 4 ] H 8 H -2 ((-(-2 ((-3(- 7l t -t r e t
n I I - - H 6 - O 1( - O (-1 H - - H - (- - 1 - 6 -) 4 ( l - - H 2 e O (- - - 1 H6 -) 4 l - - e O 2 - - H) y 3 n i 1 2 -) y 3 n i O 1 l 2- l o y - -7 3 - - e n n i d i r O l y - p o l r y - -7 3 - - e n n i d i r y r - i d i e p o r d - i d i e N p o d r y n i d i r y i p e t N p l y h i n i d i r y p i p e t p h i z a mi p ] )l a l y y h d - z a mi p ] )l a l y H O l y d - x o r y c- y h t x H O t e 4 , x o r y c- y h x N N H h N t 4 , ] 4 p ] 3 , e o b N N H m3 - ] p ] 3 , t e o b N e 3 - , 1 a - 4 [ ) o r a N i d 4 - y , x 1 a - 4 [ ) o r a O O m- y x [ ] 5 , o l d i c N [ O O 2 , o ] 5 , o l d i c 2-y o h b t [ o 1 [ o o z a m a 2- h t b e [ o 1 [ o z m a N N x o e z l r x y rd mn e o b z a y p o b r N N x o m r - z o 6 n l e o a r za y x p o b r N y r N h- y a c d y ( b r y a c 2 p ( N h p N - 3 ( e l e p l p ma 4 m5 x 1 a 1 E x E
: ) 3 7 + 3 : . d 9 . S + ) 3 7 + 3 . E 6 5 ] d 8 . S 2+] H E 8 H -7-y x o h t e m- 6l y t u b-t r e t
tn t I n I - - y 7 - - ) - o n l 6 - O x i y- h - - 4 O (- H 1 -4 t z a O e x 3-n 3 - - e e 1 n ( - - - 6 - - )l - - 3 e n mo ] i d i n i i d O O -6 4 i 2(- H2 ) l y y-3 - e i d i ( , - 1 md i i r r e O 1 - l o r -7 - n i n i d r e N 1 [ ( ] - b r 2 [ y y p p i e t N y- d y -n i d i i r ( o p ] ] c p - )l a l y p i e t y 4- h i z a m p i p ] )l a l H O - z n a- N N H 1 e 5 , 3 , y 4[ h t x H O n a e o N l b N N H r d - x y 4 , o r ] y c- y h y x 4 p ] 3 , t e o b N y b h - 1 [ H o l o l ) o o r d a N c N p O - 3 H-y , 1 [ a - 4 5 [ ) o o r d a c O O t e 2 o z i O 2 x ] b , l i yx -o z a r a r r y m a -o o r h t [ o 1 [ o ol z a m a N N o h t d y y p p- x o b N N d y e z mn e o r x z y p o e h i ( d - 6 H 1 r a N h b ar b a r r y a N m- - c N t c N - 2 4 , ) 3 l y e t p ( e l e p l p ma 6 m7 x 1 a 1 E x E
: ) 3 7 + 2 : d 3 . S . + ) 3 2 + 3 . E 6 9 ] d 4 . S + E 1 ] H 1 H -7-y x o h t e m- 6l y t u b-t r e t
n I I -2 - (- - N 2( - 1 O l - H - - - H - y H- 1- 4- O 1 l H- 1- 4- O h t 2- 6- ) e o ) l y - 3- e n i y h 2- 6- ) ) l y - 3 e n i O m r l y - ) N l d y - 3 - e n d i O t e o r l - - d y 3 - e n d i h 7 - n i i d r i e p O m) y - h 7 - n i i d r i e H y - i d n i d i r y i p e t l y i d n i d i r y p i p e t N O 4 - - 4 z a mi p ] )l a l N -2 - - 4 z a mi p ] )l a l n , x r c y y x n , x r c y y N H a 3- o y - h i 3 o y - h x O N N r y y ] 4 p ] 3 , t e o b H O l o - y ] 4 p ] 3 , t e o b O p - x o , 1 a - 4 [ ) o r a N N H h x o , 1 a - 4 [ ) o r a H h t [ ] b 5 , o l d o i c N N p O r o h t [ ] b 5 , o l d i c N N 2- e o m[ o 1 [ o z a m a O m e l m[ o 1 [ o o z a m a N r d - 6 z l ( n e o r x z y o N y h - 6 z l ( n e o r x z y o N y h a - rt 1 ( b a r p b r N t e - a p b r e y a c m1 ( b r y a c t p ( ( N - N 4 ( p ( e l e p l p ma 8 m9 x 1 a 1 E x E
84 :) 3 7 + 4 : . ) 3 7 + 3 d 4 . S + E 7 9 ] H d 3 . S . E 7+ 6 ] H -2 ((-4 (-2 ((-3(- 7l y t u b-t r e t
j3 k 1 3 t 1 n t I n I - 1 - - l - N y p H H - - H - - 1 4 6( 1 4 o 2 r - o r 6 - - ) ) l - - 3 e n N - - - 1 - 6- )l - - 3 e n O p l y d l y y-3 - e i d O ( i - O h y 2 H2 ) l t e h y y-3 - e i d i - d 7 - n i n i d r e O (- - o r -7 - n i n i i d r e N m- -n - 4 2 , i z d i i r p i e t N 1 l d - 3- a x m y -n i d i i r p i e t i y r p ] p )l a l y- h i z a mi y p p )l a l H O N N H ) N o y x o ] y p c- y ] 3 h y x H O N H 3- d - x r , t e o N N n i 4 , o ] y ] p c- y ] 3 h y x , t e o N n O i o 4 , a 4 O mh a t [ ) o b r l e 1 [ ] - 5 a N O d it 3- 4 , a 4 [ ) o b r a , o l d i c O e z y x 1 [ ] - 5 o l d i c y m - b [ o 1 [ o z m a a N N l y o h b [ , o 1 [ o z m a N N h t e 6(- z o n l o a r y x o h t t e z o n l o a r y x o N N m i 1 e z d ( ( - b a r p b r N e me z a N m- b a r p b r a - 2 2 ( y p c ( 1 y p c ( e l e p l p ma 0 m1 x 2 a 2 E x E
: ) 3 8 + 3 : d 3 . S . + ) 3 3 + 3 . E 1 8 ] d 4 . S + E 1 ] H 8 H - į - , ( -7-y x o h t e m- 6l y t u b-t r e t
l3 m 1 3 t 1 n I t n I - - -6 - 6( N - H 1 - 1 - ( 4 - N 1 H 1 -4 ( O - - 6 - - )l - - 2 H) 3 e ( n - - - 2 ) ( - 6- l - - 3 e n ( 2 l y y-3 - e i d O i - 1 H2 ) l y y-3 - e i d O - 1 - l o r -7 - n i n i d r e O l y -o r -7 - n n i i d r e N y- d 3 y -n i d i i r p i e t N -3 d y -n i i d i i r p i e t - h i z a mi y p p )l a l -n i h i z a m y p p )l a l H O n N N H i d N d - x r N i 4 , o ] y ] p c- y 3 h y x H O d , t e o N N H i l d - x i r ] c o 4 , o ] y p - y 3 h y x , t e o O l O o r 3 r - 4 y y , ] 1 [ a 4 ] - 5 [ ) o o b r N N r r 3- 4 , ] a 4 [ ) b r l d i a c O O y y 1 [ ] - 5 o o l d i a c N p x N l o y h b [ , o 1 [ o p z m l x a y o h b [ , 1 [ o z m a h t t e z o n l o a r x o N N h t e t e o z o n l o a r x o N e me z y p N b m- b a r r a N m me z y p b 1 y p c N -1 b a - r r a ( ) y c R ( p ( e l e p l p ma 2 m3 x 2 a 2 E x E
: ) 3 5 + 3 : d 4 . S . + ) 3 2 + 3 . + E 1 8 ] d 3 . S E 9 7 ] H H ^ į ^ ^ d 6 -O SM D, z H M 0 0 5 ( -y x o h t e m-6-) S ( l y t u b-t r e t
n3 o 1 3 t 1 n I t n I -6(- - - - N 1 H - 1 - 6( H - ( - 4 N - - 1 4 - 6 -) - - e 1 - 6 -) - - e O 2(- H-) l l y - 3-e n i (-2 - ( H) l l y - 3-e n i O 1 l 2- y o y-7 3-n n i d i r O - 2 1 -o y-7 3- n i d i r N - r 3- d y -n i i d i d i r e y p i p e O t l y r p d y -n n i i d i d i r e y p i p e t n h z mp ) a l N o h z mp ) a l H O i N N H d i i N l d- a 4 x i r ] c l y y , o ] y p - 3 h t x r o H O N H p i l d y - a 4 x i r ] c l y y , o ] y p - 3 h t x o N o r 3- 4 , ] a , 4 e ) b r N N h t 3- 4 , ] a , 4 e ) b r O O r y p l y x 1 [ ] - b 5 [ ,1 o o l d o i a c N O O e my 1 [ - x ] - b 5 [ , o o l d a o i c y o h [ [ z m a 2 o h [ 1 [ z m N N h t t o o l a N - t o o a a e e z n o r x o N o e z l o r x o N N m- me z y p b n a mn e z y p b 1 b a - r r a N N y b a r r a ) y c c- y c S ( p ( 2 p ( e l e p l a 4 p m 5 x 2 m a 2 E x E
: ) 3 7 + 2 : . + ) 3 6 + 3 d 4 . S E 9 0 ] H d 1 . S . E 6+ 2 ] H -7-y x o h t e m- 6l y t u b-t r e t
ia 3 r 1 3 t 1 n t I n I - -o - N -6( H - 1 -4 r d -6 H 1 -3 1 - -) - ( - 6- l - e O O y - 3 n h i ) l -)l - - e O O -3 H (- 2 ) l y y-3 - i e d i d - y - y - 3 3 - e n i d 1 - l o r -7 - n n i r 4 d e , 7 N 3 - n - n n i i d r e N y- d 4 y -n - h i i i z d i i r p i p e t -y i z i d i i r p i e t a mi y p ) n d - x r y ] l a l c y O x o a x m - p y x H N N H h t o ] i y r p p )l a l y ] c- y h y x H i O N d i 4 r , o ] p ] 3 , o r o b N e N 4 m , 1 p ] 3 , t e o b H e 3- 4 , 1 a - 4 [ p ) r a O - [] a - 4 [ ) o r a N N O p i y x [ ] 5 , o l o d c O 6(- b [ 5 , o l d i c N p l o O y h b t [ e o 1 [ o i 1 z o l z a r m a N ( N - o 2 z 1 n [ o e o l z a m r a x N h t mn o y x o (- b o y o N e e m- b z a r p b N 1 - z a p b r N y r a N l N 1 p ( c y Hr ht 2 y a c e p ( e l e p l p ma 6 m7 x 2 a 2 E x E
: ) 3 8 + 3 : . + ) 3 5 + 2 d 1 . S E 4 4 ] H d 8 . S . E 8+ 9 ] H -4 (-2 ((-3(- 7l y t u b-t r e t
s3 t 1 3 t 1 n t I n I -4 , -) - - 3 l - y H - ) 4 l - y H - y - O x 7 1 - - ) -4 , o n l - - e 3- -7 1 - - )l 3 - - e O h i t z y-3 3- O O y n e n i x o i z y-3 3 - n i d F e a x - o n i n i d i r e h t a x - e o n i n i il o N m-6 ] (- 4 , d i d i r p e 1 i e t N m ] 4 d i d i r r r y e t [ mi r y p p )l a l H - , N 6 1[ mi y p p ) a l H O N N H 1( ] b y ] c N -2 - y y O ( x -1 ] b r y ] c l y y x ( [ o p ] 3 h , t e o N N H (- [ o p ] -3 , h t o N O - O 1 z - n a - 4 [ ) o b r a O N 2( z n a - 4 [ e ) b r a o e 5 r b , 1 o d [ l i c O -1 - e 5 b , 1 o l o d i c N o - N u l H o o l z f a m N ) - [ o o z r a m - 2- o z x N R ( Hl a a N 4 o a y p o b N l y 2- o o z r a y p x o b N l r y d r y r N h t r d r y r h y a t h p ( c e y p ( a c e i d - 6 mh i d - 6 e l e p l p ma 8 m9 x 2 a 2 E x E
8 :) 3 5 + 2 : . + ) 3 6 + 2 d 8 . S E 8 9 ] H d 9 . S . E 8+ 9 ] H -y x o h t e m-6-) S ( l y t u b-t r e
t m ( y a y p e b e ( - a y p e b u3 v 1 3 t 1 n t I n I - - - ) 4, l y H - 1 - o r - - H 3 - 7 -) 3 - d y 6- 1 - - 3 O O -y - x n i l y- -3 e n i h O i d ) l ) y l y - 3 -e o z h t a x 3- - n e n d il - 4 , -7 - - - 3 - e n n i d i N e o ] i d i i d i o r O r e N 3 - n i z n i i d i t e z e H m- 4 N O 6 , r (- 1[ m ] i r y y p t a y l x a d y p ] x i r y a )l t a l c )l o y y H O h t o ] mi r p ] c y y N H 1( b [ p O N N - ] - 2 o 3 h t x o N N H N e 4 , y p - 3 h t e x o ( z a- , 4 e ) b r N O m- 1[ ] a , 4 ) o b r O - n 5 , [ o a O 6 ] - [ d a 1 e o l d c (- b [ 5 , o l i c N - N ) b S - 1 [ o i 1 ( H o 2 l z o a r m a N (- o z 1 [ o z m a N l y - o z a y x N o 2( n - e o b l o a r x y o b N h t e r d r p b y y p r N a N 1 l - z y H a p r 2 r y a c mh i ( d - c h 6 t e p ( e l e p l p ma 0 m1 x 3 a 3 E x E
: ) 3 5 + 3 : d 3 . S . + ) 3 2 + 3 . E 2 5 ] d 1 . S + E 4 ] H 2 H -2 ((-3(- 7l y t u b-t r e t
n I n I -y - x 7 - t - o - ) h n t i l n z y e - 7 - p y 3 x - - ) n i l e t y - a l y - -3 o l o h z 3 - 3 x O e a m x n - e c e t a x - n - o O - o 6 ] i d ( i n i y c t O e o a l mo ] i d e i n i -3 b r a - 4 , 1 md i i r r d y x O -6 4 , 1 md - i i r )l c- N 1 ( [ - ] 2 b r y y p y h o b N ( r -1 [] r y y p y h 6 t - e ( [ o p ] ] a a c - t c a c H ( N - b 2 [ o p ] ] c- e ) n a H O N N H -2 z N -) n e -5 3 , o ) - 5 O ( N - z n a-5 3 , o d x e N O S b , 1 4 [ l y -e l H O N N 3-) e b , 1 4 [ i mh ] O a 6 - [ o , r H o 2 l l h o o t z e o ) rr r O 6 , - [ o Ho 2 l l o o a z x 0 . o 1 . N 5 - z a r o y N S 5 - z a b 3 [ N , R o r a a d r y d N 3 p i p ] c N , R o r a r r d r y a c o l N ( y y l h p i ( - m - H a [ x a N 1 N ( l y y h p p ( - c H y c y d 6 1 o y i d - 6 1 i h - t 4 -) b e , 3 l b r h y a t - c e 4 - , ) a 3 l y z a e l e p l p ma 2 m3 x 3 a 3 E x E
: ) 3 5 + 3 : . + ) 3 4 + 3 d 5 . S E 0 4 ] H d 2 . S . E 0+ 4 ] H -4 (-2 ((-3(- 7l y t u b-t r e t
y3 z 1 3 t 1 n t I n I -o - - r - ) l d y - H O h 6 e - y - H 1 - i - 1 d ) l -)l - t a l O O 4 , 3 7 - - ) n l 4 y - - O - y 4, - y - 3-e -4 y x -y x i z - 3 3 n i - -e d i 3 7 - 3 n - n n i -)l o b r o a h x o n i n i r e N -y i x z i d o a x i d i r y h a m c N t e ] 4 , d i d i r p i p H O h i y p t ] e ) - 4 O m- 1[ mi r y p ] )l e t a N N H t o ] r y c - o - N e 4 , d e H N N H 6( ] b y c- y h t e 1 p ] 3 , i n i N -1 [ o p ] 3 , t e ) c a N m O O -6 [ ( ] a - b 1 [ - 4 [ m o a d x i r N e O O (-2 z ( n a - 4 [ o ) l y (- o 5 , l o z 1 p i - e 5 b , 1 o d [ l i n [ o o z a b r a p l N 1(- - o H o l z m a a N N 2(- e b l o r z y c y N h 2 t l 2- o r x o z a y o b N 1 - a p e N y N l y H ht 2 r y m N h t r r p r e d y y a c e p ( h p i ( d - 6 e l e p l p ma 4 m5 x 3 a 3 E x E
: ) 3 3 + 3 : d 0 . S . + ) 3 9 + 3 . E 1 4 ] d 3 . S + E 2 ] H 6 H -3 (-2 ((-3(- 7l y t u b-t r e t
y a y p e b e t 3 ( x o m a a y p e b a a b 3 a 1 3 t 1 n t I n I -o - - t r - - ) l H e - H 4 , y O - 1 m O d y h 6 i - 1 ) - e )l - t a O 3 l -y 7 - - )l ) - o n d l y y 3 - - y O x n i y - 3 i N -4 , -7 - - 3 - e n 1 - x o o h z t a x 3- - n e m n a ) e N 3-y n i x z n i i d ) i l y b r a e o ] i d i l t i d i y h a t H O o a d x i r h o mi y p t ] e c ) - m 2 - - N 6 4 , r (- 1[ mi r y t p ] e e c a) N N H h t ] r c o e ] y c m( l N e 4 y - d n 1( b [ p - )l y N O m , p 3 , i i H O - o ] 3 , y n O - 1 6 [ ( ] ] a - b [ - 4 5 [ m a z a N N H r N 2 ( z n a - 4 [ h e t h , o l x o e p N ( O O (- e 5 b , 1 o l e ) p )l N 1( N - o 2 z 1 [ o ( n o z b r i p l 3(- - [ o H o l z o d i y h N - e b l o a r a z y c y h N 2 t N l 2- o a r o z y m a N 4 l - y H a h t 2 r p e y yp m N N h t r a r p x e d ( my y h p o ( - b r e i d 6 a c e l e p l p ma 6 m7 x 3 a 3 E x E
: ) 3 4 + 3 : d 4 . S . + ) E 4 2 ] 3 3 5+S 2 . + H d . E 5 4 ] H ^ ^ ^ ^ ^ -^^ G ^^ ^ ^^ ^ ^^ į ^ ^ d 6 -O SM D, z H M 0 0 5 ( -4 (-2 ((-3(- 6l y t u b-
t r x e o l y - r o - r t , n t - r - t , t h t - 6 y p z a ) l d y e i r e t e ) o y p o z ) l o z e n i e 1 - ] a r y y h i M ( m t o x n ] a r y n M o a y e b ( m ( n p d p b1 a 1 4 t 1 n t I n I - -o - -4 , H 3 1 -4 r d -6 H 1 O , 2 - -) , 6- l y - - 3- e y ni h - i ) l -) y l y -3 e t O 1- )l - y y- 3 - e n i d i r O d- - 4 , 7 - - 3 - - n i a t e c N x o 6 h - n i d t n i d i r e p i e O 3 t - n i n y z i d d i i r y a ) H O e il y p o mi p ] )l a l H O O N O x a o x o mi p ] y x o N N H N m - n i r y c- y h y t x o N N h t ] r c e 4 y - ) 3 l y N O 7( u p - q o ] a 3 , 4 e ) b N r H , O m- 1[ p ] ] , a 4 [ o 1(- r d - N 2 y 5 [ , o o l d a o i c 6(- b [ - o o 5 , l m o a b r N (- h 1 1 a [ o l z a m N N 1 r a x ( ( z 1 [ z a ( n o l a r c ) N l rt N y h e t o z t a y o N - e b o y p l y e r p b r N 2 l - z a y a p c y h H 2 r y ( t e p ( e l e p l a 8 p m 9 x 3 m a 3 E x E
9 :) 3 6 + 2 : . ) 3 9 + 3 d 9 . S E 5+ 8 ] H d 7 . S . E 2+ 4 ] H -) s 3, s 1(( ((-3(- 7l y t u b-t r e t
b4 c 1 4 t 1 n t I n I - - 4 ) , l - -) - 3 y H l y H - 4 - -7 1 - - - )l 1- - - 1 - - e O 4 , 7- )l e n O y n i O x o i h z y- - 3 3 - n O a 3 - n i z y- -3- d i r t a - e x o n i n t i u y d b x o a x 3-n i n i e d p i m] - 4 d i i r H O O 6 , y o l c e t N h t o e ] 4 d i i r p ) l e t ( 1[ mi r p ] y c a l m , N O - - 1[ mi y r p ] y h a l N 1 ] b y N N ( H ( p c - ) y y x 6( ] b y p c - t e y x ( [ o ] a 3 , x o o b H O O O - 1 [ o ] 3 , ) y o b O -3 z - ) n - 5 4 [ )l r N a N ( ( z n a-5 4 [ x o r a s e b , 1 o l y o o c N N H (-2 e b , 1 o l o )l y c N N 3 , - [ s 1 H o l z m O (- - [ o z o N ( 2 o a r a 1 Hl a r m N l - y o z y b r r a p a N N l y 2 h - o o z a y p a b r ht d r e y y c ) h p i ( l y t r d r N e y y p a ( c ) d - 6 N h i d - 6 l y e l e p l p ma 0 m1 x 4 a 4 E x E
: ) 3 0 + 4 d 5 . S . + E 5 9 ] H
H, ) M z 1 , , s ( 2 ) 4 z 1 , m ( 3 , , s ( m ( 0 H . 0 4 1 . 8 8 Hs ( 7 . ( 1 8 = . , ) 1 . 1 5 4 - 0 6 . J 8 z 8 . 6 H= J 6 . 4 3- i -7- d i -)l - 1- - - 4 - 6 [ y -x o - 4 r - e y p o i h m- Hn i 5 He 5 . 4 , 1- . ) d i 4 n i 0 5 t 1 ( n e ( i (- d i p r )l a y b r 1 [ l o y r -- l - y o z 3 p ] r a e d x t o a = l t 9 7 R +]m4 e n a c o - c 6 (- - y ] y x : z / H 2 p i o p b ) z n r l y a r i h d 3 , i 4 d , ) 1 o b 6 + m + l y t (( l u - y h a c h t b 3 e y i 4 p m [ o -3 [ , ] r b a d S M [ c o E- ( t t e ) y ) r x l ( y - i 6 r y l o z 2-) [ h t l o z e , n i e mo t ) - l 1 p ] a r y n y - n a y p e b M ( m ha 3 1 t n I - - N 6(- H - 1 -4 - 6 - ) - - e O 1(- - O 2 H) ( l l y - 3- - 2 e n i d 1 - l o y r -7 3-n n i i r e N y- d y -n i i d i d i r p i e tH 4 h i z a m N i y p ] p )l a l O -n i d - x o r y c- y h y x d i 4 , 3 ] 4 , p ] 3 , t e ) o b O N N N H r e p -y 1 [ a ] - 4 5 [ o o r l d i a c O i p x l o h b , 1 o N y t [ N h t e o [ z o l z a m r a x e mn e o z y o N m b a r p b r N - 1 y a p c ( e l p ma 2 x 4 E
Example 43
Ethyl (R)-1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)pyrrolidine-3-carboxylate (Example 43) A solution of example 29 (38.0 mg, 0.0636 mmol) and concentrated sulfuric acid (170 μL, 3.18 mmol) in EtOH (1 mL) was stirred at 80 °C for 4 h. After cooling to RT, RM was diluted with sat.aq. NaHCO3, DCM (5 mL) and the pH adjusted to 9.5. Aqueous layer was extracted with DCM/i-PrOH (3:1; 4x5 mL) and the combined organic layers were passed through a phase separator and solvents removed in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-70 % DCM/MeOH/NH4OH (90:5:0.5) in DCM to afford the title product (28 mg). LCMS (Method 3), Rt = 4.05 min, ES+ m/z 612.3 [M+H]+ 1H-NMR (500 MHz, DMSO-d6) δ: 9.46 (d, J=1.2 Hz, 1H), 9.23 (dd, J=6.9, 1.8 Hz, 1H), 8.91 (s, 1H), 8.74 (dd, J=4.1, 1.6 Hz, 1H), 8.46 (t, J=6.0 Hz 1H), 8.24 (d, J=1.1 Hz, 1H), 7.17 (dd, J=6.9, 4.1 Hz, 1H), 6.89 (s, 1H), 6.49 (s, 1H), 6.37-6.39 (m, 1H), 4.14 (t, J=4.5 Hz, 2H), 4.06 (q, J=7.2 Hz, 2H), 3.63 (s, 3H), 3.44 (q, J=6.3 Hz, 2H), 3.37-3.40 (m, 2H), 2.97-3.03 (m, 1H), 2.85 (t, J=8.7 Hz, 1H), 2.59-2.65 (m, 3H), 2.50-2.53 (m, 2H, overlapped with DMSO), 1.91-2.01 (m, 2H), 1.17 (t, J=7.1 Hz, 3H). Examples 44 to 45 The following Examples were prepared in a similar manner to example 43 from the indicated starting materials.
Example Structure/name Intermediate 1H-NMR LCMS d , d ,
Example 46 Step 1
1-(6-Methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin- 3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Example 46-intermediate 1) A degassed mixture of intermediate 8 (50 mg, 0.14 mmol), 3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (47.6 mg, 0.19 mmol), K3PO4 (58.8 mg, 0.28 mmol) and XPhos PdG3 (5.9 mg, 7 μmol) in 1/1 water /THF (5 mL) was stirred under nitrogen at 70 °C for 1.5 h. After cooling to RT, solvent was removed in vacuo. The residue was suspended in 1M aq. HCl to form a precipitate that was collected by filtration, followed by a washing with water. The filtrate was additionally extracted with EtOAc (3x20 mL), DCM (2x10 mL) and DCM:i-PrOH (1:1, 2x20 mL). The combined organic layers were dried over Na2SO4 and solvents removed in vacuo. Combined crude materials were purified by flash chromatography on Si cartridge by eluting with 0-100 % DCM/MeOH/AcOH (90:9:1.5) in DCM to afford the title product (37.9 mg). LCMS (Method 3), Rt = 3.79 min, ES+ m/z 444.1 [M+H]+ Step 2
(4-Methylmorpholin-2-yl)methyl 1-(6-methoxy-3,4-dihydro-2H
n-7- yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (Example 46) A solution of example 46-intermediate 1 (20.0 mg, 0.04 mmol), (4-methylmorpholin-2- yl)methanol (18.5 mg, 0.14 mmol), EDC*HCl (13.5 mg, 0.07 mmol) and DMAP (4.3 mg, 35 μmol) in DMF (1 mL) was stirred at RT overnight. RM was partitioned between EtOAc (10 mL) and water (5 mL). The organic layer was washed with sat. aq. NaCl (5 mL) and solvent removed in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-20 % DCM/MeOH/NH4OH (90:9:0.5) in DCM to afford the title product (6.6 mg). 25 LCMS (Method 3), Rt = 4.21 min, ES+ m/z 557.2 [M+H]+ 1H-NMR (500 MHz, DMSO-d6) δ: 9.40 (s, 1H), 9.26-9.22 (m, 1H), 8.92 (s, 1H), 8.76-8.73 (m, 1H), 8.28 (s, 1H), 7.18 (dd, J=4.3, 7.0 Hz, 1H), 6.87 (s, 1H), 6.51 (s, 1H), 6.43 (s, 1H), 4.46-
4.41 (m, 2H), 4.15 (t, J=4.1 Hz, 2H), 3.92-3.83 (m, 2H), 3.63 (s, 3H), 3.61-3.56 (m, 1H), 3.40 (br d, J=1.5 Hz, 2H), 2.80 (br d, J=11.3 Hz, 1H), 2.62 (br d, J=11.9 Hz, 1H), 2.21 (s, 3H), 2.09-2.03 (m, 1H), 1.93 (t, J=10.7 Hz, 1H) Example 47 Step 1
1-(2-(1-(4-(tert-butoxycarbonyl)-6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylic acid (Example 47-intermediate 1) A mixture of Example 9-intermediate 1 (1.0 g, 1.38 mmol) and LiOH (1.0 M in water, 6.9 mL, 6.9 mmol) in THF (15 mL) was stirred at RT overnight. RM was diluted with water and washed with EtOAc. After pH acidification of aqueous layer to 5 by using aq. 1.0 M HCl and cooling on ice for 30 min, the formed precipitate was filtered, washed with water several times and dried to afford the title compound (842 mg). LCMS (Method 1), Rt = 0.82 min, ES+ m/z 698.3 [M+H]+ Step 2
tert-butyl 7-(3-((2-(4-((3-cyanocyclobutoxy)carbonyl)piperidin-1-yl)ethyl)carbamoyl)- 6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3-dihydro- 20 4H-benzo[b][1,4]oxazine-4-carboxylate-(Example 47-intermediate 2) To a mixture of Example 47-intermediate 1 (70.0 mg, 0.10 mmol), 2,4,6-trichlorobenzoyl chloride (39 μL, 0.25 mmol) and 3-hydroxycyclobutanecarbonitrile (21.4 μL, 0.25 mmol) in dry DMF (1 mL), TEA (70 μL, 0.50 mmol) and DMAP (3 mg, 25 μmol) were added and RM stirred
at RT overnight. RM was diluted with EtOAc (15 mL) and washed with sat. aq. NaHCO3 (3x10 mL), sat. aq. NH4Cl (15 mL) and sat. aq. NaCl (10 mL). Organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-50 % DCM/MeOH (95:5) in DCM to afford the title product (47 mg). LCMS (Method 2): Rt = 1.21 min, ES+ m/z 777.4 [M+H]+ Step 3
3-cyanocyclobutyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate (Example 47) An ice cold mixture of Example 47-intermediate 2 (45.0 mg, 57.9 μmol) in dry DCM (1 ml) was treated with TFA (222 μL, 2.90 mmol). RM was stirred for 2 h at RT, then diluted with DCM, cooled to 0 °C, neutralized with aq. sat. NaHCO3 and extracted with DCM (3x10 mL). Combined organic layers were passed through phase separator and solvent removed in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-50 % DCM/MeOH (9:1) in DCM to afford the title product (31 mg). LCMS (Method 3): Rt = 4.26 min, ES+ m/z 677.5 [M+H]+ 1H-NMR (600 MHz, DMSO-d6) δ: 9.46 (d, J=1.1 Hz, 1H), 9.24 (dd, J=7.0, 1.7 Hz, 1H), 8.91 (s, 1H), 8.74 (dd, J=4.1, 1.7 Hz, 1H), 8.45 (t, J=5.9 Hz, 1H), 8.24 (d, J=1.1 Hz, 1H), 7.17 (dd, J=7.0, 4.0 Hz, 1H), 6.89 (s, 1H), 6.49 (s, 1H), 6.37-6.40 (m, 1H), 4.87 (quin, J=7.3 Hz, 1H), 4.14 (t, J=4.4 Hz, 2H), 3.63 (s, 3H), 3.44 (q, J=6.5 Hz, 2H), 3.37-3.41 (m, 2H), 3.03-3.12 (m, 1H), 2.82- 2.90 (m, 2H), 2.70-2.78 (m, 2H), 2.51-2.53 (m, 2H), 2.26-2.34 (m, 3H), 2.01-2.08 (m, 2H), 1.77- 1.85 (m, 2H), 1.51-1.61 (m, 2H). Example-48-intermediate 1 and Example 49-intermediate 1 The following intermediates were prepared in a similar manner to example 47-intermediate 1 from the indicated starting materials.
Intermediate Structure Starting materials LCMS + i + i
Example 48 to 53 The following Examples were prepared with a two-step process (step 1 and step 2) similarly to Example 47-step 2 and step 3 respectively from the indicated starting materials. It is additionally stated if base, solvent, temperature or coupling reagent were varied.
102 :) S 3 6 0+S 3 : . 4+ ) ] 3 8 3+S 6 . +] 2 p e t S 1 p e t S
t r a e t t a m a 8 4 m r e n - a 2 y h , m 9 t 1- a 4 m r n a o r 2 d , 2 t e n a e l S m x E e t n e e x e t 1 y m i i p mn o a E n i e h d r p -1( - - - o 6 - ) - l - - 2 - ( - -)l - 3- 2 r - l d ) y l y y - - 3 3 - 4 - e - n n - i 1 H- -) 2- 6 o -) y l - 3 3 - - e e n n i e y p h i 7 n i d i r R r y n i di l m o a r d n p - -n i i d i di r e ( d p l y - / l 4 , z a my h 7- i d i di r o r i p ] i p y ) e t p i d n i my i p r ] y e t a e y r h 3-y x o r y c- l y a t o r p -4 z a r y c - p )l l y u t t e x ] 4 , p ] 3 , h t e c l y , 3 - x o ] p ] 3 , y h x o c mo u r - h t 1[ a- 4 [ e ) a ) l h t y a 4 x 4 , - [ t e ) b r t 2- e ] b 5 , o 1 l o o d i y e mo h 1 [ 5 , o 1 l o o d a c S y x m - [ o r 6( o z [ o l z a r m a -2 t ] - e b [ [ o l z a r i m d - y 1 n o h ( e z y a p- x o o n m - o 6 z o y a n z a p- x o - - b 2 2 - r ( H y 2 p Hb ( 1 r a a c y ( c- - e r 2 1 ( b y p H ( 1 b r a c e l e e p l p l m a m8 p x a 4 m a 9 4 E x E x E
103 :) 3 3 4+S 3 : . 9+ ) ] 3 1 5+S 3 . 9+]
p p o y - m- a 7 e 1 d e 5 - e 1 d R x 4 m r e n a m r 1 e m a 7 x 4 m r e n a 4 , r * o p u l 3 l y - h n i E e t e n t i n I E e t n R i 3 f ( - t 4 e d i m l -6 ( -) - - -) - - - l -3 4 - 6 ( - l -3 4- 1( - 6 - - 1- 2 H-) y-3 - e e n - i - 1( - 6 y H-) - 3 - e e n i (- 2- l o y- - 7 n i n i d d i 1 - - 2 ( 2- l y- -n i n i d d i r d ir r o - o 7 d i r r o 1 r - i y e p r o l o 1 r - i y e p u y d y n i mi p ] i p e t l - h z r a u l l y d y n i mi p ] i p e t a f- 3 - i d- a x y c p - ) 3 l y l y f x - - 4 3- h i z d- a r x y c p - ) 3 l y l y 4 n o ] , h t o -) n o ] , h t x -) i S d 4 i , , l 3 ] - 4 , a- 4 5 [ o e l ) o b r * i R d 4 i , l 3 ] - 4 , a- 4 5 [ o e ) o o b r 4 S o r r y 1 [ , a c 4 o y 1 [ , l a c y x o ] b 1 [ o d o z a i , * r r x o ] b 1 [ o d o z a i 3 ( p l h y t [ l e o r m h z o y a x R 3 y p l h t [ o l r m z o y a x t e mn z e a b r p - o ( y e n z a p - o y Hb r h t me r y Hb r m p ( 1 a c e b m p ( 1 a c e l e p l m a 0 p 1 x 5 m a 5 E x E
104 :) 3 0 5+S 3 : . + ) ] 3 4 2+S 3 . +] , d ( 6 4 . 9: δ ) d 6 -O SM D, z H M 0 0 5 ( - (- ((- (- -) ( l t -t t
p y e m- a 8 e x 4 m 1 d e 6 p- e r e n a m r 1 e m a 7 4 m 1 d r e n - a 1 x o c r y a c l e i rt E e t e d c ) n i n t x e l n E t y y a p n i I n i h ( h t o -3- - n - n i 4 i - - d z 4- 2(- - - - H- )l -3 4- i , l 3 o - a x - - - 3 - n i 1 l 2- 6 o -) y l -3 - e e n n i r y r x o ] y o p h 4 5 , , 1 H e d i y r [ 1 - n i r h t d y- -n i i d d i i r )l t 1[ o )l d i e r p i e y 7 mh i -n d i r y e p i e y e ] l b o h m [ z y - y p p )l e t ) l d- i z mi r p ] c p) t a l t - e 6 o a r 3-n ] c- y h a t e y p 4 , a 3 x y p -3 l y y x o ( r - z n y p i d 3 , t e ) c a o r p - o y ] ] a , h - 4 [ t e o b o 1( e ( i u l - b - - m4 [ o ) d l y o l x 4 o , 1 5 , o l ) o r a f 2 6 ( H-) i o l r y l o i m c y h t [ e ] b 1 [ o d o z a i c - 2 - ( 1 2 - ( 1 - -o y- p z a c 7 ] a r x o [ n m - o l r m z o y a x -) 2 r l d a y y o p b r a 6 n z a p - o R y h a y c (- e b r y Hb r ( i - d c 1 ( 1 ( p ( 1 a c e l e p l m a 2 p 3 x 5 m a 5 E x E
Example 54 Step 1
tert-Butyl 7-(3-((2-(4-((3-bromopropoxy)carbonyl)piperidin-1-yl)ethyl)carbamoyl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3-dihydro- 4H-benzo[b][1,4]oxazine-4-carboxyla mediate 1)
Title product was prepared on a similar manner to Example 47-intermediate 2 starting from Example 47-intermediate 1 and 3-bromopropan-1-ol. LCMS (Method 2): Rt = 1.33 min, ES+ m/z 818.3/820.2 [M+H]+ Step 2
tert-Butyl 7-(3-((2-(4-((3-cyanopropoxy)carbonyl)piperidin-1-yl)ethyl)carbamoyl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3-dihydro- 4H-ben
carboxylate (Example 54-intermediate 2) A mixture of Example 54-intermediate 1 (32.0 mg, 0.04 mmol) and NaCN (10.0 mg, 0.20 mmol) in DMF (1.0 mL) was stirred at 80 °C for 1.5 h. RM was diluted with EtOAc (15 mL), washed with sat. aq. NaHCO3 (3x10 mL) and sat. aq. NaCl (10 mL). Organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography on Si cartridge by eluting with 0-70 % DCM/MeOH (9:1) in DCM to afford the title product (28 mg). LCMS (Method 2): Rt = 1.18 min, ES+ m/z 765.4 [M+H]+ Step 3
3-Cyanopropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate (Example 54) Title compound was prepared on a similar manner to step 3 of Example 47 starting from Example 54-intermediate 2. LCMS (Method 3): Rt = 4.12 min, ES+ m/z 665.4 [M+H]+ 1H-NMR (500, DMSO-d6) δ: 9.45 (d, J=1.1 Hz, 1H), 9.23 (dd, J=7.0, 1.5 Hz, 1H), 8.91 (s, 1H), 8.73 (dd, J=4.3, 1.5 Hz, 1H), 8.45 (t, J=5.8 Hz, 1H), 8.24 (d, J=1.2 Hz, 1H), 7.17 (dd, J=7.0, 4.0 Hz, 1H), 6.89 (s, 1H), 6.49 (s, 1H), 6.35-6.41 (m, 1H), 4.14 (t, J=4.3 Hz, 2H), 4.08 (t, J=6.1 Hz, 2H), 3.63 (s, 3H), 3.44 (q, J=6.9 Hz, 2H), 3.36-3.41 (m, 2H), 2.80-2.93 (m, 2H), 2.56 (t, J=7.2 Hz, 2H), 2.49-2.52 (m, 2H), 2.28-2.35 (m, 1H), 2.04 (br t, J=10.5 Hz, 2H), 1.88 (quin, J=6.6 Hz, 2H), 1.78-1.85 (m, 2H), 1.51-1.64 (m, 2H). Example 55 Step 1
1-(4-(tert-Butoxycarbonyl)-6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl pyrazolo[4,3-c]pyridine-3-carboxylic acid (Example 55-
Intermediate 1) To a previously degassed mixture of aqueous potassium phosphate (1.0 M, 2.17 mL, 2.2 mmol) and THF (5 mL), intermediate 7 (500 mg, 1.1 mmol), 3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (372 mg, 1.5 mmol) and XPhos-PdG3 (46 mg, 54 μmol) were added and RM stirred at 70 oC for 1.5h. After cooling to RT, RM was diluted with water (15 mL) and basified to pH 10. RM was washed with EtOAc (2x20 mL) and aqueous layer filtered through a pad of diatomaceous earth and washed with water (100 mL). A mixture of MEK (methylethyl ketone) and i-BMK (isobutylmethyl ketone) (5:1 - 150 mL) was added and pH adjusted to 4.5. Organic layer was separated, dried over Na2SO4, filtered, and evaporated to dryness to give the title product (560 mg) that was used in the next synthetic steps without further purification. LCMS (Method 1): Rt = 1.18 min, ES+ m/z 544.4 [M+H]+ 30 Step 2
tert-butyl 7-(3-((2-((R)-3-((((R)-1-(2-fluoroethyl)pyrrolidin-3- yl)oxy)carbonyl)pyrrolidin-1-yl)ethyl)carbamoyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H- pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Example 55-Intermediate 2) A solution of Intermediate 17 (140 mg, 0.34 mmol) in conc. HCl (1.5 mL) was stirred overnight at RT. Solvent was removed in vacuo, residue dried in vacuum oven at 40°C for 72h. To the residue taken in dry DMF (2 mL), Example 55-Intermediate 1 (171 mg, 0.32 mmol), DIPEA (507 μL, 2.96 mmol) and HATU (169 mg, 0.44 mmol) were added and RM stirred at RT for 1h. A second equivalent of HATU and were added and RM stirred at RT for further 1h. RM was quenched with sat. aq. NH4Cl and the formed precipitate collected by filtration, washed several times with water. The obtained solid was purified by flash chromatography on Si cartridge by eluting with 0-40 % DCM/MeOH/NH4OH (90:9:1.5) in DCM to afford the title product (10 mg). LCMS (Method 2): Rt = 1.18 min, ES+ m/z 799.4 [M+H]+ Step 2
(R)-1-(2-fluoroethyl)pyrrolidin-3-yl (R)-1-(2-(1-(6-methoxy-3,4-dihydro-2H- be
-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)
-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)pyrrolidine-3-carboxylate (Example 55) Title compound was prepared on a similar manner to step 3 of Example 47 starting from Example 55-Intermediate 2. LCMS (Method 3): Rt = 3.44 min, ES+ m/z 699.3 [M+H]+ 1H-NMR (500 MHz, DMSO-d6) δ: 9.46 (d, J=1.2 Hz, 1H), 9.23 (dd, J=7.0, 1.5 Hz, 1H), 8.91 (s, 1H), 8.73 (dd, J=4.1, 1.7 Hz, 1H), 8.45 (t, J=6.0 Hz, 1H), 8.24 (d, J=0.9 Hz, 1H), 7.17 (dd, 25 J=7.0, 4.0 Hz, 1H), 6.88 (s, 1H), 6.49 (s, 1H), 6.37-6.40 (m, 1H), 5.02-5.08 (m, 1H), 4.48 (dt, J=48.0, 4.7 Hz, 2H), 4.14 (t, J=4.3 Hz, 2H), 3.63 (s, 3H), 3.43 (q, J=6.4 Hz, 2H), 3.37-3.41 (m,
2H), 2.94-3.03 (m, 1H), 2.83 (t, J=8.7 Hz, 1H), 2.56-2.75 (m, 9H), 2.51-2.55 (m, 1H), 2.33-2.40 (m, 1H), 2.08-2.20 (m, 1H), 1.88-2.03 (m, 2H), 1.61-1.71 (m, 1H). Example 56 to 57 The following Examples were prepared with a two step process similarly to Example 9 from the indicated starting materials.
109 S d o h = , t n i z / 3 + d . ] o = , t n i z / 3 + . ] M m m H h m m H e t 1 e t
gn l i a t i a r r e 0 b 0 t 2 2 a t a t n .t S m I n I -) - S o -6 - ) ( r - l - - -1 - )l - - 4 l d ) l y - 3- e e n i (- - - 2 H6- y - 3 - - e e y y - h i y-7 3-n n i d il (- 2 - ) l y 3-n n i n i d e 3- d- -n i d i di r o r 1 o r l r d - 7 i d di i r r e m n a i 4 , i n d / i l 3 - z a my p y p e t a y - y - i h n i my p p i e t e y x ir ] c )l l y 3-n i d z ir ] c p )l a l r o r u r x o ] y p -3 t y o h , y h x o i d - a 4 x y p -3 y y x t 4 , ] a 4 t [ e b r i t , e 3 o ] ] a , 4 h t e o c u p r l e 1[ t y ] -5 o ) h l o a - c z y 4 , -5 [ o l ) o b r a t m- b [ , 1 [ o d i - a 3 l y x 1 o [ ] , 1 [ o d i c S e 6 m( - - o z o z l a o r m a p o h t b e [ o o z l a o r m a 1 1( -) - n e b z y a p- x o r b p z o m - n z y a p- x o R 2 ( (- - r 1 H y 2 p H ( 1 r a s c i - 6 ( e b r y 1 p H ( 1 b r a c e l e l e p m p l p a m6 x a x 5 m a 7 5 E E x E
Example 58 Step 1
1-(4-(tert-Butoxycarbonyl)-6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-((3- methoxypyrazin-2-yl)amino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Example 58- intermediate 1)
To a Shlenk tube charged with Intermediate 7 (100 mg, 0.22 mmol), 3-methoxypyrazin-2- amine (41 mg, 0.33 mmol) and RuPhos-Pd-G3 (9.1 mg, 11 μmol), under nitrogen dioxane (3 mL) and LiHMDS (1.3 M in THF, 826 μL, 1.1 mmol) were added. RM was heated at 100 oC for 20h. After cooling to RT, RM was diluted with water (30 mL) and extracted with EtOAc (2x15 mL). Aqueous layer was acidified with 1N HCl (20 mL) and extracted with MEK (methylethyl ketone) (3x15 mL). Combined organic layers were dried over Na2SO4, filtered and solvent removed in vacuo. The residue was suspended in water (30 mL) and extracted with EtOAc (2x20 mL). Combined organic layers were dried over Na2SO4, filtered and solvent removed in vacuo to afford the title compound (84mg) that was used in the next synthetic steps without further purifications. LCMS (Method 2): Rt = 0.87 min, ES+ m/z 550.2 [M+H]+ Step 2
1-(6-Methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-((3-oxo-3,4- dihydropyrazin-2-yl)amino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Example 58- intermediate 2) A mixture of Example 58-intermediate 1 (84 mg, 0.15), sodium iodide (92 mg, 0.61 mmol) and TMS-Cl (78 μL, 0.61 mmol) in acetonitrile (2.0 mL) was stirred at 85 oC for 3 h. RM was cooled to RT and quenched with water (50 μL). Toluene (5 mL) was added, and solvents removed
in vacuo to afford the title compound (290 mg) that was used in the next synthetic step without further purifications. LCMS (Method 2): Rt = 0.49 min, ES+ m/z 436.2 [M+H]+ Step 3
Ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-((3-oxo-3,4- dihydropyrazin-2-yl)amino)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine- 4-carboxylate (Example 58) Title compound was prepared on a similar manner to intermediate 11a starting from Example 58-Intermediate 2 and Intermediate 1. LCMS (Method 3): Rt = 4.10 min, ES+ m/z 618.3 [M+H]+ 1H-NMR (500 MHz, DMSO-d6) δ: 9.15 (d, J=0.5 Hz, 1H), 8.81 (s, 1H), 8.39 (t, J=5.3 Hz, 1H), 8.14 (d, J=0.7 Hz, 1H), 6.94 (d, J=4.4 Hz, 1H), 6.89 (d, J=4.4 Hz, 1H), 6.83 (s, 1H), 6.46 (s, 1H), 6.35 (bs, 1H), 4.12 (d, J=3.9 Hz, 2H), 4.05 (q, J=7.1 Hz, 2H), 3.63 (s, 3H), 3.41 (q, J=6.7 Hz, 2H), 3.30 (m, 2H, overlapped with HDO), 2.83-2.86 (m, 2H), 2.48 (t, J=6.7 Hz, 2H), 2.27 (tt, J=6.7 Hz, 1H), 2.00-2.05 (m, 2H), 1.76-1.80 (m, 2H), 1.51-1.58 (m, 2H), 1.16 (t, J=7.1 Hz, 3H) Example 59 Step 1
20 tert-Butyl 7-(3-((2-(4-((ethylthio)carbonyl)piperidin-1-yl)ethyl)carbamoyl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2,3-dihydro- 4H-benzo[b][1,4]oxazine-4-carboxylate (Example 59-intermediate 1) Title product was prepared on a similar manner to step 2 of Example 47 starting from Example 47-intermediate 1 and ethanethiol.
LCMS (Method 1): Rt = 1.00 min, ES+ m/z 742.4 [M+H]+ Step 2
S-Ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine-4- carbothioate (Example 59) Title compound was prepared similarly to step 3 of Example 47, starting from Example 59- intermediate 1. LCMS (Method 4): Rt = 4.47 ES+ m/z 642.2 [M+H]+ 1H-NMR (500 MHz, DMSO-d6) δ: 9.46 (d, J=0.9 Hz, 1H), 9.23 (dd, J=7.0, 1.5 Hz, 1H), 8.91 (s, 1H), 8.73 (dd, J=4.1, 1.7 Hz, 1H), 8.45 (t, J=5.6 Hz, 1H), 8.24 (d, J=0.9 Hz, 1H), 7.17 (dd, J=7.0, 4.3 Hz, 1H), 6.89 (s, 1H), 6.49 (s, 1H), 6.38 (s, 1H), 4.14 (t, J=4.3 Hz, 2H), 3.63 (s, 3H), 3.43 (q, J=6.7 Hz, 2H), 3.39 (m, 2H), 2.92 (m, 2H), 2.82 (q, J=7.5 Hz, 2H), 2.51-2.54 (m, 2H), 2.45-2.49 (m, 1H), 2.03 (br t, J=10.7 Hz, 2H), 1.80 (m, 2H), 1.54-1.62 (m, 2H), 1.16 (t, J=7.3 Hz, 3H). PREPARATION OF COMPARATIVE EXAMPLES A1 to A12 Example A1
1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine-4-carboxylic acid (Example A1) A solution of example 9 (46.1 mg, 0.06 mmol) in THF (6 mL) was treated with solution of LiOH.H2O (6.60 mg, 0.18 mmol) in water (2 mL). RM was stirred at RT overnight. Organic solvent was removed in vacuo and pH was adjusted to 7 using aq. 1M HCl, the residue was then 25 purified by HPLC-MDAP (Method 1) to afford the title compound (24.1 mg).
LCMS (Method 3): Rt = 3.72 min, ES+ m/z 598.3 1H-NMR (500 MHz, DMSO-d6) δ: 9.45 (s, 1H), 9.22 (d, J=7.0 Hz, 1H), 8.90 (s, 1H), 8.73 (dd, J=4.3, 1.5 Hz, 1H), 8.46 (s, 1H), 8.24 (s, 1H), 7.16 (dd, J=7.0, 4.3 Hz, 1H), 6.88 (s, 1H), 6.49 (s, 1H), 6.36 (br s, 1H), 4.13 (br t, J=4.1 Hz, 2H), 3.63 (m, 5H, overlapped with HDO), 2.86 (br d, J=11.3 Hz, 2H), 2.54 (s, 1H), 2.53-2.51 (overlapped with DMSO-d6, 4H), 2.19 (br t, J=4.0 Hz, 1H), 2.04 (br t, J=10.5 Hz, 2H), 1.78 (br d, J=10.4 Hz, 2H), 1.59-1.49 (m, 2H). Examples A2 to A12 The following examples were prepared in a similar manner to example A1 from the indicated starting materia. St ti ,
. - . (m, ).
(500 MHz DMSO-d6) , ,
Example A9 (or Example 46-intermediate 1)
1- Methoxy-3,4-dihydro-2H-b
enzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin- 3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Example A9)
See procedure for the preparation of Example 46-intermediate 1. LCMS (Method 1), Rt = 3.79 min, ES+ m/z 444.1 [M+H]+ 1H-NMR (500 MHz, DMSO-d6) δ: 9.47 (s, 1H), 9.19 (dd, J=7.0, 1.6, 1H), 8.88 (s, 1H), 8.71 (dd, J=3.9, 1.5 Hz, 1H), 8.15 (d, J=0.6 Hz, 1H), 7.13 (dd, J=6.9, 3.9 Hz, 1H), 6,78 (s, 1H), 6.48 (s, 1H), 6.27 (bs, 1H), 4.14 (t, J=4.2, 2.0 Hz), 3,63 (s, 3H), 3.25-3.41 (m, 2H) Example A10
2-(((1-(6-Methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamoyl)oxy)acetic acid (Example A10) The title compound was obtained as secondary product during the preparation of example 3. LCMS (Method 1), Rt = 4.20 min, ES+ m/z 533.1 [M+H]+ 1H-NMR (500 MHz, DMSO-d6) δ: 13.11 (br s, 1H); 10.76 (br s, 1H); 9.20-9.29 (m, 2H); 8.90 (s, 1H); 8.74 (dd, J=4.0, 1.5 Hz, 1H); 8.10 (s, 1H); 7.17 (dd, J=6.9, 4.1 Hz, 1H); 6.96 (s, 1H); 6.56-6.65 (m, 1H); 6.43 (s, 1H); 4.70 (s, 2H); 3.64 (s, 3H); 3.54-3.61 (m, 2H); 2.95-3.02 (m, 2H). Examples A11 The following examples were prepared in a similar manner to example A1 from the indicated starting material. E : z
, , , 2H), 1.42-1.50 (m,2H).
Example A12
2-(1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidin-4-yl)acetic acid (Example A1
Title compound was prepared on a similar manner to step 3 of Example 47 starting from Example 48-Intermediate 1. LCMS (Method 3), Rt = 3.77 min, ES+ m/z 612.2 [M+H]+ 1H-NMR (500 MHz, DMSO-d6) δ: 12.03 (br s, 1H); 9.46 (d, J=1.2 Hz, 1H); 9.23 (dd, J=7.0, 1.5 Hz, 1H); 8.91 (s, 1H); 8.74 (dd, J=4.1, 1.7 Hz, 1H); 8.42 (t, J=5.8 Hz, 1H); 8.24 (d, J=0.9 Hz, 1H); 7.17 (dd, J=6.9, 4.1 Hz, 1H); 6.89 (s, 1H); 6.49 (s, 1H); 6.37-6.40 (m, 1H); 4.14 (t, J=4.1 Hz, 2H); 3.63 (s, 3H); 3.41-3.46 (m, 2H); 3.37-3.41 (m, 2H); 2.86-2.92 (m, 2H); 2.44-2.52 (m, 2H, overlapped with DMSO); 2.12 (d, J=6.4 Hz, 2H); 1.95 (br t, J=11.0 Hz, 2H); 1.59-1.67 (m, 3H); 1.13-1.24 (m, 2H). PHARMACOLOGICAL ACTIVITY OF THE COMPOUNDS OF THE INVENTION (1-59). Biochemical Potency on JAK1, JAK2 , JAK3 and Tyk2 Assay principle The objective of this study was to assess the capability of compounds to inhibit all 4 JAK isoforms activity in a cell-free environment. Assay for JAK 1, JAK 2, JAK 3 and TYK2 were performed by Time-resolved fluorescence resonance energy transfer (TR-FRET) technology. It consists in the interaction of two labelled binding partners detected by the energy transfer from an excited donor to an acceptor dye and measurement of light emission by the acceptor dye. LANCE Ultra kinase assay was used. In presence of JAK 1, JAK 2, JAK 3 and TYK2 kinases and ATP (corresponding to Km), the ULight peptide substrate (LANCE Ulight-JAK-1 (Tyr1023) Peptide, Perkin Elmer, TRF0121) is phosphorylated. It is then captured by Eu-anti-phospho-substrate antibody (LANCE Eu-W1024 Anti-phosphotyrosine (PT66), Perkin Elmer, AD0069), which bring the Eu-chelate donor and ULight acceptor dyes into close proximity. Upon excitation at 320 nm,
the Eu-chelate transfers its energy to the ULight dye, resulting in a fluorescent light emission at 665 nm. Compound testing Serial dilutions of compounds in pure DMSO are prepared from 10 mM DMSO stock solutions. Compounds were tested in 384-well plate for 11 consecutive 5-fold dilutions starting from 20 μM highest concentration (20 μM – 2 pM). 200 nL of compound were transferred from mother plate to test plate by using Mosquito (TTP labtech). Assay was performed in 384-well Perkin Elmer test plate in 20 μL assay volume (kinase reaction) and 40 μL total volume (stopping reagent and antibody detection reagents). In 10 μL of substrate solution (peptide + ATP) 30/50/20/10nM of peptide and 20/0.7/0.2/12μM of ATP were added for JAK 1, JAK 2, JAK 3 and TYK2 respectively. 10 μL of enzyme solution was added to kinase reaction at these concentrations: 0.15/0.083/0.025/0.144 ng/μL of JAK 1, JAK 2, JAK 3 and TYK2 respectively. After shaking and 1.5h of incubation at r.t., 20 μL of Stop (10 μL EDTA) and Detection mixture (10 μL Europium-anti-phospho antibody, final: 0.5 nM) were added. Reading was performed after 1h of incubation on a EnVision 2104 reader (Perkin Elmer). Calculation of IC50 data, curves and QC analysis was performed by using Excel tool and GraphPadPrism software, v9. Briefly, individual concentration-effect curves are generated by plotting the logarithm of the tested concentration of tested compounds (X) vs. corresponding percent inhibition values (Y) using least squares (ordinary) fit. Best fit IC50 values are calculated using Log(inhibitor) vs. normalized response - Variable slope equation, where Y=100/(1+10^((LogIC50-X)*HillSlope)). QC criteria parameters (Z’, S:B, R2, HillSlope) were checked for every IC50 curve. Calculation of IC50 data, curves and QC analysis were made using Excel tools and GraphPadPrism software. QC criteria parameters: Z' ≥ 0.5, Hill Slope range 0.5 to 5, S:B > 2. Compounds according to the invention showed values in terms of pIC50 higher than 6 with respect to their inhibitory activity on all JAK isoforms corresponding to ≤ 1 μM in terms of inhibitory concentration. Most compounds preferably showed values higher than 7.3, even more preferably higher than 8.3, at least with respect to their inhibitory activity on JAK1; corresponding to ≤50 nM, even more preferably ≤5 nM, in terms of inhibitory concentration. Data for compounds 1-46 are reported in the table hereinbelow
6 ++ +++ +++ +
7 +++ +++ +++ +++
59 +++ +++ +++ ++
The compounds are classified in the table above in term of potency with respect to their inhibitory activity on JAK1, JAK2, JAK3 and Tyk2 isoforms according to the following classification criterion: + + + : pIC50 ≥ 8.3 + + : 8.3 > pIC50 ≥ 7.3 + : pIC50 < 7.3 Inhibition of IL-13 induced pSTAT6 in BEAS BEAS-2B human cell line was seeded (100.000 cells/well) and incubated for 48h at 37°C, 5% CO2, 95% humidity. Compounds were added and incubated 30 min followed by IL-13 as trigger. After 30 min incubation, cells were lysed and pSTAT6 determined by Fastscan phospho- stat6 (Tyr641) sandwich ELISA kit (cell signaling). Inhibitors were tested at 11 consecutive 5-fold dilutions starting from 10 μM (10 μM – 40 pM) in duplicate. Calculation of IC50 data, curves and QC analysis were made using Excel tools and GraphPadPrism software. QC criteria parameters: Z' ≥ 0.35, Hill Slope range 0.5 to 5, S:B > 2. Compounds according to the invention showed measurable values in terms of pIC50 (BEAS) higher than 7.3. Predicted acid metabolites showed measurable values in terms of pIC50 (BEAS) higher than 5.
20 §§§ A1 § kkk
21 §§§§ A1 § kkkk
59 §§§§ A1 § kkkk The compounds are classified in the table above in term of potency with respect to their functional activity in BEAS according to the following classification criterion: §§§§ : pIC50 ≥ 8.3 §§§ : 8.3 > pIC50 ≥ 7.3 5 §§ : 7.3 > pIC50 ≥ 6.3 § : pIC50 < 6.3
and in terms of fold difference (ratio) of IC50 of corresponding predicted acid metabolite vs parent ester (ratio = IC50 predicted acid metabolite / IC50 ester) kkkk : ratio ≥ 200 kkk : 200 > ratio ≥ 100 kk : 100 > ratio ≥ 10 k : ratio < 10 Where a numerical limit or range is stated herein, the endpoints are included. Also, all values and subranges within a numerical limit or range are specifically included when not explicitly written out. As used herein the words “a” and “an” and the like carry the meaning of “one or more.” Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
Claims
CLAIMS 1. A compound of formula I-1 or I-2
I-2 wherein the substituent group
is comprising at least one ester or thioester moiety; V is a divalent group selected from C(O)O, C(O)N(R6), N(R6)C(O)O; Q is selected from the group consisting of (C1-C6)alkoxycarbonyl, -(CH2)mNR4R5, (C3- C8)cycloalkyl, and (C3-C6)heterocycloalkyl; wherein said (C3-C8)cycloalkyl and (C3- C6)heterocycloalkyl are optionally substituted by one or more substituent group selected from the group consisting of (C1-C6)alkoxycarbonyl(CH2)m, (C3-C8)cycloalkyl-15 oxycarbonyl, NC-(C1-C6) alkoxycarbonyl, (C1-C6)haloalkyl-oxycarbonyl, (C3- C8)heterocycloalkyl-oxycarbonyl, (C1-C6)alkyl(C3-C8)heterocycloalkyl-oxycarbonyl, (C3- C8)heterocycloalkyl-(C1-C6)alkoxycarbonyl, (C1-C6)alkyl-(C3-C8)heterocycloalkyl-(C1-
C6)alkoxycarbonyl, (C1-C6)hydroxyalkyl-oxycarbonyl, (C1-C6)aminoalkyl-oxycarbonyl, (C1-C6)alkoxy-(C1-C6)alkyl-oxycarbonyl, (C1-C6)alkylthiocarbonyl, NC-(C3- C8)cycloalkyl(C1-C6)alkoxycarbonyl, NC-(C3-C8)cycloalkyl-oxycarbonyl, (C1- C6)haloalkyl-(C3-C8)heterocycloalkyl-oxycarbonyl, halo-((C1-C6)alkyl(C3- C8)heterocycloalkyl)-oxycarbonyl, (C1-C6)haloalkyl-(C3-C8)heterocycloalkyl-(C1- C6)alkoxycarbonyl, (C1-C6)haloalkyl-(C3-C8)heterocycloalkyl-oxycarbonyl-(C1-C6)alkyl, (C1-C6)hydroxyalkyl-oxycarbonyl-(C1-C6)alkyl, (C1-C10)alkyl and halogen; K is selected from O, CH2, S; n and m are in each occurrence independently 0 or an integer selected from 1, 2, 3 and 4; R4 and R5, the same or different, are selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C6)heterocycloalkyl and (C1-C6)alkyl-(C3-C8)heterocycloalkyl; (C1-C6)alkoxycarbonyl-methyl; (C1-C6)alkoxycarbonyl-phenyl-methyl; (C1-C6)alkoxycarbonyl-(C1-C6)alkyl -phenyl-methyl; R6 is in each occurrence independently selected from the group consisting of H, (C1- C6)alkyl, (C1-C6)hydroxyalkyl; single enantiomers, diastereoisomers and mixtures thereof or a pharmaceutically acceptable salt or solvate thereof. 2. A compound according to claim 1, wherein K is O; represented by the formula (Ia) 25
Ia wherein
V is C(O)N(R6), Q is (C3-C6)heterocycloalkyl substituted by at least one group selected from (C1- C6)alkoxycarbonyl, (C3-C8)cycloalkyl-oxycarbonyl, NC-(C1-C6) alkoxycarbonyl, (C1- C6)haloalkyl-oxycarbonyl, (C1-C6)alkyl(C3-C8)heterocycloalkyl-oxycarbonyl, (C1- C6)hydroxyalkyl -oxycarbonyl and (C1-C6)alkoxy(C1-C6)alkyl -oxycarbonyl and (C1- C6)alkylthiocarbonyl; n is in each occurrence independently 0 or an integer selected from 1, 2, 3 and 4; R6 is in each occurrence independently selected from the group consisting of H, (C1- C6)alkyl and (C1-C6)hydroxyalkyl; single enantiomers, diastereoisomers and mixtures thereof or a pharmaceutically acceptable salt or solvate thereof. 3. A compound according to claim 2 selected from the list of ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine-4- carboxylate; isopropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; cyclopropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; 2-cyano-2-methylpropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; 2,2,2-trifluoroethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; 1-methylazetidin-3-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; 3-hydroxy-2,2-dimethylpropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; 2-hydroxy-2-methylpropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-
7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; 1-methoxy-2-methylpropan-2-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; (R)-1-methylpyrrolidin-3-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; S-ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carbothioate single enantiomers, diastereoisomers and mixtures thereof or a pharmaceutically acceptable salt or solvate thereof. 4. A compound according to claim 1, wherein V is a divalent group selected from C(O)O; Q is selected from the group consisting of (C1-C6)alkoxycarbonyl, -(CH2)mNR4R5, and (C3-C6)heterocycloalkyl optionally substituted by one or more group selected from (C1- C10)alkyl and halogen; n and m are in each occurrence independently 0 or an integer selected from 1, 2, 3 and 4; R4 and R5, the same or different, are selected from the group consisting of H, (C1-C6)alkyl, single enantiomers, diastereoisomers and mixtures thereof or a pharmaceutically acceptable salt or solvate thereof. 5. A compound according to claim 1, wherein K is equal to S, represented by the formula (Ib)
Ib wherein
V is a divalent group selected from N(R6)C(O)O; Q is selected from the group consisting of (C1-C6)alkoxycarbonyl; n is an integer selected from 1, 2, 3 and 4; R6 is in each occurrence independently selected from the group consisting of H, (C1-C6)alkyl; single enantiomers, diastereoisomers and mixtures thereof or a pharmaceutically acceptable salt or solvate thereof. 6. A compound according to claim 1 selected from the list of ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; ethyl (1s,3s)-3-(((1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3- yl)carbamoyl)oxy)cyclobutane-1-carboxylate; ethyl 2-(((1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamoyl)oxy)acetate; ethyl 1-(2-(((1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3- yl)carbamoyl)oxy)ethyl)piperidine-4-carboxylate; 1-methoxy-2-methylpropan-2-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; propyl N-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)-N- methylglycinate; 3-(dimethylamino)propyl 1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)- 6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate; 3-(4-methylpiperazin-1-yl)propyl 1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxylate; ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine-4- carboxylate;
sec-butyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; cyclopropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; cyclopentyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; 2,2,2-trifluoroethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; 2-hydroxy-2-methylpropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin- 7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; 3-hydroxy-2,2-dimethylpropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; 2-methoxyethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; tetrahydro-2H-pyran-4-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin- 7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; (tetrahydro-2H-pyran-4-yl)methyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; (4-methylmorpholin-2-yl)methyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; 2-(dimethylamino)-2-methylpropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate;
1-methylazetidin-3-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; 1-methylpyrrolidin-3-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; (R)-1-methylpyrrolidin-3-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; (S)-1-methylpyrrolidin-3-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; 2-cyano-2-methylpropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; 1-methylpiperidin-4-yl 1-(3-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)propyl)piperidine-4-carboxylate; ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine-3- carboxylate; ethyl 4-fluoro-1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; methyl (R)-1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)pyrrolidine-3-carboxylate; methyl (S)-1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)pyrrolidine-3-carboxylate; ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)azetidine-3- carboxylate;
ethyl (3aR,5r,6aS)-2-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)octahydrocyclopenta[c]pyrrole-5-carboxylate; ethyl (1R,5S,6r)-3-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)-3- azabicyclo[3.1.0]hexane-6-carboxylate; ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)-4-methylpiperidine- 4-carboxylate; ethyl 2-(1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidin-4-yl)acetate; ethyl 4-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)-1-methylpiperazine- 2-carboxylate; methyl 2-(3-(((2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)(methyl)amino)methyl)phenyl)acetate; ethyl 1-(2-(1-(7-methoxy-1,2,3,4-tetrahydroquinolin-6-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine-4- carboxylate; ethyl 2-(((1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5- a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamoyl)oxy)acetate; ethyl (1s,3s)-3-(((1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3- yl)carbamoyl)oxy)cyclobutane-1-carboxylate; ethyl 1-(2-(((1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3- yl)carbamoyl)oxy)ethyl)piperidine-4-carboxylate; 1-methylpiperidin-4-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; ethyl (R)-1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- 35 carboxamido)ethyl)pyrrolidine-3-carboxylate;
ethyl (S)-1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)pyrrolidine-3-carboxylate; isopropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; (4-methylmorpholin-2-yl)methyl 1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin- 7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate; 3-cyanocyclobutyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; 2-hydroxy-2-methylpropyl 2-(1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidin-4-yl)acetate; 2-cyano-2-methylpropyl (R)-1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)pyrrolidine-3-carboxylate; (3S,4S)-4-fluoro-1-methylpyrrolidin-3-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; (3R*,4R*)-4-fluoro-1-methylpyrrolidin-3-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; (R)-1-(2-fluoroethyl)pyrrolidin-3-yl 2-(1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidin-4-yl)acetate; (1-cyanocyclopropyl)methyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)piperidine-4-carboxylate; 3-cyanopropyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; (R)-1-(2-fluoroethyl)pyrrolidin-3-yl (R)-1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 35 3-carboxamido)ethyl)pyrrolidine-3-carboxylate;
(R)-1-methylpyrrolidin-3-yl (S)-1-(2-(1-(6-methoxy-3,4-dihydro-2H- benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine- 3-carboxamido)ethyl)pyrrolidine-3-carboxylate; 1-isopropylazetidin-3-yl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carboxylate; ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-((3-oxo-3,4- dihydropyrazin-2-yl)amino)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)ethyl)piperidine- 4-carboxylate; S-ethyl 1-(2-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6- (pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3- carboxamido)ethyl)piperidine-4-carbothioate; single enantiomers, diastereoisomers and mixtures thereof or pharmaceutical acceptable salts and solvates thereof. 7. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, in admixture with one or more pharmaceutically acceptable carrier or excipient. 8. A pharmaceutical composition according to claim 7 suitable to be administered by inhalation, selected from inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations. 9. A device comprising the pharmaceutical composition according to claim 8, which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler or a soft mist nebulizer. 10. A compound or a pharmaceutical composition according to any one of claims 1 to 8 for use as a medicament. 11. A compound or a pharmaceutical composition for use according to claim 10 in the prevention and /or treatment of a pulmonary disease selected from the group consisting of asthma, chronic obstructive pulmonary disease COPD, idiopathic pulmonary fibrosis (IPF), acute lung injury and acute respiratory distress syndrome (ARDS). 12. A combination of a compound as defined in any one of the claims 1 to 6 with one or more 30 active ingredients selected from the classes currently used in the treatment of respiratory disorders, and known to the skilled person, such as beta2-agonists, antimuscarinic agents, corticosteroids, mitogen-activated kinases (P38 MAP kinases) inhibitors, PI3K inhibitors
(phosphoinositide 3-kinases), nuclear factor kappa-B kinase subunit beta inhibitors (IKK2), Rho kinase inhibitors (ROCKi), human neutrophil elastase (HNE) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, leukotriene modulators, non-steroidal anti- inflammatory agents (NSAIDs) and mucus regulators.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22194841.7 | 2022-09-09 | ||
EP22194841 | 2022-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024052513A1 true WO2024052513A1 (en) | 2024-03-14 |
Family
ID=83271018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/074692 WO2024052513A1 (en) | 2022-09-09 | 2023-09-08 | Heterocyclic derivatives as janus kinase inhibitors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024052513A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008052734A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
WO2012069202A1 (en) * | 2010-11-26 | 2012-05-31 | Almirall,S.A. | Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors |
WO2018122212A1 (en) * | 2016-12-29 | 2018-07-05 | F. Hoffmann-La Roche Ag | Pyrazolopyrimidine compounds and methods of use thereof |
WO2022194781A1 (en) * | 2021-03-15 | 2022-09-22 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
WO2022194779A1 (en) * | 2021-03-15 | 2022-09-22 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
-
2023
- 2023-09-08 WO PCT/EP2023/074692 patent/WO2024052513A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008052734A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
WO2012069202A1 (en) * | 2010-11-26 | 2012-05-31 | Almirall,S.A. | Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors |
WO2018122212A1 (en) * | 2016-12-29 | 2018-07-05 | F. Hoffmann-La Roche Ag | Pyrazolopyrimidine compounds and methods of use thereof |
WO2022194781A1 (en) * | 2021-03-15 | 2022-09-22 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
WO2022194779A1 (en) * | 2021-03-15 | 2022-09-22 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
Non-Patent Citations (26)
Title |
---|
ASHINO S ET AL., J ALLERGY CLIN IMMUNOL, vol. 133, 2014, pages 1162 - 74 |
BRINGMANN GET, ANGEW. CHEMIE INT. ED., vol. 44, no. 34, 2005, pages 5384 - 5427 |
CAO Y. ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 146, 2020, pages 137 - 146 |
CONCA, W ET AL., FRONT. PHARMACOL., vol. 11, 2020, pages 5857619 |
D'ALESSANDRO M ET AL., INT. IMMUNOPHARMACOL., vol. 86, 2020, pages 106748 |
DENGLER HS ET AL., SCI TRANSL MED, vol. 10, 2018, pages eaao2151 |
DI STEFANO A ET AL., EUR RESPIR J, vol. 24, no. 1, July 2004 (2004-07-01), pages 78 - 85 |
HINKS TSC ET AL., ERJ, vol. 57, no. 1, 2021, pages 2000528 |
HODGE ET AL., CLIN EXP RHEUMATOL, vol. 34, no. 2, 2016, pages 318 - 28 |
HOWELL MD ET AL., FRONT. IMMUNOL., vol. 10, 2019, pages 2342 |
HOWELL MICHAEL D. ET AL: "Targeting the Janus Kinase Family in Autoimmune Skin Diseases", vol. 10, 1 January 2019 (2019-01-01), pages 2342, XP055863286, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794457/pdf/fimmu-10-02342.pdf> DOI: 10.3389/fimmu.2019.02342 * |
HU X ET AL., SIGNAL TRANSDUCT TARGET THER, vol. 6, no. 1, pages 402 |
HU X. ET AL., SIG TRANSDUCT TARGET THER, vol. 6, 2021, pages 402 |
ISRAEL EREDDEL HK, N ENGL J MED, vol. 377, 2017, pages 965 - 76 |
KEVIN J. COETATIANA KOUDRIAKOVA: "Metabolic Stability Assessed by Liver Microsomes and Hepatocytes", METHODS IN PHARMACOLOGY AND TOXICOLOGY, 2013 |
L DIEH KERNSY HONGH CHEN: "Development and application of high throughput plasma stability assay for drug discovery", INTERNATIONAL J OURNAL OF PHARMACEUTICS, 2005 |
OKI M, TOPICS IN STEREOCHEMISTRY, vol. 14, 1983, pages 1 - 82 |
STEVE NG ET AL., J ALLERGY CLIN IMMUNOL, vol. 148, 2021, pages 953 - 63 |
T. W. GREENEP. G. M. WUTS: "Strategic application of named reactions in organic synthesis", 2005 |
WACHTEL, H.KATTENBECK, S.DUNNE, S. ET AL., PULM THER, vol. 3, 2017, pages 19 |
WANG, W ET AL., SCLERODERMA RELAT. DISORD., vol. 5, 2020, pages 40 - 50 |
WENZEL SE, AM J RESPIR CRIT CARE MED, vol. 203, 2021, pages 809 - 21 |
WIJAYA, I. ET AL., CLIN. EPIDEMIOL. GLOB. HEALTH, vol. 11, 2021, pages 100755 |
YEW-BOOTH L ET AL., EUR RESPIR J, vol. 46, no. 3, 2015, pages 843 - 5 |
YOUNIS US ET AL., AAPS PHARMSCI-TECH, vol. 20, 2019, pages 167 |
ZHANG, Y ET AL., ANN. RHEUM. DIS., vol. 76, 2017, pages 1467 - 1475 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7041198B2 (en) | 5-Chloro-2-difluoromethoxyphenylpyrazolopyrimidine compound which is a JAK inhibitor | |
JP6283636B2 (en) | Macrocyclic compounds as TRK kinase inhibitors | |
AU2017206260B2 (en) | Heterocyclylamines as pi3k inhibitors | |
AU2017382029B2 (en) | Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-kinase inhibitors | |
ES2866152T3 (en) | Tyrosine amide derivatives as Rho-kinase inhibitors | |
AU2015225745A1 (en) | Heterocyclic compounds | |
WO2022194781A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
AU2022239752A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
TW202400581A (en) | Inhibitor of kinesin kif18a and use thereof | |
WO2024052513A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
WO2024052512A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
RU2785126C2 (en) | New compounds and their pharmaceutical compositions for treatment of inflammatory diseases | |
RU2778478C2 (en) | Bicyclic dihydropyrimidinecarboxamide derivatives as rho-kinase inhibitors | |
EP4308568A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
EP4313293A1 (en) | Tetrahydrothieno pyridine derivatives as ddrs inhibitors | |
CN117098765A (en) | Heterocyclic derivatives as Janus kinase inhibitors | |
WO2024073576A1 (en) | 4-((2-(3,5-dichlorophenyl)-6-((pyrimidin-5-yl)oxy)pyridin-4-yl)methyl)piperazine derivatives as furin inhibitors and uses thereof | |
TW202411229A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
KR20160095167A (en) | Heterocyclic compounds |